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Estrogen receptor-α negative (ERα-) tumours are a highly aggressive and 
heterogeneous class of breast cancer (BC) with higher prevalence in younger 
women. ERα- BC is associated with a worse prognosis and limited therapeutic 
options. Therefore, discovery of new therapeutic targets is a clinical imperative. 
This thesis investigated three therapeutic targets for ERα- BC: the androgen 
receptor (AR), transcription factor AP-2β (TFAP-2β) and cyclin-dependent 
kinase 9 (CDK9).  
AR is expressed in 20-50% of ERα- BC, but preclinical evidence about its role 
is equivocal, indicating both proliferative and anti-proliferative effects. To 
inform this controversy, genomic parameters associated with differential AR-
mediated growth effects were examined in two ERα-/AR+ breast cancer cell 
lines with differing proliferative responses to the natural AR ligand 5α-
dihydrotestosterone (DHT). Comparing the AR-regulated transcriptome of 
MDA-MB-453 (growth stimulated by DHT) with MFM-223 (growth inhibited 
by DHT) breast cancer cells revealed that DHT regulates a discrete set of genes 
associated with distinct biological functions in the two models. DHT increased 
expression of genes associated with metabolism, development, and cell growth 
in MDA-MB-453 cells. In MFM-223 cells, DHT induced expression of genes 
with tumour suppressor activity. Analysis of AR cistrome showed that lack of 
AR enrichment at tumour suppressor genes exclusively upregulated by DHT in 
MFM-223 cells did not explain the inability of AR to induce transcription of 
these genes in MDA-MB-453 cells. We therefore hypothesised that differential 
DHT-regulated transcriptomes are driven by distinct interactions with AR co-
13 
 
regulatory proteins. Unbiased proteomic analysis of the AR interactomes 
identified TFAP-2β as a candidate factor of interest. High TFAP-2β expression 
specifically clustered molecular apocrine tumours (ERα-/AR+/HER2+) and 
TFAP-2β was required to sustain proliferative capacity, cell viability and 
expression of C-MYC and HER2 oncogenes in a representative cell line. 
Cistrome analysis revealed substantial co-localization of TFAP-2β and AR (at 
approximately 40% of total loci) following treatment with DHT. However, this 
interaction was not a critical determinant of oncogenic AR signalling. We 
conclude that TFAP-2β has AR-independent oncogenic effects and represents a 
novel new target for the molecular apocrine sub-type of ERα- BC.  
CDK9 is a transcriptional cyclin that increases RNA Polymerase II (RNAPII) 
activity to sustain expression of normally short-lived oncogenic and anti-
apoptotic proteins. Targeting CDK9 has been hampered by poor selectivity of 
existing inhibitors (CDK9i). Here, we report a novel CDK9i, D-11, which 
exhibited high potency against CDK9 (Ki=8nM) and displayed remarkable 
selectivity over other CDKs and 369 human kinases. D-11 suppressed 
proliferation and triggered apoptosis in ERα- BC cells and these effects were 
ascribed to the reduction of p-RNAPII, C-MYC and MCL1 levels, indicative of 
targeted CDK9 inhibition. In vivo, D-11 inhibited ERα- BC tumour growth 
without affecting body weight or histology of normal tissues, indicating its 
potential for clinical translation as a treatment for ERα- BC.  
Overall, this thesis expands current knowledge about targeting AR in ERα- 
BCs, provides preclinical evidence to support TFAP-2β as a novel therapeutic 
14 
 
target and D-11 as a highly selective, non-toxic CDK9 inhibitor ready for 
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INTRODUCTION AND REVIEW OF LITERATURE 
 
 
1.1 Breast anatomy and development 
 
The mammary gland is a modified, specialised apocrine gland that shares the 
same embryological origin with salivary and sweat glands (Javed & Lteif 
2013). Breast tissue is composed of glandular, stromal and adipose tissues 
(Sharma et al. 2010), with the glandular portion consisting of 15–20 sections 
called lobes in humans, which are in turn comprised of smaller units called 
lobules (Zhu, W & Nelson 2013) (Figure 1.1 A-C). Each lobule is made up of 
grape-like clusters of acini (alveoli), the hollow sacs that produce and store 
milk during lactation (Noor, Hseon & Jeffrey 2016). Mammary gland lobes are 
connected to a network of ducts called the lactiferous sinus, which funnel milk 
to the nipple (Noor, Hseon & Jeffrey 2016).  
The mammary ducts and alveoli are lined with two types of epithelial cells, the 
inner luminal secretory cells, and outer myoepithelial cells (Lund et al. 1996). 
Two histological sub-types of luminal secretory cells have been identified: 
basal cells, which have relatively clear cytoplasm and an oval nucleus lacking a 
visible nucleolus, and luminal cells that harbour darker, basophilic cytoplasm 
(Pontén et al. 2008). Myoepithelial cells (a hybrid of  smooth muscle ('myo') 
and epithelial cells) form a continuous layer that separates luminal cells from 
the basement membrane (Omar 2014). Upon contraction, the myoepithelial 
cells decrease the length and increase the diameter of the ducts to eject the milk 
during lactation (Omar 2014). Moreover, myoepithelial cells are responsible 
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for synthesising basement membrane components and play an important role in 
mammary morphogenesis (Gudjonsson et al. 2005).  
The stromal compartment of the breast is made up of two mesenchymal 
lineages: adipocytes and fibroblasts, as well as infiltrating immune and 
endothelial cells (Dzięgelewska & Gajewska 2018; Zhu, W & Nelson 2013). 
The stroma accounts for about 60% of the total breast tissue volume and 
provides the glandular tissues with support, structure, nutrients and immune 
defense (Dzięgelewska & Gajewska 2018). Several studies have shown that 
mammary stroma is an important regulator of mammary epithelial cell 
proliferation, survival, polarity, and differentiation, via paracrine, physical, and 
reciprocal signalling between epithelial cells and underlying stromal cells 
(Arendt et al. 2010; Maller et al. 2010; Mueller et al. 2002; Polyak & Kalluri 
2010). Vascular endothelial cells are important for transporting nutrients and 
oxygen to breast tissues and represent a vital component of the epithelial 









Figure 1.1: Anatomy of the human mammary gland. (A) The mammary gland 
contains 15–20 lobes, each lobe containing a series of branched ducts that drain 
into the nipples. (B) Hematoxylin and eosin-stained section of human breast 
tissue showing a terminal ductal lobular unit comprised of ducts and acini 
embedded in a fibrous connective tissue stroma. (C) Higher magnification 






The mammary gland undergoes dynamic changes throughout various female 
developmental stages (Macias & Hinck 2012). At birth, the mammary glands 
are rudimentary structures consisting of very few ducts (Javed & Lteif 2013). 
During puberty and under the effect of ovarian sex steroid hormones (estrogen 
and progesterone) and pituitary gland growth hormone, the rudimentary 
mammary ducts elongate and branch out (Brisken & O’Malley 2010; 
Gusterson & Stein 2012). Once ovulation and menstruation begin, maturation 
of the breast tissue begins with the formation of secretory glands at the end of 
the milk ducts (Gusterson & Stein 2012; Javed & Lteif 2013). The breast tissue 
and ductal system continues to grow and mature, with the development of a 
number of glands and lobules (Dzięgelewska & Gajewska 2018; Inman et al. 
2015; Javed & Lteif 2013). Another stage of mammary gland development 
occurs upon exposure to elevated hormone levels during pregnancy (Brisken & 
O’Malley 2010), when estrogen, progesterone, and prolactin levels rise 
(Brisken & O’Malley 2010). Estrogen stimulates proliferation of ductal cells 
and promotes secretion of prolactin and progesterone (Javed & Lteif 2013; 
Macias & Hinck 2012), which are the hormones responsible for formation and 
growth of milk-producing cells (Brisken & O’Malley 2010; Javed & Lteif 
2013; Macias & Hinck 2012). After weaning, these hormones return to pre-
pregnancy levels and the mammary gland undergoes post-lactational regression 
leading to collapse of the alveolar structures, and removal of the secretory 
epithelial and myoepithelial cells by apoptosis (Lund et al. 1996). With the 
onset of menopause, the ductal and glandular elements of the breast begin to 
shrink (Aranda-Gutierrez & Diaz-Perez 2019; Hassiotou & Geddes 2013),  
triggered by declining ovarian function and reduced levels of estrogen and 
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progesterone (Aranda-Gutierrez & Diaz-Perez 2019; Hassiotou & Geddes 
2013). As menopause progresses, the breast connective tissues (fat and stromal 
elements) lose elasticity, leading to breast shrinkage and loss of shape 
(Hassiotou & Geddes 2013).   
1.2 Breast cancer 
1.2.1 Pathology and epidemiology  
Breast cancer has a major impact on public health globally. It is one of the 
most common malignancies in women and the leading cause of cancer-related 
deaths among women worldwide (Bray et al. 2018). Each year, over 1.1 
million women are diagnosed with breast cancer and more than 410,000 
women die from the  disease worldwide (Siegel, Miller & Jemal 2016). For 
Australian women, the lifetime risk of developing breast cancer by the age of 
85 is one in seven (Australian Institute of Health and Welfare 2019a), and in 
2020 it is estimated that 19,998 Australian women will be diagnosed with 
breast cancer, an average of 55 cases each day, with 3049 deaths (Australian 
Institute of Health and Welfare 2019b).  
Breast cancer is an uncontrolled growth of neoplastic breast epithelial cells that 
arises due to genetic alterations/mutations in proto-oncogenes and/or tumour 
suppressor genes (Hartwell & Kastan 1994). Breast cancer most commonly 
develops in epithelial cells that line the glandular tissue of the breast, primarily 
within the milk-producing lobules (lobular carcinoma) and the milk ducts 
(ductal carcinoma) (Benson et al. 2009). The earliest recognisable form of 
breast cancer is non-invasive, in situ carcinoma, which is defined as a tumour 
that resides within the duct or lobules of the breast (Pinder 1995) (Figure 1.2). 
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Pure in situ carcinoma represents approximately 20% of all diagnosed breast 
cancers (Pinder 1995). In contrast, most (~80%) breast cancers are identified 
once they have become invasive or infiltrating (Sharma et al. 2010), where they 
have broken through the walls of the glands or ducts and diffused into 
surrounding breast tissues (Sharma et al. 2010) (Figure 1.2). Cancer cells can 
then spread (metastasise) to other parts of the body through the bloodstream or 
lymphatic system (Nguyen, Bos & Massagué 2009). It is this metastatic form 
of breast cancer that is most lethal, with many essential organs (e.g., liver, and 










Figure 1.2: A schematic depicting the various pathologically defined stages of 
breast tumour progression, as well as various functions associated with 
metastatic spread. In situ carcinoma is tumour growth that remains within the 
duct or lobules of the breast. Invasive carcinoma occurs when the malignant 
cells break the walls of the glands or ducts where they originated and diffused 
into surrounding breast tissues. Metastasis, the final stage of cancer 
progression, occurs when cancer cells travel via the bloodstream or lymph 




1.2.2 Risk factors 
More than three decades of epidemiologic studies have identified many risk 
factors that increase the likelihood of developing breast cancer. One of the 
strongest risk factors is age (Howlader et al. 2019; Singletary 2003), whereby 
the risk of developing breast cancer increases with increasing age in women 
(Howlader et al. 2019; Singletary 2003). The incidence of breast cancer for a 
woman in her 30s is approximately one in 227, compared with approximately 
one in 28 for a woman in her 70s, and more than three-quarters of breast cancer 
cases were diagnosed in women over the age of 50 (Howlader et al. 2019). 
Another important risk factor is genetics. Hereditary breast cancers are 
responsible for one-third of all breast cancer cases and up to 30% of all early-
onset breast cancer (Mehrgou & Akouchekian 2016). The best-described breast 
cancer susceptibility genes are BRCA1 and BRCA2 (Langston et al. 1996). 
BRCA1 and BRCA2 act as tumour suppressor genes and play a role in the 
maintenance of genome integrity by repairing double-strand DNA breaks via 
the homologous recombination repair (HRR) pathway (Langston et al. 1996; 
Roy, R, Chun & Powell 2012). Women carrying BRCA1 or BRCA2 genetic 
mutations have a 60–80% lifetime risk of developing breast cancer (Mehrgou 
& Akouchekian 2016). Inherited mutations in other genes critical for genome 
integrity, including CHEK2, PALB2, ATM, p53, PTEN, STK11, CDH1, are also 
associated with increased risk of breast cancer (Launonen 2005; Lei, Haixin et 
al. 2002; Olivier, Hollstein & Hainaut 2010; Walsh & King 2007), albeit they 
are less common than BRCA mutations.  
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Lifetime exposure to ovarian hormones (e.g., estrogen) also influences risk for 
breast cancer, as early menarche, late menopause, and older age at first 
pregnancy all increased risk of breast cancer (Dall & Britt 2017; Li, CI et al. 
2008; MacMahon et al. 1970).  
For each one year delay in onset of menopause, the risk of breast cancer 
increases by 3% (Surakasula, Nagarjunapu & Raghavaiah 2014), while each 
one year delay in menarche and each additional birth decreases the risk of 
breast cancer by 5% and 10%, respectively (Dall & Britt 2017; Surakasula, 
Nagarjunapu & Raghavaiah 2014). Such increases in risk might be explained 
by a longer lifetime exposure to elevated sex steroid hormones, which can 
increase the proliferation of the mammary cells and suppress apoptosis (Dall & 
Britt 2017).  
Estrogens are a group of steroid hormones that regulate female reproductive 
function and secondary sex characteristics, including breast development 
(Darbre 2015). Increases in the endogenous concentration of circulating 
estrogens is strongly associated with increased risk of breast cancer in 
postmenopausal women (Baglietto et al. 2010; Thomas, HV et al. 1997; Travis 
& Key 2003; Zeleniuch-Jacquotte, A et al. 2004). Postmenopausal women with 
high serum estrogen concentrations have a nearly two-fold risk of breast cancer 
compared with postmenopausal women with low serum concentrations of 
estrogens (Travis & Key 2003). Exogenous estrogens administered as part of 
oral contraception or menopause hormone therapy (MHT) can stimulate 
mammary epithelial cell proliferation and thereby increase breast cancer risk 
with long term use (Lancet 2019; Marjoribanks et al. 2012; Perkins, Louw-du 
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Toit & Africander 2018). Evidence from a large meta-analysis study looking at 
the relationship between estrogen-alone MHT and breast cancer risk, reported 
that current users had a 1.14 fold (95% confidence interval (CI) = 1.05–1.22) 
excess risk for developing breast cancer compared to women that never used 
MHT (Wang, K et al. 2017).  
Androgen hormones, a primary focus of this thesis, also have a role in the 
aetiology of breast cancer. Androgens are generally considered as classical 
male sex hormones, but androgens are also made by  reproductive and adrenal 
organs in women and play important biological roles, in part as precursors for 
the production of estrogen hormones (Dimitrakakis & Bondy 2009). In 
postmenopausal women, most prospective epidemiologic studies reported that 
higher levels of androgens including testosterone, dehydroepiandrosterone-
sulphate (DHEAS) and androstenedione (A4) were significantly associated 
with an increased breast cancer risk (Kaaks, Rinaldi, et al. 2005; Key T 2002; 
Missmer et al. 2004; Zeleniuch-Jacquotte, A et al. 2004). However, the 
association between increased androgen levels and risk of breast cancer does 
not hold up when factoring in the conversion of testosterone to estrogen (Adly 
et al. 2006; Hankinson et al. 1998; McNamara, KM et al. 2014). In other 
words, conversion of testosterone to estrogen by aromatase activity could 
contribute to the association between testosterone and breast cancer risk 
(McNamara, KM et al. 2014). In premenopausal women, the association 
between circulating androgens and breast cancer risk is not so clear, with 
studies reporting either no association (Helzlsouer et al. 1992; Lee, SH et al. 
1999) or a positive association (Kaaks, Rinaldi, et al. 2005; Key T 2002; 
Missmer et al. 2004; Zeleniuch-Jacquotte, A et al. 2004). A more detailed 
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review of epidemiological data relating to androgens in breast cancer is 
presented in Section 1.4.4. 
Taken together, these studies provide evidence that sex steroid hormones (i.e., 
estrogens and androgens), play an important role in breast cancer.  
1.3 Estrogen signalling in breast cancer. 
1.3.1 Estrogen and the estrogen receptor axis 
Notable attention has been given to the role of estrogen in breast cancer since 
British surgeon George Beatson (Beatson 1896) published his findings on the 
beneficial effects of ovariectomy in a premenopausal patient with advanced 
breast cancer. Beatson's findings signified that ovarian hormones (i.e., 
estrogens) are critical determinants of breast cancer growth. 
Estrogens are a class of sex steroid hormones that are secreted mainly by the 
ovaries (Nelson & Bulun 2001). Estrogens are also produced at peripheral sites 
(extragonadal sites) such as breast, adipose tissue, adrenal glands, bone, and 
brain (Nelson & Bulun 2001) in humans. In the ovaries, estrogens are 
ultimately synthesised from cholesterol by a series of biochemical reactions 
collectively called steroidogenesis (Figure 1.3), where they can act locally as 
well as being secreted into circulation. Estrogens are transported through the 
circulation bound to sex hormone binding globulin (SHBG) to act on distal 
target tissues in an endocrine manner (Nelson & Bulun 2001; Zhao, H et al. 
2016). About 55% of estrogens in women are bound to circulating SHBG 
(Laurent et al. 2016). Within extragonadal sites, estrogens are also locally 
produced by the aromatisation of circulating androstenedione or testosterone 
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via the  aromatase (P450arom) enzyme and act in an intracrine manner (Nelson 
& Bulun 2001). In postmenopausal women, when the ovaries cease to produce 
estrogen and circulating estrogen levels  precipitously drop, tissue levels of 
estrogen remain relatively constant due to intracrine activity (Yaghjyan, 
Colditz & Control 2011). Van Landeghem et al (1985) published one of the 
earliest studies showing  that estrogen levels were similar in normal breast 
tissue from both pre- and postmenopausal women (Van Landeghem et al. 
1985), which may be attributed to an increase in aromatase activity in the 






Figure 1.3: Estrogen biosynthesis in the ovaries. Estrogen production begins 
with the conversion of cholesterol into progestogens, androgens, and finally 
estrogens. Progesterone is converted to androgens via cytochrome P450 17α-
hydroxylase (P45017) and 17-beta-hydroxysteroid dehydrogenase (17β-HSD). 
Androgen is converted to estrone, and estradiol via aromatase (P450arom). 
P450scc, cholesterol side-chain cleavage enzyme; 3β-HSD, 3β-hydroxysteroid 







Naturally, estrogens occur in three structurally related forms; estrone (E1), 
estradiol (E2, or 17β-estradiol), and estriol (E3) (Cui, Shen & Li 2013). E2 is 
the most common and potent circulating estrogen in females (Cui, Shen & Li 
2013). Estrogens exert their effects via binding to the estrogen receptor (ER) 
(Enmark et al. 1997). There are two major isoforms of ER, ERα and ERβ, that 
govern a wide range of physiological processes including development of the 
female reproductive system, maintenance of bone mass, and protection of 
cardiovascular tissue (Enmark et al. 1997; Harvell et al. 2008). ERα and ERβ 
are encoded by two unique genes that reside on distinct chromosomes, ESR1 
and ESR2 on the sixth and fourteenth chromosome (6q25.1 and 14q23.2), 
respectively (Enmark et al. 1997). While the role of ERβ in breast cancer 
initiation and progression is still debated, the role of ERα as a key 
transcriptional regulator and oncogenic driver of the majority of breast cancers 
is well established (Kurebayashi et al. 2000; Shoker et al. 1999). Like all 
steroid receptors, ERα is a ligand-activated nuclear transcription factor that 
regulates transcription of target genes responsible for controlling cell 
proliferation, maturation, and death of breast epithelial cells (Kurebayashi et al. 
2000; Shoker et al. 1999). Deletion of ERα in mice results in a rudimentary 
mammary ductal system that fails to branch out (Bocchinfuso et al. 2000). A 
study by Feng et al (2007) showed that ERα not only regulates ductal 
morphogenesis during puberty but is also involved in alveologenesis during 
pregnancy and lactation (Feng, Yuxin et al. 2007) .  
Aberrant ERα signalling is the key driver of breast carcinogenesis, responsible 
for the initiation and progression of at least 70% of all breast cancers (Zhou, Z 
et al. 2014). Activation of ERα by E2 stimulates growth of breast cancer cells 
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in vitro and in vivo (Bocchinfuso et al. 2000; Couillard et al. 1998; Huseby, 
Maloney & McGrath 1984). Preclinical studies showed that estrogen-induced 
proliferation of breast cancer cell lines is driven by ERα modifying expression 
of hormone-responsive genes involved in the cell cycle and/or apoptosis 
(Altucci et al. 1996; Carroll et al. 2006; Eeckhoute et al. 2006; Foster & 
Wimalasena 1996). E2 stimulated the growth of ERα positive cell lines, MCF-
7, ZR-75-1, and T47-D, by inducing expression of the master transcription 
factor and oncogenes C-MYC, C-MYB and the cell cycle regulator cyclin D1 
(Abdullah et al. 2018; Altucci et al. 1996; Drabsch et al. 2007; Dubik & Shiu 
1988; Eeckhoute et al. 2006; Foster & Wimalasena 1996; Watts et al. 1994). 
Cyclin D1 regulates progression of cells through the G1 phase of the cell cycle 
(Allen-Petersen & Sears 2019), and overexpression of cyclin D1 is strongly 
associated with ERα expression in breast cancer (Mohammadizadeh et al. 
2013), present in approximately 60% of ductal carcinomas (Pietras & 
Márquez-Garbán 2007). Other in vitro studies have shown that E2 can inhibit 
breast cancer cell apoptosis by regulating the expression of anti-apoptotic 
proteins such as BCL2, and MCL1 (Gompel et al. 2000; Schacter, Henson & 
Gibson 2014). Moreover, ERα interacts with several key growth stimulatory 
proteins, including c-Src, (the p85 subunit of phosphoinositide 3-kinase 
(PI3K)), epidermal growth factor receptor (EGFR), insulin-like growth factor 
receptor 1 (IGFR1), and human epidermal growth factor receptor-2 (HER2) 
(Driggers & Segars 2002; Manavathi et al. 2013; Pietras & Márquez-Garbán 
2007; Stoica et al. 2003). These interactions activate multiple signal 
transduction pathways, such as MAPK/ERK and phosphoinositide 3-kinase 
(PI3K)/Akt, which are known to promote tumour angiogenesis, proliferation, 
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invasion, and metastasis (Driggers & Segars 2002; Manavathi et al. 2013; 
Pietras & Márquez-Garbán 2007; Stoica et al. 2003).  
Although aberrant ERα signalling plays a crucial role in breast cancer, there are 
also some breast cancers that develop in the absence of ER signalling. 
Therefore, breast cancer can be broadly categorised into two main subtypes: 
ERα-positive (ERα+) and ERα-negative (ERα-). 
1.3.2 ERα-positive and ERα-negative subtypes of breast cancer 
Breast tumours that are positive for ERα and/or progesterone receptor (PR; a 
biomarker of ERα activity) by immunohistochemistry (IHC) are classified as 
luminal breast cancers (Yersal & Barutca 2014). Luminal tumours represent 
approximately 65% and 80% of tumours diagnosed in premenopausal and 
postmenopausal women, respectively (Dai et al. 2016; Rakha et al. 2010). 
Women with luminal tumours have longer relapse-free and overall survival 
rates compared to those with ERα-negative tumours (Dai et al. 2016; Zhang, 
MH et al. 2014). Using gene expression profiling, luminal breast cancers were 
further divided into two molecular subgroups, luminal A and B (Sørlie et al. 
2001; Yaşar et al. 2017; Yersal & Barutca 2014). The luminal A subtype is 
characterised by higher levels of ERα, PR positivity, lack of HER2 
overexpression, and lower levels of proliferation-related genes (Szostakowska 
et al. 2019; Yersal & Barutca 2014). The luminal B subtype is ERα positive 
and either PR positive or negative and HER2 positive or negative, with high 
levels of proliferation-related genes (e.g., MYB, CCNB1, and GGH) compared 
to luminal A breast cancer (Szostakowska et al. 2019; Yaşar et al. 2017; Yersal 
& Barutca 2014). Endocrine therapies (ET) are a key treatment modality in the 
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management of ERα-positive breast cancers (Martinkovich et al. 2014). ET is a 
general term for drugs that target ERα, including aromatase inhibitors (AIs), 
selective ERα modulators (SERMs), and selective ERα down-regulators 
(SERDs) (Szostakowska et al. 2019). AIs attenuate ER signalling by 
decreasing estrogen production (Fabian 2007; Lønning 2009). SERMs 
competitively block the effect of estrogen at the receptor level, as they can 
interfere with the binding of estrogen to the ER, with interaction between ERα 
and its co-activators and/or binding of ERα to the promoter elements of its 
target genes (Szostakowska et al. 2019). For many decades, the SERM 
tamoxifen was the gold standard for treating both pre- and postmenopausal 
patients with hormone receptor-positive breast cancer and has vastly improved 
survival outcomes for those patients (Howell et al. 2004; Lønning 2009). 
However, de novo and acquired resistance to these treatments led to generation 
of a new class of endocrine therapy drugs called SERDs (Howell et al. 2004; 
Wardell et al. 2015). SERDs such as fulvestrant are competitive antagonists 
whose interaction with ER induce proteasome-dependent degradation (Howell 
et al. 2004; Wardell et al. 2015). In part, response to an ET underpins the 
greater chance of survival in women with ERα-positive disease compared to 
ERα-negative disease (Zhou, Z et al. 2014). 
ERα-negative breast cancer, which represents up to 30% of all cases, is a 
highly aggressive and heterogeneous class of breast tumours with a higher 
prevalence in younger women, and is associated with a poorer prognosis 
compared to ERα-positive breast cancer (Barcellos-Hoff 2013). ERα-negative 
breast cancer can be divided into HER2-enriched and basal-like, the latter also 
called triple negative breast cancer (TNBC) (Chen, J-Q & Russo 2009; Yersal 
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& Barutca 2014). ERα-negative/HER2-enriched tumours are characterised by 
amplification or overexpression of HER2 and can be treated with HER2-
targeting agents such as trastuzumab (Yersal & Barutca 2014). However, the 
presence of primary or acquired resistance to anti-HER2 treatments remains a 
significant challenge for ERα-negative/HER2-enriched breast cancer patients 
(Wahdan-Alaswad, Liu & Thor 2020). TNBC tumours represent 15–20% of all 
diagnosed breast cancer cases, and lack ERα, HER2 and PR expression (Chen, 
J-Q & Russo 2009). Women diagnosed with TNBC usually present with much 
more severe disease states, including  larger tumours, higher pathology grade 
and lymph node metastasis (Chen, J-Q & Russo 2009; Haffty et al. 2006). The 
absence of well-defined molecular targets means TNBC patients will not 
respond to most currently available ERα and HER-2 targeted therapies (Yao et 
al. 2017). They are mainly managed with standard chemotherapy treatment, 
which is associated with a high rate of local and systemic relapse (Chen, J-Q & 
Russo 2009; Yao et al. 2017) .  
Microarray gene expression studies have led to the discovery of the molecular 
apocrine subtype of ERα-negative breast cancer, distinguished by elevated 
androgen receptor (AR) signalling (Farmer et al. 2005). Molecular apocrine 
tumours overlap with ERα-negative/HER2-enriched tumours (Doane et al. 
2006; Farmer et al. 2005). The molecular apocrine sub-type also overlaps with 
the "Luminal-AR (LAR)" subtype of TNBC as defined in the Vanderbilt 
TNBC classification metric (Lehmann et al. 2011). Molecular apocrine 
tumours  lack the expression of ERα and PR but have high expression of AR, 
as well as genes known to be regulated by AR in prostate cancers (Farmer et al. 
2005; Lehmann et al. 2011). Preclinical reports have shown that AR likely 
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plays a role in the growth of molecular apocrine tumours (Doane et al. 2006; 
Lehmann et al. 2011; Naderi & Hughes-Davies 2008; Ni et al. 2011), 
instigating widespread interest in targeting AR in this breast cancer sub-type. 
However, the exact role of AR in clinical molecular apocrine tumours, or 
indeed, any sub-type of ERα-negative breast cancer remains unclear. The role 
of AR in breast cancer is discussed in more detail in Section 1.4.  
What is clear, is that ERα-negative tumours pose a significant therapeutic 
challenge due to the limited available molecular targets for drug development. 
Thus, there is an urgent need to develop new target therapies and therapeutic 
strategies to improve outcomes for ERα-negative breast cancer patients. The 
overarching aim in this PhD project is to test novel and distinct therapeutic 
targets for the ERα-negative subtype of breast cancer including the AR, and 
cyclin-dependent kinase 9 (CDK9), as discussed in the sections below.  
1.4 Androgen signalling in ERα-negative breast cancer. 
1.4.1 Androgen sources and synthesis in females 
Androgens are cholesterol-derived steroid hormones primarily responsible for 
the development and maintenance of masculine characteristics (Mooradian, 
Morley & Korenman 1987). Androgens are also produced in females and have 
important physiological roles that include regulation of mammary gland 
growth, precursors for estrogen production (Figure 1.3), anabolic effects, 
stimulation of bone formation, and erythropoietin production in the kidneys 
(Shahani et al. 2009; Vanderschueren & Bouillon 1995). The five major 
androgens present in the systemic circulation, listed in descending order of 
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serum concentration, include dehydroepiandrosterone sulphate (DHEAS), 
dehydroepiandrosterone (DHEA), androstenedione (A4), testosterone, and 5α-
dihydrotestosterone (DHT) (Labrie 2004). In women, androgen synthesis takes 
place primarily in the ovaries and adrenal glands but can also be synthesised in 
peripheral tissues (Greenblatt et al. 1976; Labrie 2004) (Figure 1.4). In 
premenopausal women, 25% of testosterone is produced by the ovaries, 25% 
by the adrenals, and 50% by peripheral conversion (Lobo, Kelsey & Marcus 
2000; Longcope et al. 1986). In postmenopausal women, 50% of testosterone is 
produced by the ovaries, 10% by the adrenals and 40% by peripheral 
conversion (Laughlin et al. 2000; Lobo, Kelsey & Marcus 2000). Ovaries and 
adrenal glands synthesise androgens from cholesterol through enzymatic 
conversions (Figure 1.3) and these are transported through the circulation 
bound to SHBG or albumin to reach their intended target tissues, where they 
exert tissue-specific effects (Antoniou-Tsigkos et al. 2019; Miller, Geller & 
Rosen 2006). In the cytoplasm of target tissue cells, testosterone can bind to 
the AR, or can be converted to the more potent androgen DHT, by the 
cytoplasmic enzyme 5α-reductase (Miller, Geller & Rosen 2006). In women, 
approximately 66% of total circulating testosterone is bound to SHBG, and 
alterations in the level of SHBG have a dramatic effect on the free levels of 
testosterone in serum (Bartsch et al. 1980; Botwood et al. 1995). Increased 
levels of E2 and thyroxine increase SHBG, whereas growth hormone, insulin-
like growth factor 1 (IGF-1), androgens, prolactin, and obesity suppress SHBG 
(Bartsch et al. 1980; Enriori et al. 1986; Plymate et al. 1990). 
Peripheral tissues such as adipose, breast, muscles, and liver produce 
androgens from circulating steroid precursors (Labrie et al. 2001; Labrie et al. 
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2000) (Figure 1.4). The adrenal glands mostly secrete the steroid precursors 
DHEA and DHEAS, which are converted within peripheral tissues to 
androstenedione via 3β-hydroxysteroid dehydrogenase (3β-HSD), and then to 
testosterone via 17β-HSD (Labrie 2004; Labrie et al. 2001). Androgens 
produced in peripheral tissues exert mostly local actions (intracrine) within the 
cells of synthesis, with only a minimal amount released into circulation 
(Sasano et al. 2008). Therefore, the serum levels of androgens are not 
















Figure 1.4: The classic androgen synthesis pathway, as established in the 
adrenal cortex and peripheral tissues. AIs, aromatase inhibitors; DHEA, 





1.4.2 AR structure and signalling 
The biological action of androgens is mediated through binding to the 
androgen receptor (AR), a ligand-inducible transcription factor that belongs to 
the nuclear receptor superfamily (Tilley et al. 1989).  AR is encoded by a 
single copy gene (>90 kb) located on the X chromosome at position Xq11-12 
(Brown, C et al. 1989; Tilley et al. 1989) (Figure 1.5). The coding sequence of 
AR is comprised of 8 exons, which produce a protein of approximately 917 
amino acids at a molecular weight of about 98.8 kD (Brown, C et al. 1989; 
Tilley et al. 1989) depending on the size of two polymorphic microsatellite 
regions in Exon 1 of the AR gene (Brown, C et al. 1989; Edwards et al. 1992). 
Post-translational modifications, such as phosphorylation, increase the apparent 
molecular weight of the AR (~110 kD) when analysed by SDS-polyacrylamide 
gel electrophoresis (Gioeli et al. 2002). Like other members of the nuclear 
receptor superfamily, AR exhibits a modular structure composed of three 
functional regions: amino-terminal domain (NTD), DNA binding domain 




















Figure 1.5: AR gene and protein structure. (A) Schematic overview of the 
different functional domains of the human AR.  Numbers below the bars refer 
to the amino acid residues which separate the domains starting from the N-
terminus (left) to C-terminus (right). NTD, N-terminal domain; DBD, DNA-
binding domain; LBD, ligand-binding domain; AF, activation function, TAU, 
transcription activation units. (B) The amino acid sequence of the human AR 
protein, based on NCBI accession number P10275. The diagram highlights 
sequences representing the domains by colour, NTD (green), DBD (light 




The NTD accounts for more than half of the AR protein (residues 1–555), and 
its entirety is encoded by exon one (Tan et al. 2015). The NTD contains an 
activation function (AF)-1 region that plays an important role in 
transactivation, dimerisation, and recruitment of co-regulatory proteins crucial 
for AR’s transcriptional function (Alen et al. 1999; Jenster et al. 1995; Onate et 
al. 1998; Yu, Xinzhe et al. 2020). The AF-1 of the AR is composed of two 
units, known as transcription activation units 1 and 5 (Tau-1, 102-371 and Tau-
5, 361-537) (Jenster et al. 1995). Tau-1 is crucial for the transcriptional activity 
of AR when the receptor is activated by androgens (Jenster et al. 1995). 
Although Tau-5 is less well characterised, it has been shown to be more 
important than Tau-1 when activation occurs via androgen independent 
mechanisms in androgen independent cell lines and mouse xenograft models of 
prostate cancer (Dehm et al. 2007; Metzger et al. 2003). Moreover, the first 20 
amino acids of the NTD are highly conserved across species and contain an 
FxxLF motif (where x is any amino acid) important for interactions with the 
AR LBD, termed the AR N-C interaction (Steketee et al. 2002; Yu, Xinzhe et 
al. 2020). This is a key interaction for normal receptor function, stabilising the 
bound ligand, and is crucial for AR-dependent gene regulation, since mutations 
that disrupt this interaction impair AR activity (Langley, Kemppainen & 
Wilson 1998). The AR DBD, (residues 556–623) represents a cysteine-rich 
region that is highly conserved among steroid hormone receptors (Chang, 
Kokontis & Liao 1988; Lubahn et al. 1988; Tilley et al. 1989). The DBD 
contains two zinc finger motifs, each of them consisting of four cysteine 
residues that incorporate a zinc ion (Zilliacus et al. 1995). A conserved amino 
acid motif (P-Box) within the first zinc finger directs AR DNA binding to 
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androgen response elements (AREs) that are inverted hexameric DNA half-
sites that are spaced by 3 base pairs (e.g. CCAGAACATCAAGAACAC) in the 
regulatory regions of target genes (Davey & Grossmann 2016; Zilliacus et al. 
1995). The second zinc finger, containing the D-box motif, stabilises the DNA-
bound receptor complex and mediates dimerisation of AR monomers 
(Centenera et al. 2008; Davey & Grossmann 2016; Zilliacus et al. 1995). 
Located at the carboxyl terminus of AR, the LBD (residues 666–919) mediates 
high affinity binding of AR to its natural androgenic ligands DHT and 
testosterone (Kd = 0.2-0.5nM) (Grino, Griffin & Wilson 1990; Kemppainen et 
al. 1999), as well as synthetic androgens such as R1881 (Kd = 0.6nM) and 
mibolerone (Kd = 0.53nM) (Kemppainen et al. 1999; Murthy et al. 1986). A 
ligand-dependent AF-2 function is located within the LBD (He, B et al. 1999; 
Moilanen et al. 1997). AF-2 is involved in the interaction between AR and co-
regulators containing the LxxLL motif (He, B et al. 1999), where mutation of 
this region is found to dramatically reduce ligand-dependent AR activation 
(Buchanan et al. 2001). However, unlike other steroid hormone receptors, the 
LBD of AR has a weak affinity for factors containing LxxLL motifs, and 
instead, preferentially binds to aromatic-rich motifs that are found within the 
AR NTD and AR-specific co-regulators (He, B, Kemppainen & Wilson 2000). 
The hinge region (residues 624–665) is a flexible region that connects the DBD 
with the LBD (Haelens et al. 2007). The hinge region contains a nuclear 
localisation signal (NLS) that is exposed upon ligand-induced conformational 
changes to the AR structure, and contains important sites for receptor 
phosphorylation, acetylation, and degradation (Clinckemalie et al. 2012; 
Haelens et al. 2007). 
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In the absence of its ligand, AR resides primarily in the cytoplasm of cells as 
part of a large multi-protein complex, which consists of receptor polypeptide 
and molecular chaperones including heat shock proteins, co-chaperones, and 
cytoskeletal proteins , maintaining structural integrity of the AR and keeping it 
in an inactive form (Pratt & Toft 1997) (Figure 1.6). Upon ligand binding, AR 
adopts an active conformation that facilitates the dissociation of chaperones, 
formation of N/C termini interaction, exposure of the NLS and translocation of 
AR into the nucleus (Cutress et al. 2008; Tyagi et al. 2000; van Royen et al. 
2012). Once in the nucleus, AR forms a homo-dimer (i.e. two AR proteins 
bound together) which facilitates its binding to AREs within the promoter and 
enhancer regions of AR target genes (Shaffer et al. 2004). A study by Van 
Royen et al (2012) suggests that dimerisation of the AR only occurs after 
nuclear translocation and may require prior binding to the DNA (van Royen et 
al. 2012). On the other hand, AR DNA binding events may not be limited to 
loci containing classic AREs. Previous genome-wide profiling studies have 
shown that 16-22% of AR-DNA binding sites do not contain AREs, which may 
suggest that AR tethering to other factors bound to DNA. Prior to development 
of ChIP-seq technology to profile genome-wide DNA binding patterns, it was 
thought that AR predominantly bound to the promoters of target genes. 
However, ChIP-seq studies revealed that most AR binding sites were greater 
than 10kb from the transcription start site (TSS) of target genes (Massie et al. 
2007; Wang, Q et al. 2007). Therefore, the current paradigm involves AR 
binding to enhancer sites. AR-DNA binding allows recruitment of the basal 
transcription machinery (e.g. TATA box-binding protein (TBP) and 
transcription factor IIF (TFIIF)) as well as other regulators such as CREB-
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binding protein (CBP), transcription-activated p300 and AR-binding protein 70 
(ARA70) to AR (Frønsdal et al. 1998; McEwan & Gustafsson 1997; Zhou, Z-x 
et al. 2002). AR binds to enhancer sites that are generally distant from the 
promoter, but AR at these sites interacts with gene promoters by chromatin 
looping (Wang, Q, Carroll & Brown 2005; Wu, D et al. 2011). Wang and 
colleagues showed that RNA-polymerase II tracks through a large DNA loop 
formed between AR target gene enhancers and promoters (Wang, Q, Carroll & 
Brown 2005). Transcription elongation then occurs via RNA-polymerase II to 
transcribe AR target genes (Massie et al. 2007; Wang, Q et al. 2007). After 
completion of its transcriptional function, free AR receptors are exported back 
to the cytoplasm for a new round of protein importation, activation, and gene 
transcription (Massie et al. 2007; Wang, Q et al. 2007).  
Although the aforementioned processes are considered as the canonical AR 
signalling mechanism, not all cellular responses to androgens fit within this 
genomic model, and not all require transcription mediated by AR. This is 
because ligand-transformed AR can associate with molecular substrates in the 
cytoplasm and cell membrane, triggering release of intracellular calcium and 
activation of kinases such as MAPK (ERK), protein kinase A (PKA), Akt and 
protein kinase C (PKC) (Baulieu & Robel 1995; Foradori, Weiser & Handa 
2008; Michels, G & Hoppe 2008). This mode of action is referred to as rapid, 
non-genomic signalling of AR. The non-genomic signalling by AR is 
distinguished from genomic signalling by speed, with response times being 
seconds to minutes, as opposed to genomic signalling which requires at least 
30 min (Michels, G & Hoppe 2008), indicating a lack of transcription and 
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translation from androgen-responsive genes (Boonyaratanakornkit & Edwards 






Figure 1.6: Simplified model of the AR canonical pathway in androgen target 
tissue. Testosterone (T) enters the cell and is converted by 5α-reductase into 
dihydrotestosterone (DHT). Upon steroid binding, AR undergoes a 
conformational change and releases heat-shock proteins (HSP). The AR 
translocates to the nucleus where DNA binding, and the recruitment of 
coactivators occur. Target genes are transcribed (mRNA) and translated into 
proteins (Bennett et al. 2010). 
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1.4.3 Androgen signalling in normal breast epithelial cells. 
In the luminal epithelial cells of primate mammary glands, AR protein 
expression is  high (59-75% AR positive) and remains stable during the 
menstrual cycle and early stages of pregnancy, only showing a significant 
decrease during the late stage of pregnancy and lactation (Cheng, G et al. 
2005). In contrast, the expression level of ERα is much lower (0-12.5% of 
epithelial cells are positive) and  changes dramatically during different stages 
of menstruation and pregnancy (Cheng, G et al. 2005). Similar patterns of AR 
and ERα expression are found within the normal breast epithelia of women 
without breast cancer (Hickey, T et al. 2012). Since breast epithelia have high 
expression of AR, the role of androgen signalling in regulating proliferation 
and development of normal mammary glands has been investigated in several 
studies (Forsbach et al. 2000; Hofling et al. 2007; Peters et al. 2011). 
Compelling evidence suggests that androgens normally inhibit mammary 
epithelial proliferation and breast growth (Forsbach et al. 2000; Hofling et al. 
2007; Peters et al. 2011; Zhou, J et al. 2000). Administration of testosterone to 
ovariectomised rhesus monkeys was able to inhibit E2-induced mammary cell 
proliferation (Zhou, J et al. 2000). Inhibition of androgen signalling in normal 
cycling monkeys by treatment with the AR antagonist flutamide resulted in 
more than a two-fold increase in the proliferation of mammary epithelial cells 





Similar results were obtained in mice by Peters et al. (2011),  whereby 
treatment of females at  mid-puberty (5 weeks) with DHT or flutamide altered 
mammary gland development/morphology, with stimulation of the AR 
pathway resulting in reduced ductal extension, a known estrogen-dependent 
process (Peters et al. 2011). A potential explanation for the inhibitory effect of 
androgens in intact animals is the feedback effect of androgens on the 
production of follicle stimulating hormone (FSH) and luteinizing hormone 
(LH), which in turn decreases E2 levels (Marques et al. 2018). Furthermore, 
the influence of circulating testosterone on the proliferation of breast epithelial 
cells is in part dependent upon the relative expression and activity of aromatase 
and 5α-reductase (Li, X 2010), the enzymes responsible for conversion of 
testosterone to E2 or DHT, respectively. In studies of transgenic mice with 
overexpression of the aromatase gene (AROM+), males undergo abnormal 
breast development due to excess exposure to E2, highlighting the importance 
of the estrogen/androgen balance in regulating proliferation in mammary 
epithelia. 
Observations from other studies indicate similar effects of androgens on breast 
development in humans (Forsbach et al. 2000; Hofling et al. 2007; Quigley et 
al. 1995). Androgen excess due to an adrenal tumour or hyperplasia suppresses 
normal breast development in girls, despite apparently adequate estrogen levels 
(Forsbach et al. 2000). In male patients with hypogonadism and androgen 
deficiency, gynecomastia (enlargement of breast tissue in males) is often 
observed (Quigley et al. 1995). Moreover, the effect of testosterone in 
combination with estrogen and a synthetic progestin (norethindrone) as part of 
MHT in postmenopausal women was studied by Hofling et al. (2007). While 
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the estrogen and progestin combination MHT enhanced breast epithelial cell 
proliferation, no significant changes were observed when testosterone was 
added (Hofling et al. 2007). Taken together, these studies demonstrate that in 
normal, pre- and post-menopausal breast tissue, AR activity is critical to 
counter-balance E2-induced cell proliferation, ultimately influencing normal 
glandular development. 
1.4.4 Androgens and breast cancer risk 
The association of androgen levels with risk of developing breast cancer has 
been deliberated in several studies (Kaaks, Berrino, et al. 2005; Zeleniuch-
Jacquotte, A et al. 2004). In postmenopausal women, most of the prospective 
epidemiologic studies have shown that circulating androgens are positively 
associated with increased breast cancer risk (Kaaks, Berrino, et al. 2005; 
Zeleniuch-Jacquotte, A et al. 2004). Higher levels of testosterone, DHEAS and 
androstenedione, were associated with increased breast cancer risk (Kaaks, 
Berrino, et al. 2005; Zeleniuch-Jacquotte, A et al. 2004). A pooled analysis of 
nine prospective studies, including up to 663 incident cases of breast cancer 
and 1102 controls, reported a two-fold increase in breast cancer risk between 
women in the upper versus the lower quartiles of sex steroid serum 
concentrations (estrogen and testosterone) (Key T 2002). This positive 
correlation is most likely due to the fact that circulating androgens are 
substrates for estrogen production. Indeed, Adly and Colleagues (2006) 
showed that breast cancer risk is linked only to higher serum levels of 
estrogens, independently of androgen levels (Adly et al. 2006), suggesting that 
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circulating androgen hormones might only influence breast cancer risk 
indirectly through conversion to E2 by aromatase activity (Adly et al. 2006). 
In premenopausal women, the association between androgens and breast cancer 
risk is also not so clear, with studies reporting either no association (Helzlsouer 
et al. 1992; Lee, SH et al. 1999), a positive association (Kaaks, Rinaldi, et al. 
2005; Key T 2002; Missmer et al. 2004; Zeleniuch-Jacquotte, A et al. 2004) or 
negative association (Helzlsouer et al. 1992; Lee, SH et al. 1999). A case-
control study nested within the European Prospective Investigation into Cancer 
and Nutrition (EPIC) included 370 cases of premenopausal breast cancer and 
726 individually matched controls and showed significantly higher levels of 
serum testosterone in breast cancer patients compared with controls (Kaaks, 
Berrino, et al. 2005). The same study reported that serum testosterone 
concentration was positively associated with breast cancer risk, where women 
in the highest quartile of serum testosterone had approximately 80% greater 
breast cancer risk than women in the lowest quartile (Kaaks, Berrino, et al. 
2005). The results of this study were supported by two other prospective cohort 
case studies conducted in America and Colombia (Dorgan et al. 2010; 
Zeleniuch-Jacquotte, Anne et al. 2012). Other studies on premenopausal 
women have reported an inverse relationship between levels of androgens and 
breast cancer risk (Helzlsouer et al. 1992; Lee, SH et al. 1999). A study 
compared the levels of androgens measured in urine samples from benign and 
malignant breast tumours with normal samples, and found lower androgen 
levels in breast cancer patients compared to controls (Lee, SH et al. 1999), 
indicating a protective role of androgens on the breast. The protective effect of 
androgens is further supported by clinical studies showing that male breast 
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cancer (which accounts for <1% of all breast cancers) is associated with 
deficient androgen production (Hsing et al. 1998; Thomas, DB et al. 1992). In 
contrast to the above-mentioned studies, Thomas et al (1997) and Page et al 
(2004) found no association between levels of circulating androgens and the 
risk of breast cancer  (Page et al. 2004; Thomas, HV et al. 1997) 
As outlined above, studies to date have not provided consensus on the 
association between androgens and breast cancer risk. The discrepancies in the 
reported results are likely to be attributed to limitations in the methodology 
used to measure androgens and differences in experimental conditions (e.g. 
time of samples collection, sample size, and type of fluid measured - serum 
versus urine) (McNamara, KM et al. 2014). The androgen assays (mainly 
immunoassays) used were developed mainly to measure the higher levels 
found in men and lack the sensitivity and specificity in low ranges found in 
women (Harwood & Handelsman 2009; McNamara, KM et al. 2014). 
Testosterone levels vary hourly in response to diurnal rhythm, diet, stress, and 
exercise, so a single value may be inadequate to assess true tissue exposure 
(Bui et al. 2013; Opstad & Metabolism 1992; Rothman et al. 2011). The 
sample size may also contribute to contradicting results as larger studies have 
more statistical power to detect smaller differences as significant (McNamara, 
KM et al. 2014). New studies using a more accurate and sensitive method 
(such as mass spectrometry) and an appropriate experimental design to 
measure androgens, accounting for their conversion to estrogen before 
assessing the association of circulating androgens to breast cancer risk, are 
needed. Such studies would be informative in developing a rationale for 
targeting AR in breast cancer.  
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1.4.5 Clarifying the role of androgen signalling in ERα- negative 
breast cancer  
Androgen therapy has been used historically to treat advanced breast cancer 
(Goldenberg 1964; Kennedy 1958). However, this therapeutic strategy was 
eventually phased out due to virilizing side effects (e.g. hirsutism, and 
deepening of the voice) and the advent of drugs that oppose ER signalling (e.g. 
Tamoxifen) (Lønning 2009). While anti-estrogenic therapies are effective in 
the majority of breast cancer cases, 30% of breast cancers are negative for ER 
(previously described in section 1.3.2) and cannot benefit from this treatment 
strategy (Harvell et al. 2008). The characterization of AR expression in most 
breast cancers has renewed interest in androgen therapy for this disease, 
especially since non-virilising selective AR modulators (SARMs) are now 
clinically available (Chen, F, Rodan & Schmidt 2002). The AR is expressed in 
approximately 20-50% of ERα and PR negative breast cancers, and its 
expression is correlated with a lower Nottingham grade and apocrine 
differentiation (Liu, YX, Zhang & Tang 2018; McNamara, K et al. 2013; 
Niemeier et al. 2010; Xu, M et al. 2020), but controversy over how best to 
therapeutically target AR in this disease context hampers clinical advancement 
of androgen therapy.  
In contrast to ERα-positive breast cancer in which AR independently and 
reproducibly predicts a better survival outcome (Ricciardelli et al, Clin Can 
Res, 2019), there have been no consistent findings linking AR expression to 
patient survival in ER-negative breast cancer. Where some studies reported no 
association between AR expression and patient survival (Adamo et al. 2017; 
Gonzalez et al. 2008; Hu, Rong et al. 2011; Peters et al. 2009; Sunar et al. 
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2018; Xu, M et al. 2020), other studies have shown a positive correlation with 
good prognosis and improved overall survival (Adamo et al. 2017; Agoff et al. 
2003; Guiu et al. 2018; Kucukzeybek et al. 2018; Luo et al. 2010; Ricciardelli 
et al. 2018; Witzel et al. 2013). Moreover, some studies have suggested that 
AR expression is associated with increased mortality among women with ERα-
negative tumours (Choi, JE et al. 2015; Hu, Rong et al. 2011). Park and co-
investigators (2011) have shown a trend toward poorer outcomes in AR-
positive, ERα-negative breast cancers (Park, S et al. 2011). A recent study by 
Liu et al (2018) showed that AR expression had no correlation with 
disease‑free and overall survival of patients with TNBC; rather, it predicted a 
poor survival of patients specifically with stage III TNBC in comparison with 
those at earlier stages (Liu, YX, Zhang & Tang 2018). Disparate results may be 
attributed to the vast heterogeneity of the ERα-negative subset of breast cancer 
(McNamara, KM et al. 2014). ERα-negative breast cancers show a high degree 
of tissue and molecular heterogeneity (Yersal & Barutca 2014), especially at 
the AR level, as some groups exhibit higher AR expression (molecular 
apocrine) than others (basal) (Farmer et al. 2005). Accordingly, the percentage 
of these different sub-groups in the study population may affect the results. 
Therefore, studying the association of AR with patient survival necessitates 
very large cohort numbers to determine the role of AR expression on patient 
survival in specific ERα-negative breast cancer subtypes. 
Like the discrepancy in the above-mentioned clinical studies, pre-clinical 
studies are also equivocal, indicating that AR signalling may exert proliferative 
or anti-proliferative effects in ERα-negative breast cancer cell line models 
(Birrell, S et al. 1995; Doane et al. 2006; Farmer et al. 2005; Hackenberg et al. 
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1991; Ni et al. 2011; Robinson, JL et al. 2011; Thakkar et al. 2016; Zhu, A et 
al. 2016). Targeting AR with antagonists in ERα-negative disease is considered 
a promising therapeutic strategy since preclinical data suggests that AR has 
oncogenic activity in at least a subset of ERα-negative subtypes (Birrell, S et 
al. 1995; Naderi & Hughes-Davies 2008; Ni et al. 2011; Robinson, JL et al. 
2011). However, the role of AR in ERα-negative disease is still debated.  
Discrepancies among studies are detailed below and highlight the need for a 
better understanding of AR in this disease context. To date, clinical trials of 
AR antagonists for ERα-negative disease have shown little efficacy (Bonnefoi, 
H et al. 2016; Gucalp et al. 2013; Traina et al. 2018), likely due to the lack of 
understanding the biological role of AR in this disease. This PhD project aims 
to determine the molecular mechanisms that underpin divergent AR-mediated 
growth effects in ERα-negative breast cancers to facilitate development of 
rational clinical AR target strategies.  
1.4.6 Androgens induce divergent proliferative responses in 
ERα-negative/AR-positive breast cancer models. 
Androgenic effects have been most widely studied in the molecular apocrine 
subgroup of ERα-negative breast cancer, which is characterised by high levels 
of AR and high expression of genes known to be regulated by AR signalling in 
prostate cancer cells (Doane et al. 2006; Farmer et al. 2005). A sub-set of these 
genes are also ERα regulated genes in ERα-positive breast cancers (Doane et 




The most commonly used cell line model of molecular apocrine breast cancer 
is MDA-MB-453, shown to be growth stimulated by DHT long before 
identification of this breast cancer subtype (Bentel et al. 1999; Birrell, S et al. 
1995). Subsequent studies using this cell line in vitro (Cochrane et al. 2014; 
Doane et al. 2006; Naderi & Hughes-Davies 2008; Ni et al. 2011) and in vivo 
(Cochrane et al. 2014; Huang, R et al. 2017; Ni et al. 2011) support the concept 
that AR signalling may have an oncogenic role in molecular apocrine breast 
cancers. Similarly, androgens have been shown to increase the in vitro growth 
of other, less commonly used cell line models of this disease, including HCC-
202, SUM190, and SUM185PE (Naderi & Hughes-Davies 2008; Ni et al. 
2011). Consistent with these findings, blocking AR action by treatment with 
AR antagonists (e.g. bicalutamide or enzalutamide) abolished the in vitro 
growth stimulatory effect of natural and synthetic AR ligands in MDA-MB-
453 and SUM185PE cells (Cochrane et al. 2014; Doane et al. 2006; Lehmann 
et al. 2011; Naderi, Chia & Liu 2011) and decreased in vivo  growth of cell line 
xenografts (Huang, R et al. 2017; Lehmann et al. 2011; Naderi, Chia & Liu 
2011; Speers et al. 2017). In contrast to these findings, a study by Wang et al. 
(2011) showed that DHT inhibits proliferation of MDA-MB-453 cells, whereas 
knockdown of AR by siRNA promoted cell growth (Wang, Y et al. 2011). The 
different proliferative outcomes in this study compared to the others could be 
attributed to their differences in experimental conditions that might impact on 
AR activity, such as cell culture conditions (particularly medium composition 
and fetal bovine serum type), nature of the AR ligand used, and the time and 
dosing of treatment schedules. However, due to insufficient methodology 
reporting by Wang et al (2011), determining the reasons for this discrepancy is 
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problematic. Despite this, the anti-proliferative effect of AR signalling in the 
MDA-MB-453 cells is supported by other preclinical data demonstrating that 
the androgenic progestin medroxyprogesterone acetate (MPA) has high affinity 
for AR and inhibits cell proliferation in an AR dependent manner (Bentel et al. 
1999). MPA is a synthetic progestin once frequently used as a second line 
hormonal therapy for the treatment of tamoxifen-resistant metastatic breast 
cancer. Although MPA was thought to exert its therapeutic effect by acting 
exclusively through the PR, clinical response to MPA was correlated to AR 
expression in the tumours and non-responders were shown to have inactivating 
AR mutations (Birrell, SN et al. 1995). Hence, MPA has clinical relevance as 
an AR agonist in breast cancer cells. (Birrell, SN et al. 1995). Collectively, 
these findings suggest that AR-mediated proliferative effects in the MDA-MB-
453 model of molecular apocrine breast cancer are context-dependent. There 
are also inconsistencies in the literature concerning the proliferative effect of 
AR signalling in other ERα-negative breast cancer cell lines. Proliferation of 
MFM-223 and CAL-148 cell lines, which are both genetically similar to MDA-
MB-453 as they transcriptionally cluster with this cell line due to high 
expression of AR and known AR target genes, is inhibited by androgens in 
vitro (Hackenberg et al. 1993; Hackenberg et al. 1991; Thakkar et al. 2016). 
Similarly, a recent study showed that activation of AR signalling via DHT or 
the androgenic progestin D-Norgestrel inhibits growth of MFM-223 xenograft 
tumours (Thorek et al. 2019).  
The divergent proliferative effects of androgens on different cell line models of 
ERα-negative/AR-positive breast cancer likely reflects the inherent 
heterogeneity of the disease and suggests that not all will benefit from therapies 
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that inhibit AR activity. This is further supported by the variable results of 
clinical trials involving androgen deprivation therapy (ADT) in women with 
molecular apocrine breast cancers (Bonnefoi, H et al. 2016; Gucalp et al. 2013; 
Kumar et al. 2017; Traina et al. 2018). These clinical studies have given 
inconclusive results, where about 25% of patients showed clinical benefit, 
including some prolonged responses, but most did not (Venema et al. 2019). 
Moreover, AR expression did not predict response in these trials. This lack of 
efficacy may be explained partly by problems with patient selection, but a 
more fundamental problem is a lack of understanding around the mechanistic 
basis of AR signalling in different ERα-negative breast cancer contexts. Based 
on all the described data, we can say that AR expression alone is not sufficient 
to identify patients suitable for AR-targeting therapies, and characterisation of 
additional markers of favourable response to these therapies is required. 
The different AR-mediated growth effects observed in the molecular apocrine 
cell lines (as described above) might be attributed to disparities in the 
expression profile of AR co-regulatory proteins. Considerable evidence from 
prostate cancer cell lines and clinical studies indicates that altered expression 
of AR co-regulators that either promote or repress target gene expression can 
modulate cellular responses to androgens or non-androgenic steroids (Chmelar 
et al. 2007; Lonergan & Tindall 2011; Wasmuth et al. 2020). Although breast 
and prostate cancer arise in separate organs, they are both endocrine driven 
cancers and have many parallels in their biological characteristics (Risbridger 
et al. 2010). Indeed, AR action in prostate cancer is similar to that observed in 
some models of ER-/AR+ breast cancer, and it is therefore reasonable to argue 
that AR co-regulatory proteins could have a similarly important role in 
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determining AR action in ER-/AR+ breast cancers. The MDA-MB-453, 
HCC202, SUM190 cell lines could express different AR co-regulators, or 
differentially interact with the same AR co-regulators, compared to other 
molecular apocrine cell lines, potentially mediating oncogenic activity of AR 
in those cells. Altered growth responses to androgens might also be influenced 
by the mutational status of AR. The AR gene in MDA-MB-453 cells contains a 
G-T transversion in exon 7. This results in an AR protein variant consisting of 
a glutamine to histidine substitution at amino acid 865 (Q865H) of the ligand 
binding domain (Moore et al. 2012a). Compared to wild type AR, mutant AR 
decreases sensitivity to DHT and alters the growth response of MDA-MB-453 
cells to androgens (Moore et al. 2012a).  Molecular modelling of this mutant-
AR protein shows conformational changes likely to influence the structure of 
the ligand binding pocket, which affects AR function (Moore et al. 2012a). 
Therefore, mutant variants of the AR could alter growth responses to androgen 
by recruiting a discrete subset of mutant-AR coregulators that mediate AR 
oncogenic effects. To date, this line of investigation has not been pursued.
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Table1.1: Effect of AR targeting on proliferation of ERα-negative breast cancer cell lines in vitro. 
 
Citation Cell line Medium 
Type of 
FBS 



















0.1-10 nM 6-18 ↑* 
 
 
(Bentel et al. 
1999) 
DMEM/F12 DCC-FBS MPA 100nM 12 ↓* 
 
 











DMEM DCC-FBS Testosterone 1µM 4 ↑* 
 
 
(Ni et al. 
2011) 
DMEM DCC-FBS DHT 10nM 5 ↑* 
 
 
(Wang, Y et 
al. 2011) 





FBS DHT 10nM 10 ↑* 
 
 




DCC-FBS DHT 10 nM 3 NS* ND 
(Ni et al. 
2011) 
HCC-202 RPMI DCC-FBS DHT 10nM 7 ↑* ND 
(Ni et al. 
2011) 










et al. 1993) 
MFM-223 
MEM DCC-FBS DHT 0.1 &10 nM 7 ↓* 
 
 
(Thakkar et al. 
2016) 
MEM DCC-FBS DHT/ Enobosarm 
10nM / 100 
nM 
8-10 ↓* ND 
Thakkar et al. 
2016) 
CAL-148 MEM DCC-FBS DHT/ Enobosarm 
10nM / 100 
nM 
8-10 ↓* ND 
AR antagonist effect 
Citation Cell line Medium 
Type of 
FBS 
















FBS Hydroxyflutamide 5-30µM 2 ↓* 
ND 
 
(Speers et al. 
2017) 
RPMI FBS Enzalutamide 0.1 &1 µM 6 ↓* 
(Naderi, Chia 
& Liu 2011) 
HCC-202 RPMI ND Hydroxyflutamide 20-100µM 2 ↓* 
(Speers et al. 
2017) 
SUM-185PE ND ND Enzalutamide 0.1 &1 µM 6 ↓* 
(Speers et al. 
2017) 
ACC-422 MEM FBS Enzalutamide 0.1 &1 µM 6 ↓* 
(Speers et al. 
2017) 
ACC-460 ND ND Enzalutamide 0.1 &1 µM 6 ↓* 
 
(DCC-FBS) Dextran coated charcoal fetal bovine serum                             Growth assay      
(NS) no significant change in baseline proliferation                                   * Cytotoxicity assays (MTT & MTS) 
(ND) Not determined                                                                                   * Cell counting 

























             (NS) no significant change in baseline proliferation 
             (ND) Not determined


















1.5 mg 60-day 
release pellet 
~35 day ↑  





49 day ↑  





12.5 mg 60-day 
release pellet 
65 days ↓ ND 
(Naderi, Chia 







30 days NS 
ND 
(Speers et al. 
2017) 
Enzalutamide 10 mg/kg/day 45 days 
 
↓ 
(Huang, R et 
al. 2017) 





Bicalutamide 100 mg/kg/day 21 day ↓ 
(Lehmann et 
al. 2011) 
CAL-148 Bicalutamide 100 mg/kg/day 21 day ↓ 
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1.4.7 AR co-regulatory proteins 
Over 300 proteins have been identified as AR-interacting co-regulators that can 
influence transcription of AR target genes either positively (co-activators) or 
negatively (co-repressors) (Figure 1.7) (Chmelar et al. 2007; DePriest et al. 
2016; Heemers & Tindall 2007; Heinlein & Chang 2002; van de Wijngaart et 
al. 2012). AR co-regulators have been extensively studied in the context of 
prostate cancer. Based on their functional characteristics, co-regulators are 
broadly categorised into two main types. Type I co-regulators function 
primarily with AR at the promoters of target genes to facilitate DNA 
occupancy, chromatin remodelling, histone modifications, as well as 
recruitment of the basal transcriptional machinery (Aarnisalo, Palvimo & Jänne 
1998; Lemon, Tjian & development 2000; Marshall et al. 2003). Examples of 
this type of co-regulator are p160 coactivators, cAMP-response element-
binding protein (CREB)-binding protein (CBP)/p300, and the SWI/SNF 
chromatin remodelling complex (Aarnisalo, Palvimo & Jänne 1998; Bevan et 
al. 1999; Marshall et al. 2003). The p160 family of co-regulators consists of 3 
160‐kDa proteins, namely steroid receptor coactivator 1 (SRC1); nuclear 
receptor coactivator 2 (NCoA-2) and its mouse homolog glucocorticoid 
receptor interacting protein 1 (GRIP1); and steroid receptor coactivator-3 
(SRC-3) (Montell 2003; Zhou, H-J et al. 2005). The p160 coactivators 
influence AR transactivation capacity directly via their intrinsic histone 
acetyltransferase (HAT) activity, by which they are able to add an acetyl group 
to the lysine residues of histones, leading to a more open chromatin structure 
that is more accessible to the transcriptional machinery (Aarnisalo, Palvimo & 
Jänne 1998; Ogryzko et al. 1996; Spencer et al. 1997). P160 coactivators also 
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function as bridging factors to recruit secondary coactivators that also possess 
chromatin remodelling and HAT capabilities, such as (CBP)/p300 and pCAF, 
or protein methyltransferase activity like CARM1 or PRMT1, and basal 
transcription factors, TFIIB and TBP (Aarnisalo, Palvimo & Jänne 1998; 
Chakravarti et al. 1996; Stallcup et al. 2003). Ablation of SRC-1 in androgen-
dependent LNCaP prostate cancer cells represses activation of AR target genes 
and reduces AR-dependent cellular proliferation (Agoulnik et al. 2005). 
NCoA-2 amplification is commonly observed in prostate cancer and may 
sensitize AR to be activated by low levels of androgen (Taylor et al. 2010; 
Zhou, XE et al. 2010). SRC-3 is a known AR co-activator in prostate cancer 
(Zhou, XE et al. 2010), and increased SRC-3 expression is associated with a 
more aggressive phenotype and worse prognosis (Gnanapragasam et al. 2001; 
Zhou, H-J et al. 2005). The SWI/SNF chromatin remodelling complex 
regulates activity of transcription factors generally by re-organising chromatin 
structure through either facilitating nucleosome condensation (which induces 
transcriptional repression) or nucleosome dispersion (assisting in 
transcriptional activation) (Montecino et al. 2007). A study by Marshall et al 
(2003) reported that complete ligand-dependent activation of two AR target 
genes, KLK3 and probasin, requires SWI/SNF function (Marshall et al. 2003).  
Type II co-regulators include molecular chaperones that coordinate AR 
maturation and movement, as well as coordinators of transcription (Chmelar et 
al. 2007). Examples of type II co-regulators are androgen receptor associated 
protein 70 (ARA70), ARA55, melanoma antigen gene protein (MAGE-11), 
supervillain, gelsolin (GSN), and the TRAP-mediator complex (Chmelar et al. 
2007). ARA70 has been shown to enhance AR transcriptional activity while 
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only slightly enhancing the transcriptional activity of other steroid receptors 
(i.e., glucocorticoid, progesterone and estrogen receptors) (Yeh, S & Chang 
1996). ARA70 enhanced AR transcriptional activity by ten-fold in the presence 
of 10-10 M DHT or 10-9 M testosterone in prostate cancer cells (Yeh, S & 
Chang 1996). ARA55 binds to the AR-LBD in a hormone‐dependent manner 
through its C‐terminal LIM domains, and results in increased AR activity 
(Fujimoto et al. 1999). ARA55 mRNA expression is lower in normal prostate 
tissue compared with adjacent malignant tissue, and in hormone refractory 
prostate cancer compared with untreated tumours (Mestayer et al. 2003). High 
ARA55 expression has been associated with shorter recurrence free survival 
and overall survival in hormone refractory prostate cancer patients (Miyoshi et 
al. 2003). MAGE-11 binds the AR N-terminal FxxLF motif that mediates the 
androgen-dependent N/C interaction with AF2 in the AR LBD (Bai et al. 
2005). MAGE-11 forms a stable complex with the ligand-free AR that results 
in increased AR stability, and in the presence of the DHT  it competes with the 
N/C interaction, thereby increasing the exposure of the LBD coactivator 
groove to the recruitment and activation by other coactivators (Bai et al. 2005). 
AR activity is also enhanced by cytoskeletal proteins, such as supervillin and 
GSN, which regulate AR trafficking into the nucleus (Nishimura et al. 2003; 
Ting et al. 2002). Overexpression of GSN enhances AR transcriptional activity 
in the presence of either androgen or the AR antagonist flutamide (Nishimura 
et al. 2003). The TRAP-mediator complex consists of over 12 polypeptides and 
is recruited to AR in a ligand-dependent manner via a 220kDa component, 
referred to as PBP, that contains two alternatively utilised LxxLL NR 
interaction motifs (Wang, Q et al. 2002; Zhu, Y et al. 1997). The TRAP-
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mediator complex enhances AR transcriptional activity by recruiting the RNA 
polymerase II holoenzyme and core transcription factors to the promoter 
(Wang, Q et al. 2002; Zhu, Y et al. 1997). A recent study by our group 
identified a new AR coregulator, Grainyhead Like Transcription Factor 2 
(GRHL2) (Paltoglou et al. 2017). GRHL2 mRNA level is amplified in primary 
and metastatic tissues of prostate cancer and elevated in malignant compared to 
non-malignant prostate tissues (Paltoglou et al. 2017). The same study showed 
that GRHL2 is important to maintain AR expression in many prostate cancer 
models, and to enhance AR transcription activity, and is co-located with AR at 
specific sites on chromatin to regulate genes relevant to prostate cancer 
progression (Paltoglou et al. 2017). 
Besides co-activators, AR can also recruit co-repressors. Corepressors can 
inhibit transtractional activity of AR in different ways, such as inhibition of  
AR DNA binding or nuclear translocation, recruitment of histone deacetylases, 
or interrupting  the interaction between AR and its co-activators (Chmelar et al. 
2007). Well characterised AR corepressors are the nuclear receptor corepressor 
(NCoR1) and the silencing mediator of retinoid and thyroid hormone receptor 
(SMRT/NCoR2) (Wang, L, Hsu & Chang 2005). NCOR1 and SMRT interact 
directly with AR in the absence or presence of agonist/antagonist (Wang, L, 
Hsu & Chang 2005). In addition to the recruitment of histone deacetylases 
(HDACs), NCOR1 and SMRT may repress AR transactivation through other 
mechanisms, such as inhibition of the AR N/C interaction or competition with 
the key coactivators, including the p160 family, for the same AR binding 
surfaces (Alland et al. 1997; Berrevoets et al. 2004; Cheng, S et al. 2002; Choi, 
KC & Yoon 2006; Liao et al. 2003). Other AR corepressors, such as cyclin D1, 
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LCoR and Glycogen Synthase Kinase 3 β (GSK3β) have also been identified 
(Burd, Morey & Knudsen 2006). The C-terminal domain of cyclin D1 binds to 
the hinge region of AR in a hormone‐dependent manner, and results in 
decreased AR activity (Coqueret 2002; Knudsen, Cavenee & Arden 1999). 
Cyclin D1-mediated inhibition of AR may result from its capacity to inhibit the 
association between coactivator (CBP)/p300 and the AR, as both cyclin D1 and 
the AR can bind to the same domains of (CBP)/p300 (Knudsen, Cavenee & 
Arden 1999; Reutens et al. 2001). LCoR (Ligand Dependent Nuclear Receptor 
Corepressor) interacts with AR and is recruited to chromatin in an androgen-
induced manner (Asim et al. 2011). Overexpression of LCoR in prostate cancer 
cell lines repressed AR activation by the natural agonist DHT and the anti-
androgen cyproterone acetate (CPA) (Asim et al. 2011). The protein expression 
level of LCOR is found to be lower in human prostate carcinoma cell lines 
such as LNCaP, C2-4B, 22RV1, and PC3 compared with the RWPE1 cell line, 
a non-tumorigenic, normal prostate epithelial model (Asim et al. 2011). GSK3β 
is a serine/threonine protein kinase that phosphorylates a broad range of 
substrates, including transcription factors such as C-MYC and c-Jun 
(Rogatsky, Waase & Garabedian 1998; Sears et al. 2000). It has been shown 
that GSK3β can phosphorylate the AR N-terminus and thereby suppress AR 
transactivation (Wang, L et al. 2004).   
Collectively, these studies show that AR relies on functional and structural 
interactions with multiple co-regulatory proteins to ensure transcription of its 
target genes and highlight the fact that most of these studies were conducted in 
prostate cancer. Very little is known about co-regulators of AR in breast cancer 
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in general and in ERα-negative /AR positive breast cancer in particular. 






Figure 1.7: Co-regulator complexes in AR-mediated transcription. Coactivator 
complexes include factors involved in chromatin remodeling (SWI/SNF), 
histone modification (CBP/SRC-1/p/CAF) and recruitment of core 
transcription factors (TRAP/DRIP/ARC). Corepressor complexes include 
factors that (A) inhibit AR DNA binding or nuclear translocation, (B) recruit 
histone deacetylases, and (C) interrupt the interaction between AR and its 




1.4.8 Molecular mechanisms implicated as mediators of 
divergent AR activity in ERα- /AR+ breast cancer. 
In addition to AR co-regulators, pioneer factors that collaborate with AR are 
also important for androgen responsive gene expression. FOXA1, a member of 
the forkhead family of transcription factors, is considered a ‘pioneer factor’ 
because it is able to bind to regions on the DNA that have compacted 
chromatin, opening it up for other transcription factors to access DNA (Zaret & 
Carroll 2011). For example, FOXA1 is required for ERα to bind chromatin in 
ERα-positive breast cancers (Hurtado et al. 2011) and is a major regulator of 
AR chromatin binding in prostate cancer (Mirosevich et al. 2006; Robinson & 
Carroll 2012) as well as the ERα-negative MDA-MB-453 cell line model of 
molecular apocrine breast cancer (Ni et al. 2011; Robinson, JL et al. 2011). AR 
activation in MDA-MB-453 cells stimulates a FOXA1-dependent AR 
transcriptional program that is similar to transcriptional programs associated 
with ERα agonist activity in ERα positive breast cancer cell lines (Robinson, 
JL et al. 2011). Loss of FOXA1 in MDA-MB-453 cells in vitro decreased 
colony formation and blocked androgenic induction of the oncogenic 
transcription factor MYC (Robinson, JL et al. 2011). In the absence of AR 
activation in ERα-negative breast cancer cell lines, transcription factor 7 like 2 
(TCF7L2) physically interacts with FOXA1 on DNA to mediate transcriptional 
repression of specific AR target genes, including MYC (Ni et al. 2013). Upon 
DHT stimulation, AR replaces TCF7L2 in the FOXA1 complex, leading to 
transcriptional upregulation of MYC (Ni et al. 2013).  
AR signalling can also crosstalk with other molecules that have been suggested 
as potential biological therapeutic targets in breast cancer (Chia et al. 2011; 
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Naderi, Chia & Liu 2011; Ni et al. 2011). Several studies have shown crosstalk 
between AR and HER2 signaling in molecular apocrine breast cancer cells 
(Chia et al. 2011; Ni et al. 2011) and HER2 amplification is commonly 
reported in molecular apocrine breast cancers (Farmer et al. 2005; Sanga et al. 
2009). In molecular apocrine tumours without HER2 amplification, activating 
mutations are found in HER2 in 9% of cases, suggesting that activation of the 
HER2 pathway may be a universal feature of this subtype (Jiang, Y-Z et al. 
2019). In molecular apocrine disease, AR activation induces extracellular 
signal-regulated kinase (ERK) phosphorylation and kinase activation through a 
HER2-dependent pathway (Chia et al. 2011). This study by Naderi and 
colleagues showed that the AR-mediated induction of ERK requires HER2, 
and AR activity, in turn, regulates HER2 expression as an AR target gene 
(Chia et al. 2011). A concurrent study by Ni and colleagues added to this 
mechanistic insight by demonstrating androgen-dependent stimulation of 
wingless-type (Wnt)/β-catenin and HER2 oncogenic signalling pathways by 
transcriptional up-regulation of the canonical Wnt ligand WNT7B and HER3 
(Ni et al. 2011). Wnt signalling is required for normal development of the 
mammary gland (Turashvili et al. 2006), and high expression of WNT7B has 
been reported in approximately 10% of breast cancer cases (Huguet et al. 
1994). The canonical Wnt pathway involves the binding of Wnt proteins to the 
cell surface and inactivation of glycogen synthase kinase 3β (GSK-3β), which 
phosphorylates the cell adhesion molecule β-catenin (Lange et al. 2007; Wang, 
Zhishan et al. 2005). Hypo-phosphorylated β-catenin translocates to the 
nucleus, where it binds to transcription factors of the LEF/TCF family and 
activates downstream target genes (Wang, Zhishan et al. 2005). In the 
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molecular apocrine cell lines MDA-MB-453 and SUM185PE, ligand-
dependent activation of AR induces WNT7B expression, leading to activated 
nuclear translocation of β-catenin (Ni et al. 2011). This in turn leads to the 
direct interaction of β-catenin with AR, which induces expression of HER3, an 
activating binding partner of HER2 (Ni et al. 2011). Inhibition of AR, Wnt/β-
catenin, or HER2 signalling pathways attenuates growth of MDA-MB-453 and 
SUM185PE cells (Ni et al. 2011). These findings were further supported by in 
vivo results showing that treatment with the AR antagonist bicalutamide 
inhibited DHT-stimulated growth of MDA-MB-453 xenografts, diminished 
activation of HER3, and induced apoptosis (Ni et al. 2011).  
The significance of HER3 in HER2 positive breast cancer is well known for its 
ability to form heterodimers with HER2 to upregulate the PI3K/AKT pathway 
(Ni et al. 2013). This is interesting since in MDA-MB-453 cells, the 
PI3K/AKT pathway enhances transcriptional activity of oncogenic MYC via 
phosphorylation and degradation of MAD1, disrupting the MAD1-MAX 
complex and increasing levels of MYC/MAX heterodimers (Ni et al. 2013). In 
contrast to these findings, Wang et al. (2011) found that in MDA-MB-453 
cells, DHT up-regulated expression of the tumour suppressor gene PTEN, via 
AR binding to an androgen-responsive element in the PTEN upstream 
promoter (Wang, Y et al. 2011). While induction of this critical tumour 
suppressor gene through AR activation is consistent with the anti-proliferative 




The precise mechanisms by which androgenic stimulation may inhibit 
proliferation of some molecular apocrine cell lines but promote the 
proliferation of others are not clearly understood. The studies described above 
support the concept that AR interacting proteins are critically important 
determinants of AR action in ERα-negative breast cancer. With the advent of 
new technology and development of contemporary models of breast cancer, 
which I will describe in chapter three, this PhD project provides the perfect 
opportunity to better define how AR acts in ERα-negative/AR positive breast 
cancer. Understanding the intricacies of AR signalling will better inform AR 
targeting strategies for treatment of ERα-negative breast cancer and could lead 
to discovery of novel biomarkers of therapeutic response.  
1.5 Targeting cyclin dependent kinase 9 (CDK9) for treatment of ERα- 
negative breast cancer. 
1.5.1 Overview of CDK proteins 
At most, 50% of ERα-negative breast tumours express the AR, and of these, 
not all are expected to respond to AR-targeted therapies (Narayanan & Dalton 
2016). Additional therapeutic targets are essential to improve outcomes for 
ERα-negative breast cancer patients, independent of their AR status.  Targeting 
cyclin-dependent kinase 9 (CDK9) is emerging as a potential treatment strategy 
for ERα-negative breast cancer patients (Sonawane et al. 2016). As a 
transcriptional regulator, CDK9 can enhance growth of multiple cancers, 
including ERα-negative breast cancer, by promoting sustained transcription of 
normally short-lived oncogenic and anti-apoptotic gene transcripts (i.e., C-
MYC, BCL2, MCL1, and XIAP), leading to abnormally high expression of their 
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associated proteins (Franco et al. 2018; McLaughlin et al. 2017; Morales & 
Giordano 2016; Polier et al. 2011; Rajput et al. 2016). CDK9 is a member of 
the broad CDK family, which consists of conserved serine (Ser) /threonine 
(Thr) protein kinases (Sonawane et al. 2016). These protein kinases mediate 
transfer of a  phosphoryl group (–PO3) from adenosine triphosphate (ATP) to 
hydroxyl groups in the side chains of Ser or Thr of the substrate (Sonawane et 
al. 2016). CDK’s activate their target substrates upon binding to a regulatory 
cyclin subunit bound to that substrate (Shapiro 2006). Cyclins are a group of 
proteins generally characterised by having an oscillating (cyclic) pattern of 
expression and a cyclin box motif (a domain of approximately 100 amino acid 
residues) that forms a stack of five α-helices (Pines 1995).  
CDK/Cyclin complexes were first identified in starfish, xenopus and yeast 
species and cloned in the 1970s–1980s as gene products involved in regulation 
of the cell cycle (Hartwell et al. 1974; Labbe et al. 1988; Labbe et al. 1989; 
Lee, MG & Nurse 1987; Lohka, Hayes & Maller 1988). These pioneering 
studies and other follow-up studies showed that CDK/Cyclin complexes 
represent bona fide regulators of cell growth and division through 
phosphorylation of substrates involved in DNA replication, chromatin 
condensation, assembly of the mitotic spindle and disassembly of the nuclear 
envelope (Elledge & Spottswood 1991; Hartwell et al. 1974; Labbe et al. 1988; 
Labbe et al. 1989; Lee, MG & Nurse 1987; Lohka, Hayes & Maller 1988; 
Matsushime et al. 1992; Meyerson et al. 1992; Nurse 1990). To date, twenty 
different CDKs have been discovered in mammalian cells and about the same 
number of cyclins (Table 1.3) (Malumbres & Barbacid 2005). Notably, not all 
of them are regulators of cell cycle progression (Lolli 2010). Biological 
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research has revealed the existence of a transcriptional class of CDKs (CDK 7, 
9, 10, 12, and 19), which have a pivotal role in controlling transcription, since 
they determine the initiation and elongation of mRNA transcripts by 
phosphorylating the C-terminal domain (CTD) of RNA polymerase II 
(RNAPII) (Cao, L et al. 2014; Elmlund et al. 2006; Malumbres & Barbacid 
2005; Nigg 1996; Tassan et al. 1995; Wang, S & Fischer 2008). A more 
detailed review of the bona fide cell cycle and transcriptional CDKs is 














Table 1.3: Cyclin dependent kinases with corresponding cyclins and their main 
function. Adapted from (García-Reyes et al. 2018). 












Cell cycle (G1–S) 



















CDK5 Cyclin I Senescence CDK15 Unknown Unknown 









CDK17 Unknown Unknown 













CDK19 Cyclin C 
Transcription 
regulation 
CDK10 Cyclin M 
Transcription 
regulation 
CDK20 Unknown Unknown 
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1.5.2 Structure and regulation of CDKs 
The structure of CDKs is conserved throughout this family of kinases (Echalier 
et al. 2010) and exhibits the classical bi-lobal structure, with an amino-terminal 
lobe (N-lobe), carboxy-terminal lobe (C-lobe) with the ATP-binding site 
(active or catalytic site) sandwiched in-between (Endicott, Noble & Johnson 
2012; Wood & Endicott 2018). The N-lobe is composed mainly of β-sheets, 
containing five anti-parallel β-strands, and one conserved α-helix (also called 
C-helix) (Endicott, Noble & Johnson 2012; Wood & Endicott 2018). The C-
helix contains the  cyclin consensus sequence, which is important for cyclin 
binding (Echalier et al. 2010; Lim & Kaldis 2013). The C-lobe is rich in α-
helices and contains the activation segment (also referred to as the T-loop) 
(Lolli 2010). Full activation of CDKs requires the phosphorylation of highly 
conserved threonine residues in the T-loop region, mainly via CDK-activating 
kinase (CAK) (Endicott, Noble & Johnson 2012). Close to the activation 
segment is a functionally opposite segment, the inhibitory loop, named the 
glycine-rich loop (G-loop) because of its primary sequence that includes three 
highly conserved glycine residues (Gu, Rosenblatt & Morgan 1992). The G-
loop includes two possible target sites for drug inhibition, Thr14 and Y15 
(Where Y is any amino acid; examples of Y: Tyrosine in CDK2, alanine in 
CDK4, and phenylalanine in CDK9) (Gu, Rosenblatt & Morgan 1992). The 
two terminal domains are connected through a single peptide strand which acts 
as a hinge linker to ensure that the two lobes can rotate with respect to each 




Activity of CDKs is tightly controlled by cyclin binding, phosphorylation, and 
binding of proteins that directly inhibit CDK action (Lim & Kaldis 2013; 
Pavletich 1999). CDK protein levels are constant throughout the cell cycle, 
whereas levels of cyclins rise and fall depending upon the stage of the cell 
cycle, thus resulting in the periodical activation of CDKs (Lim & Kaldis 2013). 
Without cyclin, the T-loop blocks the entrance of the catalytic cleft (which 
contains the ATP and substrate binding sites) and prevents  kinase activity 
(Endicott, Noble & Johnson 2012). Furthermore, within the inactive CDK, 
several amino acids at the active sites are incorrectly positioned, so that 
phosphates of ATP are not ideally oriented for an optimal kinase reaction 
(Crosby 2007). Cyclin binding induces a conformational change and positional 
switch of the T-loop, which opens the catalytic cleft, affects the orientation of 
the putative substrate binding site of CDKs, and leads to appropriate exposure 
of T-loop Thr residues (e.g. Thr160 in CDK2 and Thr-186 in CDK9) for 
phosphorylation (Gu, Rosenblatt & Morgan 1992; Nekhai, Petukhov & Breuer 
2014). Subsequent phosphorylation of Thr residues induces further 
conformational changes in the T-loop and C-terminal domain, which stabilises 
the substrate binding site, enabling the kinase to be a fully functional enzyme 
(Nekhai, Petukhov & Breuer 2014).  
Phosphorylation of CDKs can also negatively regulate kinase activity (Crosby 
2007). Phosphorylation of Thr14 and Y15 residues of the G-loop results in the 
inhibition of CDK activity, even in the presence of CAK (Gu, Rosenblatt & 
Morgan 1992; Malumbres & Barbacid 2005; Nekhai, Petukhov & Breuer 
2014). Wee1 and Myt1 have been identified as the kinases responsible for the 
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phosphorylation of the inhibitory sites (Malumbres & Barbacid 2005; Pavletich 
1999). 
CDK activity may also be regulated by CDK inhibitors (CDKi), which form 
stable complexes with the CDK prior to cyclin binding, preventing it from 
binding with its cyclin partner (Lim & Kaldis 2013). Two distinct families of 
CDKi have been identified, the INK4 (Inhibitors of CDK4) family and the 
Cip/Kip (CDK interacting protein/Kinase inhibitory protein) family (Echalier 
et al. 2010; Pavletich 1999). The INK4 family includes p15INK4b, p16INK4a, 
p18INK4c, p19INK4d, which specifically inactivate CDK4 and CDK6 (Pavletich 
1999). The second family of inhibitors, the Cip/Kip family, includes p21Cip1, 
p27Kip1, and p57Kip2, pan-inhibitors that can inactivate any CDK family 
member (Borriello et al. 2011; Ma et al. 2010) 
1.5.3 Cell cycle CDKs 
Uncontrolled proliferation mediated by dysregulation of many cell cycle 
pathways is extremely common in cancer cells, and thus, regulators of the cell 
cycle have long been considered attractive targets for cancer therapy (Diaz-
Padilla, Siu & Duran 2009; Hanahan & Weinberg 2011; Thu et al. 2018). The 
eukaryotic cell cycle contains two distinct stages: interphase and mitosis 
(Hartwell & Kastan 1994). Interphase is further divided into three sub-phases, 
gap 1 (G1), DNA synthesis (S), and gap 2 (G2) (Alberts et al. 2018; Bertoli, 
Skotheim & De Bruin 2013). During the G1-phase, the cell doubles in size and 
accumulates proteins and enzymes required for the S-phase (Bertoli, Skotheim 
& De Bruin 2013; Hartwell & Kastan 1994). During S-phase, DNA is 
duplicated, histones are synthesised, and the cell moves into the G2-phase 
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(Bertoli, Skotheim & De Bruin 2013; Hartwell & Kastan 1994). In G2-phase, 
protein synthesis continues, microtubules are assembled, any errors in DNA 
replication are rectified and the cell then enters mitosis (Hartwell & Kastan 
1994). In the mitotic phase, chromosomes are segregated and the cell divides, 
resulting in formation of two daughter cells each having a nucleus containing 
the same number of chromosomes as the mother cell (Hartwell & Kastan 
1994). Cell cycle CDKs (CDK 1-6) govern cell cycle transitions and eventual 
cell division (Ding et al. 2020; Thu et al. 2018) (Figure 1.8). When cells are 
stimulated to replicate, expression of D-type cyclins (D1, D2 and D3) is 
induced, and the resulting proteins associate with and activate their partner 
kinases CDK4 and 6, which were kept in an inactive state by interaction with 
INK4 family members (p16INK4A, p15INK4B, p18INK4C, and p19INK4D) or by 
p21cip1 and p27Kip1 (Ding et al. 2020; Echalier et al. 2010; Malumbres & 
Barbacid 2001). The main function of both CDK 4 and 6 within the cell cycle 
is to phosphorylate the retinoblastoma tumour suppressor protein (Rb) (Ding et 
al. 2020; Echalier et al. 2010). Under normal circumstances, the Rb protein 
recruits co-repressors to suppress the transcription of target genes regulated by 
the E2 family (E2F) transcription factor, in order to inhibit the G1/S transition 
(Malumbres & Barbacid 2001). Therefore, phosphorylation of Rb by CDK4/6 
leads to a conformational change within the protein, resulting in the release of 
E2F (Malumbres & Barbacid 2001). In turn, E2F induces the transcription of 
G1/S mediators including cyclin A, cyclin B, cyclin E, ribonucleotide 
reductase M1 (RRM1), RRM2, spindle checkpoint protein (mitotic arrest 
deficient 2 (MAD2)), and BUB1 mitotic checkpoint serine/threonine kinase 
(BUB1) (Asghar et al. 2015; Ding et al. 2020; Malumbres & Barbacid 2001). 
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During the late G1-phase, cyclins E1 and E2 are activated, thereby binding and 
activating CDK2, which until then is held in check  by CDK inhibitors p21cip1 
and p27Kip1 (Watanabe, Broome & Hunter 1995). The CDK2/Cyclin E complex 
phosphorylates Rb at additional Ser/Thr sites, which leads to total inactivation 
of Rb (Tsai et al. 1993). Subsequently, the hyper-phosphorylated Rb no longer 
binds E2F, which results in a further increase of E2F levels within the cell 
(Tsai et al. 1993). Furthermore, active CDK2 can phosphorylate several 
proteins required for DNA replication (e.g., replication factors A and C), 
duplicate the centrosome (e.g., nucleophosmin (NPM)) and synthesise histones 
(e.g., nuclear protein, coactivator of histone transcription (NPAT)) (Ding et al. 
2020; Okuda et al. 2000; Sever-Chroneos et al. 2001). Later in the S-phase, 
cyclin E is no longer needed and is decomposed via the ubiquitin proteasome 
pathway (Ding et al. 2020). The newly biosynthesised cyclin A then associates 
with CDK2 to terminate the S-phase by phosphorylating and deactivating E2F. 
This initiates the cell-cycle transition from S- to G2-phase, in which cyclin A 
subsequently activates CDK1, leading cells to enter transition to the mitotic 
phase (Asghar et al. 2015; Ding et al. 2020). Upon mitosis, CDK1 activity is 
maintained by cyclin B (Gavet & Pines 2010). Active CDK1 phosphorylates a 
large number of substrates that mediate breakdown of the nuclear envelope, 
condensation of chromosomes, and assembly of the mitotic spindle (Gavet & 
Pines 2010; Murray 2004). The mitotic metaphase to anaphase transition is 
controlled by spindle assembly checkpoints (SAC), and anaphase is dependent 
on decreased activity of CDK1 via the degradation of cyclin B via the 
cyclosome (Gavet & Pines 2010). The reduced expression of CDK1 enables 






Figure 1.8: A schematic view of the cell cycle regulation by cyclin-dependent 
kinases (CDKs) and associated cyclins. Each phase in cell cycle progression is 
regulated by CDKs and their regulatory partner cyclins, as well as CDK 
inhibitors. G1 (Gap1), G2 (Gap2), S (DNA synthesis), Rb (retinoblastoma 
tumour suppressor protein), E2F (E2 family transcription factor), INK4 
(Inhibitors of CDK4), p21cip1 & p27Kip1 (Kinase inhibitory proteins), RRM1 





In breast cancer, alterations in cell cycle regulatory proteins have been 
described and have been associated with tumorigenesis and progression of 
disease (An et al. 1999; Buckley et al. 1993; Ding et al. 2020; Malumbres & 
Barbacid 2009; Malumbres & Barbacid 2005). Dysregulation of the cyclin 
D/CDK4/6/INK4/Rb axis, in particular, has been extensively characterised in 
breast cancer (An et al. 1999; Bohn et al. 2010; Buckley et al. 1993). 
Amplification of CCND1 (cyclin D1 gene) is observed in up to 15-20% of 
breast cancers (Buckley et al. 1993), while the cyclin D1 protein is 
overexpressed in over 50% of breast cancers (Buckley et al. 1993; Dickson et 
al. 1995; Gillett et al. 1994). Overexpression of cyclin D1 demonstrates a 
positive correlation with ERα expression, whereby 58% of ERα-positive breast 
cancer cases harboured cyclin D1 overexpression compared with 21% of ERα-
negative breast cancer cases (Kenny et al. 1999; Umekita et al. 2002). 
Crosstalk between ERα signalling and cyclin D1 is well established. Cyclin D1 
is an ERα target gene and an important mediator for estrogen induction of cell 
cycle progression in breast cancer (Butt et al. 2005; Musgrove et al. 2011). 
High cyclin D1 mRNA levels and amplification of CCND1 in ERα positive 
breast cancers were strongly correlated with increased risk of relapse, local 
recurrence, metastasis, and death (Kenny et al. 1999; Roy, PG et al. 2010; 
Utsumi et al. 2000). Amplification of the CDK4 and CDK6 genes were also 
detected in about 16% of primary breast cancers (An et al. 1999; Hamilton & 
Infante 2016). A study by An and colleagues (1999) reported that the mean 
proliferative index (measured by IHC of the proliferative marker Ki-67) in 
breast tumours with CDK4 gene amplification was significantly higher than in 
those without (An et al. 1999).  
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Loss of CDK inhibitor p16INK4a expression was reported in 49% of primary 
breast cancers, particularly in ERα-positive breast tumours (Campbell, I et al. 
2000; Dick & Rubin 2013). Given these observations, preclinical and clinical 
studies have been conducted to evaluate the effect of targeting CDK4/6 using 
pharmacological CDK inhibitors in breast cancer (Finn, Aleshin & Slamon 
2016; Rizzolio et al. 2010; Skowron et al. 2020). The most extensively 
investigated CDK4/6 inhibitor is flavopiridol (Finn, Aleshin & Slamon 2016). 
Flavopiridol is an intravenously administered CDK inhibitor that reduces 
CDK4/6 activity, with half-maximal inhibitory concentration (IC50) values of 
3.66 and 20.6nM in cell free assay, respectively (Sedlacek 2001). However, 
Flavopiridol can inhibit activity of other kinases including CDK1, 2, 7 and 9 
with IC50 values ranging from 20 to 170 nM in cell free assay (Finn, Aleshin & 
Slamon 2016). Flavopiridol underwent clinical testing in ERα-positive breast 
cancer and gave largely disappointing results (Fornier et al. 2007; Rizzolio et 
al. 2010). It was shown to be non-selective (i.e. off target effects), with 
flavopiridol having an unfavourable safety profile, causing a wide range of 
drug-mediated, dose-limiting side effects including neutropenia, 
hyperglycemia, cardiac and pulmonary dysfunction (Fornier et al. 2007; 
Ribnikar, Volovat & Cardoso 2019). Subsequently, more selective CDK4/6 
inhibitors were developed including palbociclib (PD 0332991) and ribociclib 
(LEE011) (Dhillon 2015; Hortobagyi et al. 2016). Palbociclib, the first FDA 
(Food and Drug Administration) approved CDK4/6 inhibitor, is an orally 
active, potent, and highly selective CDK4/6 inhibitor with IC50 value of 11 
nmol/l and 15 nmol/l in cell free assay, respectively (Cadoo et al. 2014). 
Ribociclib, another selective CDK4/6 inhibitor that is currently approved for 
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clinical use, is a structural analogue of palbociclib and shares its target 
selectivity and pharmacological characteristics (e.g. absorption, metabolism & 
bioavailability) (Kim, S et al. 2020). In preclinical studies, both palbociclib and 
ribociclib inhibit proliferation of ERα/Rb positive breast cancer cell lines and 
growth of xenograft tumours (Fry et al. 2004; Kim, S et al. 2020; Kishino et al. 
2019). The inhibitory effects of these inhibitors were accompanied by G1 
arrest, dephosphorylation of Rb as well as a decrease in E2F-dependent gene 
expression (Fry et al. 2004). Dean and colleagues showed that treatment of Rb-
positive primary breast cancer tissues cultured ex vivo as explants with 
palbociclib significantly reduced proliferation (Dean et al. 2012). The same 
study also reported that Rb-negative breast tumours were less sensitive to 
palbociclib (Dean et al. 2012). Moreover, synergistic effects of combining 
palbociclib or ribociclib with the ERα antagonist tamoxifen in ERα-positive 
breast cancer cell lines were demonstrated (Finn et al. 2009; Tripathy, Bardia 
& Sellers 2017). These observations were followed by a translation of the 
laboratory findings into clinical studies (Finn et al. 2014; Im et al. 2019; Turner 
et al. 2015; Verma et al. 2016). A combination of palbociclib or ribociclib with 
the aromatase inhibitor letrozole or the anti-estrogen fulvestrant, prolonged 
progression free survival in ERα-positive/HER2-negative advanced breast 
cancer patients (Finn et al. 2014; Im et al. 2019; Turner et al. 2015; Verma et 
al. 2016).  
In contrast to the impressive therapeutic efficacy of CDK4/6 inhibitors in ERα- 
positive breast cancer, ERα-negative breast cancers show less sensitivity to 
these inhibitors (Finn, Aleshin & Slamon 2016; Jennifer et al. 2020; Klein et al. 
2018). The lack of efficacy of CDK4/6 inhibition in ERα-negative breast 
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cancer is likely attributed to the absence of Rb or overexpression of p16 INK4a 
that is common in this sub-type of disease (Bohn et al. 2010; Hashmi et al. 
2018; Pandey et al. 2019). Rb is lost or mutated in approximately 20% of ERα-
negative breast cancers (Witkiewicz et al. 2018). Overexpression of p16 INK4a 
in the presence of functional Rb also confers resistance to CDK4/6 inhibitors as 
a result of diminished CDK4 activity (Pandey et al. 2019). Collectively, 
preclinical, and clinical studies have shown that targeting CDK4/6 has good 
therapeutic efficacy for ERα-positive breast cancer, specifically through its 
combination with other treatment regimens. However, it is not efficacious in 
ERα-negative breast cancer, warranting investigation into alternative CDK 
therapeutic targets in this disease context. 
1.5.4 Transcriptional CDKs  
1.5.4.1 Function in transcription 
The transcription of protein-coding genes by eukaryotic RNA polymerase II is 
divided into discrete phases of initiation, elongation, and termination (Fuda, 
Ardehali & Lis 2009; Yan et al. 2019) (Figure 1.9). In the initiation phase, 
general transcription factors (TFIIA, TFIIB, TFIID, TFIIF, TFIIS, TFIIE, and 
TFIIH), and un-phosphorylated RNAPII are recruited to the promoter of a 
gene, forming the pre-initiation complex (PIC) (Buratowski 1994; Pietras & 
Márquez-Garbán 2007). Promoter recognition occurs via TFIID, a multi-
subunit complex containing the TATA-binding protein (TBP) and at least 14 
tightly associated factors (Buratowski 1994; Pietras & Márquez-Garbán 2007). 
The binding of TFIID acts as a platform for the nucleation of the remaining 
factors (Dvir et al. 2001). TFIIB and TFIIA enter and stabilise TFIID binding 
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at the promoter by interacting directly with TFIID and DNA sequences 
flanking the TATA box (Buratowski 1994). TFIIB and TFIIA, in turn, recruit 
the RNAPII–TFIIF complex, but transcription cannot occur until TFIIE is 
incorporated and TFIIH recruited (Dvir et al. 2001). TFIIH has helicase and 
ATPase activities that unwind DNA and initiate transcription by RNAPII 
(Ohkuma et al. 1995). While the pre-initiation complex alone is able to drive 
basal transcription (Kanin et al. 2007; Serizawa, Conaway & Conaway 1993), 
the phosphorylation and activation of RNAPII via transcriptional CDKs in the 
initiation and elongation phases of transcription is required to achieve a 
continuous and high rate of transcription (Peissert et al. 2020). Five CDKs have 
been shown to be involved in controlling transcription:  CDK7, CDK9, 
CDK10, CDK12, & CDK19. Among these, the role of CDK7 and CDK9 is the 
most well characterised (Fisher 2017; Glover-Cutter et al. 2009; Malumbres & 
Barbacid 2005; Peissert et al. 2020). CDK7, along with cyclin H and RING-
finger protein MAT1, forms the CDK-activating kinase (CAK) complex, which 
associates with core subunits of TFIIH to form holo-TFIIH (Peissert et al. 
2020). The first identified target of TFIIH-associated kinase activity was the 
carboxy-terminal domain (CTD) of Rpb1 (the largest subunit of RNAPII), 
which contains multiple repeats (52 in human Rpb1) of a heptad sequence 
(consensus: Y1S2P3T4S5P6S7) (Wong, Jin & Struhl 2014). Within the CTD 




These phosphorylation events are thought to disrupt stable interaction between 
CTD and PIC components, thereby permitting RNAPII to be released from  the 
promoter (Coin & Egly 2015). Before continuing to the elongation phase, 
RNAPII is paused by binding with negative elongation factor (NELF) and the 
DRB-sensitivity-inducing factor (DSIF) (Dvir et al. 2001). RNAPII pausing 
appears as a key regulation step in transcription, during which several quality-
control processes take place, including mRNA 50 capping by the human 
capping enzyme (HCE), which protects pre-mRNA from decay during 
transcription (Akhtar et al. 2019; Kanin et al. 2007). The transition from the 
paused state to elongation is promoted by the positive transcription elongation 
factor (P-TEFb), a complex of CDK9 and cyclin T (Bacon & D’Orso 2019). 
CDK9 facilitates release of paused RNAPII into the elongation phase, leading 
to the synthesis of mRNAs through phosphorylation of three main substrates: 
1) Ser2 residues located in the heptad repeats of the RNAPII CTD; 2) DSIF, 
transforming it into a positive elongation factor; and 3) NELF, resulting in its 
ejection from the pre-mRNA chain (Bacon & D’Orso 2019). The termination 
phase follows elongation, where RNAPII separates from the DNA template 
and releases mRNA (Rosonina et al. 2006).  
Unlike basal or low rates of transcription, where phosphorylation of the 
RNAPII CTD by P-TEFb is not required (Scafe et al. 1990; Serizawa, 
Conaway & Conaway 1993), the kinase function of P-TEFb plays a critical 
role in promoting expression of genes that are regulated by super enhancers, 
large clusters of DNA regulatory elements (“enhancers”) that drive 
transcription of genes controlling cell identity and stimulating oncogenic 
transcription (Bacon & D’Orso 2019). Such genes include MYC (Boffo et al. 
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2018; Huang, C-H et al. 2014), C-MYB (Drabsch et al. 2007) and anti-
apoptotic proteins e.g. MCL1 and BCL2 (Boffo et al. 2018; Cidado et al. 
2020). By controlling gene expression of tumour driving genes, CDK9 is 
implicated in the initiation and progression of several types of cancer including 
leukemia (Boffo et al. 2018; Cidado et al. 2020), breast (McLaughlin et al. 
2019; Mitra et al. 2016), colon (Rahaman, Lam, et al. 2019), and prostate 
(Falco, Giordano & therapy 2002; Franco et al. 2018; Rahaman et al. 2016). 
Since this study focuses on targeting CDK9 in the ERα-negative subtype of 
breast cancer, the following sections will provide an in-depth focus on the 





















 Figure 1.9: Schematic representation of transcription phases. (A) General 
transcription factors (TF) & RNAPII are recruited to the promoter of the gene, 
forming the pre-initiation complex (PIC). (B) Holo-TFIIH (TFIIH, RING-
finger protein MAT1, CDK-activating kinase (CAK)) phosphorylates the c-
terminal domain of RNAPII at Ser5 to initiate transcription. (C) RNAPII is 
paused by the negative elongation factor (NELF) and the DRB-sensitivity-
inducing factor (DSIF). (D) Transition from the paused state to elongation is 
promoted by the positive transcription elongation factor (P-TEFb, a complex 
containing CDK9 & Cyclin T). (E) The termination phase occurs when 













1.5.4.2 Isoforms and genetic aspects of CDK9 
CDK9 exists in two isoforms in mammalian cells, a lighter 42 kDa protein 
(CDK942) and a heavier 55 kDa protein (CDK955) (Liu, H & Herrmann 2005). 
The CDK955 isoform has 117 additional amino acid residues in front of the 
amino terminus of CDK942 (Fu, T-J et al. 1999). The two CDK9 isoforms are 
encoded by the same gene, which is located at 9q34.1, near the telomeric end 
of the chromosome 9 long arm (chr9:127,785,679-127,790,792) (dos Santos 
Paparidis, Durvale & Canduri 2017). The CDK9 encoding gene has two 
different promoters, located more than 500 bp apart from each other (dos 
Santos Paparidis, Durvale & Canduri 2017; Shore et al. 2003) (Figure 1.10). 
CDK955 is transcribed from a TATA-containing promoter and has an additional 
351 bp in its coding sequence (corresponding to the 117 exclusive N-terminal 
residues) (dos Santos Paparidis, Durvale & Canduri 2017). The CDK9 
promoter that encodes for CDK942 mRNA does not have a functional TATA 
box, but contains a GC-rich transcription sequence, which is characteristic of 
promoters within constitutively active genes required for basic cell functions 
(termed housekeeping genes) (dos Santos Paparidis, Durvale & Canduri 2017; 








Figure 1.10: Gene structure and protein sequences of human CDK9. (A) 
Schematic overview of the CDK9 gene showing exons (orange blocks), introns 
(purple) and positions of start codons (ATG) for each CDK9 isoform. (B) 
Human CDK9 protein sequence. An additional 117 amino acid fragment 





The two isoforms of CDK9 display differences in subcellular localisation, 
tissue distribution and function (Liu, H & Herrmann 2005). CDK942 has been 
reported to localise to the nucleoplasm, whereas CDK955 localises to the 
nucleolus (Liu, H & Herrmann 2005). Moreover, substantial variations in 
relative abundance of the two isoforms were observed among various human 
tissues (Shore et al. 2005). For example, spleen, breast and testis tissues have 
high levels of CDK942 expression, whereas CDK955 expression is high in lung, 
liver and brain tissues (Liu, H & Herrmann 2005). Both isoforms are found to 
hyper-phosphorylate the CTD of RNAPII and mediate transcription elongation 
(Bacon & D’Orso 2019). However, preclinical studies have shown that 
CDK955, but not CDK942, is able to bind to Ku70 (a DNA repair protein that 
binds to DNA double-strand break ends and helps repair DNA via the non-
homologous end-joining) and is therefore involved in the DNA repair process 
(Liu, H et al. 2010; Yu, DS & Cortez 2011).  
1.5.4.3 Regulation of CDK9 activity 
The regulation of CDK9 function is a complex process that includes post-
translational modifications as well as binding of the P-TEFb complex to 
specific factors that induce or inhibit kinase activity (dos Santos Paparidis, 
Durvale & Canduri 2017; Egloff et al. 2006). Phosphorylation at residue 
Thr186 of the activation (T-loop) segment is the most important modification 
that CDK9 undergoes because it is essential to kinase enzymatic activity (Lolli 
2010). Phosphorylation of Thr186 triggers major conformational changes that 
opens the ATP binding pocket and substrate binding site, making CDK9 fully 
active (dos Santos Paparidis, Durvale & Canduri 2017). Unlike other CDKs, 
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Thr186 is not phosphorylated by the CDK‐activating kinase (Kim, JB & Sharp 
2001), and instead it has been suggested that it is an autophosphorylation site 
(Li, Q et al. 2005). In addition to Thr186, a cluster of CDK9’s C-terminal 
residues (Ser-347, Ser-353, and Ser-357; Thr-350 and Thr-354) are also known 
to be auto-phosphorylated and have been reported to be important for 
CDK9/Cyclin T complex nuclear localisation (Mueller et al. 2002; Napolitano, 
Majello & Lania 2003).  
Factors that inhibit CDK9 include 7SK and HEXIM1 (Kiss, Michels & 
Bensaude 2001; Michels, AA et al. 2003). 7SK is a small, abundant 331-
nucleotide-length nuclear RNA (snRNA) showing high-sequence conservation 
in vertebrates (Kiss, Michels & Bensaude 2001). HEXIM1 was initially 
identified as a protein whose expression is stimulated in vascular smooth 
muscle cells in response to hexamethylene bisacetamide (HMBA) treatment, an 
inhibitor of proliferation (Michels, AA et al. 2003). In association with 7SK, 
HEXIM1 is able to bind P-TEFb and inhibit its kinase and transcriptional 
activity (Dey, Chao & Lane 2007; Michels, AA et al. 2003). HEXIM1 contains 
a peptide sequence that binds to the kinase to block the active site, thereby 
preventing CDK9 from binding to its substrates (Peterlin, Brogie & Price 2012; 
Sonawane et al. 2016). HEXIM1 can interact with P-TEFb and inhibit its 
kinase activity only in the presence of 7SK, suggesting that 7SK provides the 
structural scaffold for assembly of the kinase-inactive 7SK/HEXIM1/P-TEFb 
complex (Egloff et al. 2006). Upon transcription, release of the CDK9/Cyclin T 
complex from 7SK/HEXIM1 occurs through post-translational modifications 
of CDK9 (Chen, R et al. 2008; Chen, R, Yang & Zhou 2004). A study by Chen 
and colleagues (2008) showed that dephosphorylation of the phospho-Thr186 
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in the T-loop segment of CDK9 by PP1α (protein phosphatase 1α) and PP2B 
(protein phosphatase 2B) results in its release from 7SK (Chen, R et al. 2008). 
In addition to post-translational modifications, bromodomain-containing 
protein 4 (BRD4) can release P-TEFb from the HEXIM/7SK complex 
(Cassandri et al. 2020). BRD4 competes with the inhibitory complex 
HEXIM/7SK and recruits free P-TEFb to the transcription start site via histone 
acetylation (Yang, Z et al. 2005). However, the recruitment of BRD4 depends 
on the transcription factors that bind to the promoter and/or enhancer of the 
target gene (Yang, Z et al. 2005). Nuclear Factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) has been the first discovered transcription factor 
implicated in CDK9/BRD4 delivery to transcriptional complexes via 
interaction of CDK9 and the RelA subunit (Barboric et al. 2001). Moreover, C-
MYC can also recruit and place CDK9 into promoter regions of its gene 
targets, with presence of CDK9 sufficient to drive expression of C-MYC-target 
genes (Cassandri et al. 2020; Galbraith, Bender & Espinosa 2019; Pereira et al. 
2015). 
1.5.4.4 CDK9 related pathways in cancer 
The kinase activity of CDK9 facilities transcription of crucial  transcription 
factors that are involved in several biological processes, including cell growth, 
protection against apoptosis, and DNA repair (dos Santos Paparidis, Durvale & 
Canduri 2017; Franco et al. 2018). The master regulator C-MYC, a well-known 
CDK9 target, controls the expression of several genes involved in cell cycle 
and proliferation (Bretones, Delgado & León 2015). Cell cycle-related genes 
cyclin D2, cyclin E1, CDK4, CDK6, Cdc25A, E2F1 were among the first 
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described C-MYC target genes (Amati, Alevizopoulos & Vlach 1998; 
Bretones, Delgado & León 2015; Mateyak et al. 1999; Meyer & Penn 2008). 
Moreover, one of the most important targets of C-MYC is the CDK inhibitor 
p27 (Mateyak et al. 1999; Yang, W et al. 2001). In lymphoid and breast cancer 
cells, C-MYC accelerates cell proliferation rates through its ability to 
antagonise p27 function as a CDK inhibitor (Chandramohan et al. 2008; Yang, 
W et al. 2001). In normal cells, expression and activity of C-MYC are tightly 
controlled to maintain the optimal levels to maintain homeostatic cell 
proliferation (Meyer & Penn 2008). In contrast to non-malignant cells, C-MYC 
expression is estimated to be elevated or dysregulated in up to 70% of human 
cancers (Dang, CVJC 2012). High levels of C-MYC expression have been 
linked to aggressive human prostate cancer and TNBC (Gurel et al. 2008; 
Palaskas et al. 2011). Since CDK9 is important to sustain C-MYC mRNA 
transcripts, inhibition of CDK9 has been investigated as one avenue to reduce 
production of the C-MYC protein in cancer cells (Cassandri et al. 2020; Lu et 
al. 2015; Rowland et al. 2016).  
Short half-life anti-apoptotic BCL2 proteins such as MCL1, BCL2 and XIAP, 
which are determinants of cancer cell survival, also require CDK9 to maintain 
their transcription at high levels (Barille-Nion et al. 2012; Scherr et al. 2020; 
Xiao et al. 2015). Anti-apoptotic proteins restrain the apoptotic pathway by 
binding and sequestering pro-apoptotic factors (Williams et al. 2017). 
Specifically, anti-apoptotic proteins either 1) bind to BCL2 effectors (Bak and 
Bax) to block pore formation in the outer mitochondrial membrane caused by 
Bak/Bax oligomerisation (Emily et al. 2001; Willis et al. 2005), or 2) sequester 
BCL2 activators (e.g., Bim, Bid, and Puma), which facilitate Bak/Bax 
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oligomerisation (Emily et al. 2001). High expression of BCL2 and MCL1 have 
been reported in breast cancer (Dawson et al. 2010; Merino et al. 2016; Oakes 
et al. 2012) and high MCL1 levels were associated with poor prognosis in 
TNBC cancer (Campbell, KJ et al. 2018). Interestingly, levels of MCL1 and 
BCL2 gene products have been shown to decrease dramatically upon exposure 
to CDK9 inhibitors, leading to reduced cell proliferation and survival in several 
types of cancer, including breast cancer (Cidado et al. 2020; Luedtke et al. 
2020; Mitra et al. 2016; Thomas, D et al. 2013). 
An association of CDK9 with AR has reported, indicating CDK9 has the  
ability to  phosphorylate AR at the Ser81 residue of the AR NTD in prostate 
cancer cells (Rahaman et al. 2016). Several investigations attribute the role of 
Ser81 phosphorylation to the regulation of AR stability, nuclear translocation, 
as well as binding to chromatin (Chen, S et al. 2012; Gioeli et al. 2002; Wu, K 
et al. 2014). According to Gordon et al. (2010), overexpression of CDK9 along 
with its partner cyclin T increased Ser81 phosphorylation of AR in prostate 
cancer cells in vitro (Gordon et al. 2010). Silencing the CDK9 protein in 
LNCaP cells resulted in a significant reduction in Ser81 phosphorylation even 
after androgen induction (Rahaman et al. 2016; Richters et al. 2021). Based on 
these observations, we hypothesise that inhibition of CDK9 could also help in 
inhibiting the oncogenic effects of AR in molecular apocrine breast cancer 
cells.  
Together, these studies provide compelling evidence that CDK9 related 
pathways play a pivotal role in the initiation and/or progression of the 
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malignant cell phenotype. Hence, targeting CDK9 represents a potential 
therapeutic strategy for ERα-negative breast cancer.  
1.5.4.5 CDK9 inhibitors and ERα- negative breast cancer 
Pharmacological CDK9 inhibitors have been extensively investigated as 
therapeutics for a variety of hematologic cancers, as high CDK9 and MCL1 
expression is correlated with poor survival in patients of blood cancers (Boffo 
et al. 2018; Li, X-x et al. 2019). Table 1.4 provides CDK inhibition profiles for 
the most common CDK9 inhibitors (Boffo et al. 2018). These inhibitors are 
deemed competitive inhibitors of the ATP-binding site, which is a highly 
conserved feature across the CDK family, and consequently, these CDK9 
inhibitors lack specificity, incurring side effects in patients (Boffo et al. 2018; 
Mariaule & Belmont 2014; Sonawane et al. 2016).  
Elevated CDK9 expression has been shown to be associated with worse overall 
survival in ERα-negative breast cancers (Brisard et al. 2018). However, very 
few studies have examined the effect of CDK9 inhibition in ERα-negative 
breast cancer models, and of these few studies the compounds that were used to 
inhibit CDK9 activity had the undesirable effect of also inhibiting several other 
related enzymes. Dinaciclib is a potent pan-CDK inhibitor with IC50 of 1, 1, 3, 
4, 60 and 70 nM  for CDK2, CDK5, CDK1 ,CDK9, CDK6, and CDK7, 
respectively (Parry et al. 2010). Dinaciclib effectively inhibits growth of ERα-
negative breast cell lines in vitro and in vivo (Rajput et al. 2016). The 
inhibitory effects of dinaciclib were accompanied by a decrease in C-MYC, as 
well as a decrease in protein levels of CDK1 and its partner cyclin B1 (Rajput 
et al. 2016). A Phase 1 clinical trial ( NCT01624441) began with dinaciclib in 
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patients diagnosed with advanced TNBC at the MD Anderson Cancer Center 
(USA), but was not completed due to toxicity of the treatment including 
neutropenia, syncope (a temporary loss of consciousness usually related to 
insufficient blood flow to the brain) and haemolytic anemia (Mitri et al. 2015). 
CYC065 is a second-generation, orally available ATP-competitive inhibitor of 
CDK2/CDK9 kinases with an IC50 of 5 and 26 nM, respectively (Rao et al. 
2017). CYC065 inhibits proliferation and viability of ERα-negative breast 
cancer cell lines and patient derived xenografts (PDXs) (Rao et al. 2017). 
Treatment with the CYC065 resulted in decreased CDK9 activity and C-MYC 
expression, along with increased G1 phase cell cycle distribution due to off 
target CDK2 inhibition (Rao et al. 2017). Collectively, these data demonstrate 
that targeting CDK9 has been hampered by the poor selectivity of existing 
drugs. 
Herein, we evaluated the pre-clinical efficacy of a newly developed, highly 
selective, and potent CDK9 inhibitor called D-11 in ERα-negative breast 
cancer cell lines and xenografts. D-11 was developed by Professor Shudong 
Wang (Drug Discovery and Development Group, University of South 
Australia, Australia). To improve selectivity for CDK9, D-11 was developed 
by leveraging  the striking difference in the way transcriptional CDK9 
associates with Cyclin T compared to the way  cell cycle CDKs associate with 
their cyclin partners (e.g., CDK2/Cyclin A) (Baumli et al. 2008). The 
orientation of cyclin T with respect to CDK9 is rotated by about 26°, resulting 
in a comparatively sparse number of contacts between CDK9 and Cyclin T 
(Baumli et al. 2008). The buried molecular surface area of CDK9/Cyclin T is 
60% wider than the molecular surface area buried on complex formation of 
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CDK2/Cyclin A (Baumli et al. 2008). The big size of D-11 enables it to pass 
through the space that exists between CDK9 and cyclin T but does not enable it 
to reach the ATP binding site of other CDKs. Indeed, D-11 demonstrates 
superior selectivity towards CDK9 over the other known CDK9 inhibitors such 
as dinaciclib. D-11 inhibits the CDK9 catalytic activity with kinase inhibition 
(Ki) of 8 nM but is far less effective on other CDKs with Ki of 1530, 430, 
2620, 1540, and 600 nM for CDK1, CDK2, CDK4, CDK6, and CDK7, 
respectively.  
In summary, selective CDK9 inhibition is an attractive therapeutic strategy for 
TNBC tumours since they are addicted to continuous transcription of short 
half-life oncogene and pro-survival factors. Therefore, a highly selective, 
potent, and orally bioavailable CDK9 inhibitor D-11 is a promising treatment 











Table 1.4: CDK inhibition profiles of the most common CDK9 inhibitors 




Mode of administration 
Dinaciclib 
CDK9: 4 nM 
CDK1: 3 nM 
CDK2: 1 nM 
CDK5: 1 nM 
Intravenous 
AT7519 
CDK9: 10 nM 
CDK2: 47 nM 
CDK4: 100 nM 
CDK5: 13 nM 
CDK6: 179 nM 
Intravenous 
LY2857785 
CDK9: 11 nM 
CDK8: 16 nM 




CDK9: 20 nM 
CDK1: 79 nM 
CDK2: 224 nM 




CDK9: 4 nM 
CDK2: 38 nM 




CDK9: 3 nM 
CDK1: 9 nM 
CDK2: 5 nM 
CDK3: 8 nM 
CDK5: 4 nM 
CDK7: 37 nM 
Oral 
CDKI-73 
CDK9: 6 nM 
CDK1: 8 nM 
CDK2: 3 nM 
CDK4: 8 nM 
CDK6: 37 nM 





CDK7: 20 µm 








1.6 Hypothesis and aims 
It is evident that AR and CDK9 represent two very promising targets for 
therapeutic interventions in ERα- negative breast cancer. However, there are 
important issues that need to be addressed before these targets can be 
considered as novel effective therapeutic strategies for ERα- negative breast 
cancer. Targeting AR in ERα-negative breast cancer has both proliferative and 
anti-proliferative effects, and the precise mechanisms of these divergent effects 
are still unclear. Additionally, targeting CDK9 has been limited by the poor 
selectivity and toxicity of existing inhibitors. 
Hypothesis 
Targeting the AR or CDK9 is an effective therapeutic strategy for ERα- 
negative breast cancer.  
Objectives of this thesis 
Aim 1: To define genomic parameters of AR activity associated with proliferative 
versus anti-proliferative cellular responses in ERα- negative/AR positive breast 
cancer. 
1.1 Bioinformatically mine unpublished genomic and proteomic datasets, generated by 
my host laboratory, of ERα-negative breast cancer cell lines with divergent responses 
to ligand activation in vitro.  
1.2 Determine the effect of differential expression of candidate AR factors 
from Aim 1.1 on proliferation and AR chromatin binding in ERα-





Aim 2: Examine the anti-tumour efficacy of CDK9 inhibition in ERα- negative 
breast cancer. 
 
2.1 Evaluate the effect of a novel and highly selective CDK9 inhibitor (D-11) on the    
proliferation, apoptosis, and cell cycle status of ERα- negative breast cancer cells in 
vitro. 
 
2.2 Determine the mechanisms behind CDK9 targeted effects in ERα- negative breast   
cancer cells in vitro. 
 
2.3 Evaluate the effect of D-11 on normal breast tissues cultured ex vivo. 
 
Aim 3: Assess AR or CDK9 treatment strategies in contemporary models of ERα- 
negative breast cancer.  
3.1 Evaluate anti-tumour effect of D-11 using cell-line xenograft model of  ERα- negative 
breast cancer. 
3.2 Examine AR treatment strategy in patient-derived models of ERα- negative /AR 
positive breast cancer. 
The results of this project will provide important preclinical data for new 
therapeutic strategies that could change the standard of care in many women 












Table 2.1: Reagents  
 
Name Supplier Catalogue number 
DAB Sigma D9015 
Acetic acid Sigma 320099 
Agar Sigma A7002 
Ampicillin Sigma A8351 
Antimycotic-antibiotic Sigma A5955 
BD™ CS&T BD 642412 
Bovine serum albumin  Sigma A9647 
Bromophenol blue Sigma B0126 
Chloroform Sigma C2432 
Citric acid monohydrate Sigma C7129 






Criterion precast gel (4-
12%) 
Bio-Rad 567-1084 
DAPI Thermo Scientific D1306 
 DHT Sigma D-5027 
DMSO Sigma D2650 
D-luciferin Promega P1043 
Donkey serum Sigma D9663 
DPX  Sigma 06522 
DMEM-High Glucose Sigma D5671 
Duolink II Detection Kit Sigma Duo92008 
Dynabeads™ Protein A Thermo Scientific D2214 
Dynabeads™ Protein G Thermo Scientific K1816 
E2 Sigma E2758 
EMEM Sigma M0325 
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Eosin Australian Biosatin AEPA 
Ethanol Scharlau ET00110500 
EGTA Sigma E3889 
EDTA Sigma E5134 
Fetal bovine serum Sigma 12003C 
Formaldehyde Sigma 8775 
Glucose Sigma G5400 
Glycerol Chem Supply GA010-2.5L-P 
Glycine Sigma G8898 
Glycoblue Thermo Scientific AM9515 
Glycogen Thermo Scientific AM9516 
Goat serum Sigma G9023 
H2O2 Chem -Supply 01552 
Halt phosphatase inhibitor Thermo Scientific 862495 







Hydrocortisone Sigma H0888 
IncuCyte® caspase-3/7 
green apoptosis assay 
reagent 
Essen Bioscience 4440 
IncuCyte® NucLight rapid 
red reagent 
Essen Bioscience 4717 
ITS) Sigma I1884 
iQ SYBR green supermix Bio-Rad 170-8885 
iScript cDNA synthesis kit Bio-Rad 170-8891 
Isoflurane Henry Schein 5100XN 
Isopropanol Sigma I9516 
L-glutamine Sigma G7513 
Lipofectamine RNA 
iMAX 
Thermo Scientific 13778150 
Lithium chloride Sigma L9650 
Luria broth  Sigma L3522 
Magnesium chloride  Sigma M-1028 
Magnesium sulfate  Sigma M-9397 
Mayer's hematoxylin Australian Biosatin ALLM 
Methanol Chem Supply MA004-2.5L-P 
MOPS buffer Bio-Rad 161-0788 






N-laurylsarcosine Sigma L9150 
NP-40 Roche 11332473001 
Nuclease free water Ambion AM9937 
NucleoBond Xtra Maxi 
Plus kit 
Macherey-Nagel 740420.50 
Opti-MEM Thermo Scientific 31985070 




Pierce BCA protein assay 
kit 
Thermo Scientific 23225 
PLA mounting media Dako S3023 
PLA wash buffer A Sigma Duo82046 
PLA wash buffer B Sigma Duo82048 
Polyethylenimine Poly-Sciences 24765 
Ponceau Sigma P3504 
Potassium acetate  Sigma P1190 
Potassium chloride  Sigma P9541 
Potassium hydroxide  Sigma P1767 
Precision plus protein dual 
colour standards 
Thermo Scientific 350001695 
Propidium Iodide Sigma P4170 
Proteinase K Boehringer Mannheim 1000144 




RNase A Sigma R4642 
RPMI 1640 Gibco 13412 
Sodium chloride  Ajax Fine Chemicals 465 
Sodium deoxycholate Sigma D6750 
Sodium dodecyl sulphate  Sigma 75746 
Sodium hydroxide  Chem Supply 8A178 
Sodium pyruvate Sigma S8636 
Stratagene MycoSensor 
qPCR kit  
Agilent 302106 
Tris-base Sigma T1378 
Tris-HCl Sigma T3253 
Triton X-100 Sigma T8787 
Trizol Sigma T9424 
Trypan blue Sigma T6146 
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Trypsin-EDTA Sigma T4049 
Tryptone Sigma T-7293 
Turbo-DNase kit Thermo Scientific AM1907 
Tween 20 Sigma P7949 
Yeast extract Fluka Analytical 92144 
β-mercaptoethanol Sigma 63689 
 
Table 2.2: Solutions  
Name Preparation 
0.4% Trypan blue 






Propidium iodide staining solution 
50µg/mL PI 
0.1% Triton X-100 
100µg/mL RNase A 









Luria broth  
25g LB 
1L H2O 
(Add 20g agar for plates) 
P1 Buffer 
50mM Tris-HCl, pH 8.0 
10mM EDTA 




P3 Buffer 3.0M potassium acetate, pH 5.5 




50mM Tris-HCl pH 8.0 
150mM NaCl 
0.5% Sodium deoxycholate, 
0.1% SDS 
0.1% Triton X-100 






0.05% Bromophenol blue 




in 2.5L H2O 
Adjust pH into 7.4 
TBST (Tris-buffered saline, 0.1% Tween 20) 
(1x) 
 
2.5mL Tween 20 
250mL 10x TBS 
in 2.5L H2O 
Transfer Buffer (10x) 
 
77.5g Tris -base 
360g Glycine 
in 2.5L H2O 
Ponceau stain 
1% Ponceau S in 
5% Acetic Acid 
Chromatin immunoprecipitation (ChIP) solutions 
Solution A 
1% Formaldehyde 




Lysis buffer 1 (LB1) 





0.25% Triton X-100 
Lysis buffer 2 (LB2) 






Lysis buffer 3 (LB3) 

















10mM tris-HCL, pH 8.0 
1mM EDTA 
Immunohistochemistry solutions 
10 mM citrate buffer (pH 6.5) 
2.10g Citric acid monohydrate in 
1L H2O 
Adjust pH to 6.5 
DAB solution 




Table 2.3: Primers 
Primer name Sequence 
Annealing 
temperature 
C-MYC F 5′-TTCGGGTAGTGGAAAACCAG-3′ 55℃ 
C-MYC R 5′-CCCCCTCGTCGCAGTAGAAA-3′  
MCL1 F 5′-CCAAGAAAGCTGCATCGAACCAT-3′ 60℃ 
MCL1 R 5′- CAGCACATTCCTGATGCCACCT-3′  
GAPDH F 5′- TGCACCACCAACTGCTTAGC-3′ 55 ℃ 
GAPDH R 5′- GGCATGGACTGTGGTCATGAG-3′  
HER2 F 5′- ACACGATTTTGTGGAAGGACAT-3′ 60℃ 
HER2 R 5′- AGCCCTTACACATCGGAGAA-3′  
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ALDH1A3 F 5′- TGGCACGAATCCAAGAGTGG-3′ 55 ℃ 
ALDH1A3 R 5′- TTGTCCACGTCGGGCTTATC-3′  
KMO F 5′- TGCCATCCCTCTAATTGGAGA-3′ 55 ℃ 
KMO R 5′- GCCCGCATTCATTCCTTGC-3′  
CLCA2 F 5′- ATGCAAGTACCCACAACCAAG-3′ 60 ℃ 
CLCA2 R 5′- GATTACATCCCATGCACTTCTGA-3′  
FAR2 F 5′- CCGTGCAGTACAAGCTCTCC-3′ 55 ℃ 
FAR2 R 5′- CTGCTCAGTCGTGTTCAAGTATT-3′  
KMO ChIP-PCR 
F 
5′- ACAGCTGCTCTGCTGAAGGG-3′ 60 ℃ 
KMO ChIP-PCR 
R 
5′- TCCTGCTGTTCCCTCTGCCT-3′  
ALDH1A3 ChIP-
PCR F 
5′- CACCCGGGCTTGATCAGAAT-3′ 55 ℃ 
ALDH1A3 ChIP-
PCR R 
5′- GTCACCCGCTTCAGATTGCT-3′  
CLCA2 ChIP-
PCR F 
5′- CAAGGCCAGAGGGAAAGGG-3′ 60 ℃ 
CLCA2 ChIP-
PCR R 
5′- AATCCATTCTGCAGCCCAGT-3′  
FAR2 ChIP-PCR 
F 






5′- GTGAGTGCCCAGTTAGAGCATCTA-3′ 55 ℃ 
NC ChIP-PCR 
R 













2.2.1 Test compounds 
 
DHT (Sigma) was dissolved in 100% ethanol to a concentration of 10mM 
stock. D-11 and L-453 were provided by Professor Shudong Wang (Drug 
Discovery and Development group, Cancer Research Institute, University of 
South Australia, Australia). For the in vitro assays, concentrated 10mM stocks 
of D-11 and L-453 were prepared in 100% Dimethyl sulfoxide (DMSO). 
10mM concentrated stocks of D-11 and L-453 were stored at -20 and 4°C, 
respectively, and diluted into growth media as required on the day of the 
treatment. For the in vivo study, D-11 was freshly formulated in 0.1M sodium 
acetate buffer, pH 4.5. 
2.2.2 Cell culture 
2.2.2.1 Maintenance of cell lines 
 
MDA-MB-453, MDA-MB-231, MDA-MB-468, and HEK 293T/17 cell lines 
were obtained from the American Type Culture Collection (ATCC, USA) and 
maintained in Dulbecco's Modified Eagle’s Medium (DMEM) (with high 
glucose) supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine 
and 2mM sodium pyruvate. MFM-223 cell line was purchased from the 
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell 
Cultures (Braunschweig, Germany) and maintained in Eagle's Minimum 
Essential Medium (EMEM) supplemented with 10% FBS, 2mM L-glutamine, 
and a 1x concentration of insulin–transferrin–sodium selenite (ITS) 
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supplement. All cell lines were kept at 37°C in a humified incubator with 5% 
CO2. Cell lines were routinely tested for mycoplasma infection using 
Stratagene MycoSensor qPCR kit and cell line identity by short tandem repeat 
profiling (Cell Bank Australia).  
2.2.2.2 Reviving, passaging, and freezing of cells. 
 
To revive cells from frozen stocks stored in liquid nitrogen, cryo-vials were 
rapidly thawed by gently swirling in a 37°C water bath. In a laminar flow 
hood, cryo-vials were decontaminated by spraying with 70% ethanol, and cell 
suspension was transferred to a 15mL conical tube containing 10mL of growth 
media. Cells were centrifuged at 1500rpm for 5min, the supernatant was 
removed, and the cell pellet was resuspended in 12mL of growth media and 
transferred to a T-25 sterile tissue culture flask (Corning). T-25 flasks were 
incubated at 37°C in a humified incubator with 5% CO2.  
For regular passaging of cell lines, cell lines were grown in sterile T-75 tissue 
culture flasks (Corning) and were passaged at regular intervals when cells 
reached approximately 75% confluency. At the time of passaging cells, culture 
media was aspirated from the flask and cells were washed with 5mL pre-
warmed 1x concentration phosphate-buffered saline (PBS). PBS was aspirated 
and 3mL of pre-warmed 0.25% (w/v) Trypsin-EDTA solution was added. Cells 
were incubated with trypsin at 37℃ for 3-5 min (until cells detached from the 
flask). Trypsin was neutralized with 10mL pre-warmed media containing 10% 
FBS and collected in a 50mL conical tube. Cells were pelleted by 
centrifugation at 1500rpm for 5min and resuspended with 12mL growth media. 
Cell count was determined by diluting 30μL of cell suspension with 30μL of 
115 
 
0.4% Trypan blue dye and counting manually with a hemocytometer 
(Hirschmann). Cells were re-seeded at appropriate density into a new sterile T-
75 tissue culture flask. 
For the freezing protocol, cells were detached using trypsin, counted (as 
outlined above), and resuspended in freezing media (10% DMSO, 40% FBS, 
50% culture media) at a concentration of 2-3 x 106 cells/mL. The cells were 
mixed gently, and 1mL of cell suspension was added to each labelled cryo-vial 
(Corning) and placed in isopropanol filled Mr. Frosty freezing containers 
(Thermo Scientific) at -80°C. Cells were transferred to liquid nitrogen once 
frozen. 
2.2.3 Transduction of human breast cancer cell lines with 
mKate2 and Luciferase-Tomato-Puro (LTP). 
2.2.3.1 Bacterial cell transformation 
 
mKate2 and LTP plasmids (Appendix 1) were a kind gift from Prof. Richard 
Iggo (University of Bordeaux). Bacterial cell transformation was carried out by 
mixing 1.5µL of plasmid (mKate2 or LTP) with 10μL of Stbl3 E. coli cells to 
give a final concentration of 2 x 109 cells/µg of DNA. The DNA-cell mixture 
was transferred into a chilled 1 mm-gap cuvette for electroporation at 1250 volt 
using Gene Pulser XcellTm Electroporation System. The cuvette was then 
flushed with 400µL SOC media (Super Optimal broth with Catabolite’s 
repression) and the cells were recovered by incubation at 37 °C for 30min. 
After incubation, cells were streaked on Luria broth (LB) plates containing 
100µg/mL ampicillin. Plates were incubated overnight at 37°C.   
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2.2.3.2 Preparation of plasmid DNA  
 
Plasmid mini-cultures were prepared by inoculating a single bacterial colony 
containing the plasmid of interest (from section 2.2.3.1) into 3mL LB media 
containing 100µg/mL ampicillin and grown overnight at 37°C with vigorous 
shaking. Small-scale plasmid (mini-prep) preparations were performed using 
the QIAquick Plasmid Miniprep Kit according to the manufacturer’s 
instructions. Briefly, 1mL of the bacterial culture was transferred to a 1.5mL 
microcentrifuge tube and centrifuged at 14,000g for 30sec followed by 
resuspension in 100µL of buffer P1 (containing 100µg/ml RNase A). For cell 
lysis, 100µL of P2 buffer (containing 1%SDS and 200mM NaOH) was added 
and mixed well by inverting the tube 4-6 times. To neutralise the pH of the cell 
lysate, 100µL of P3 buffer (3.0M potassium acetate, pH 5.5) was added and 
gently mixed by inverting the tube several times. Separation of cell debris from 
plasmid DNA was performed by centrifugation at 14,000g for 5min at room 
temperature (RT). After centrifugation, the upper phase was transferred into a 
new microcentrifuge tube and an equal volume of isopropanol was added, 
mixed well, and incubated for 10min at RT. DNA was pelleted by 
centrifugation at 12,000g at 4°C for 30min, washed with 70% ethanol, and 
resuspended in nuclease-free water. The resulting DNA concentration and 
purity were determined by spectrophotometry using a Thermo Scientific 
NanoDrop 2000. 
Plasmid maxi-cultures were prepared in a volume of 250mL as described 
above by 1/1000 dilution of starter cultures. Plasmid DNA prep (large scale) 
was performed using the NucleoBond Xtra Maxi Plus kit (Macherey-Nagel) 
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according to the manufacturer’s instructions. Bacterial cells were harvested by 
centrifugation of maxi-cultures at 4000g for 30min at 4°C. The supernatant 
was poured off and the cell pellet was resuspended with 8mL of resuspension 
buffer. Lysis solution (8mL) was added to the cells, mixed, and incubated at 
RT for 5min. Meanwhile, 15mL of equilibration buffer was applied to the 
column filter to equilibrate the NucleoBond® Xtra column. Following 
incubation, cell lysate was neutralised with 8mL of neutralisation buffer and 
mixed thoroughly by inversion. The neutralised bacterial cell lysate was slowly 
loaded into the column filter and allowed to pass through the filter by gravity 
flow. The filter was washed with 5mL of FIL-EF wash buffer and the filter was 
discarded after all the solution passed through the filter. The NucleoBond® 
Xtra column was then washed with 35mL of ENDO-EF wash buffer followed 
by 15mL of WASH-EF wash buffer. To elute the plasmid DNA from the 
column, 5mL of elution buffer was added into the column and the flowthrough 
elute containing the plasmid DNA was collected in a sterile 15mL conical tube. 
DNA was precipitated using isopropanol as described above and dissolved in 
200µL of endotoxin- free water.  
2.2.3.3 Transfection 
 
Lentiviral particles (LVs) were produced by transfection of HEK 293T/17 cells 
with vector plasmid (mKate2 or LTP) and packaging plasmids (psPAX2, 
Addgene, #12260; pMD2-G Addgene, #12259). 293T/17 cells were seeded at a 
density of 2 x1 06 in T-75 tissue culture flasks and incubated until cells reached 
~70% confluence. DNA solution was mixed with polyethylenimine (PEI), at a 
ratio of 1:3, allowed to form complexes for 15min at RT and then 1mL of the 
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complex mixture was added to the cells. The medium was replaced with Opti-
MEM media after 12hr. Conditioned medium containing viral particles was 
harvested after 48hr, concentrated 200-fold using Vivaspin 20 Ultrafiltration 
columns (GE Healthcare) by centrifugation at 3000g at 10°C and stored at -
80°C.  
MDA-MB-453 and MFM-223 cells were seeded in 6-well cell culture plates 
(CoStar) at a seeding density of 4 x 105 cells/well and infected with mKate or 
LTP viral particles at a multiplicity of infection equal to 1. After 48hr, the 
medium was refreshed with standard media with 2µg/mL puromycin. Cells 
were expanded under puromycin selection for at least two passages, then 
frozen into multiple cryovials and stored in liquid nitrogen for future assays. 
2.2.4 Proliferation and apoptosis assays 
Cells were seeded into 96-well cell culture plates (CoStar) in media containing 
IncuCyte® Caspase-3/7 Green Apoptosis Assay Reagent (final concentration 
5µM) and IncuCyte® NucLight Rapid Red Reagent for Live-Cell (diluted 
1:2000). For cell lines already labelled with mKate2, only Caspase-3/7 Green 
Apoptosis Reagent was added. Plates were imaged over a period of 5-7days, 
collecting four images per well every 3 hours at 10x magnification using the 
IncuCyte S3 (Essen Bioscience). The resultant images were analysed to 






2.2.5 Western blot 
2.2.5.1 Preparation of cell lysates 
For protein extraction, cells were seeded in 6-well cell culture plates (CoStar), 
allowed to attach for at least 24hr and then treated as designated for each 
experiment. After treatment, plates were placed on ice, the media removed, and 
the cells were washed three times with 1x cold PBS. Cells were then harvested 
into 1.5mL Eppendorf tubes with radioimmunoprecipitation assay buffer 
(RIPA) supplemented with 1x cOmplete Protease Inhibitor and 1x Halt 
Phosphatase inhibitor using a cell scraper. Protein lysate was passed through a 
27-gauge needle to shear DNA and centrifuged at 10,000g for 15min at 4℃ to 
pellet cell debris. The supernatant (containing the protein) was transferred to a 
new 1.5mL microcentrifuge tube and stored at -80°C.  
2.2.5.2 Protein concentration assay 
The total protein concentration of cell lysates was quantified by the Pierce 
BCA protein assay kit (Thermo Scientific). Six different concentrations of 
bovine serum albumin (BSA, 0-5mg/mL) were used as protein standards. The 
appropriate volume of protein standards or 1µL of protein samples were added 
into each well of a flat bottom 96-well plate (CoStar). After that, 200μL of 
BCA working reagent (WR) (prepared by mixing 50 parts of BCA Reagent A 
with 1 part of BCA Reagent B) was added into each well and incubated at 37℃ 
for 30min. Absorbance of protein samples was measured using a PolarStar 
microplate reader at a wavelength of 562nm. Protein concentration in the test 
samples was calculated against the standard curve. 
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2.2.5.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Protein samples were prepared for electrophoresis by denaturing ~40μg of 
lysate in a final concentration of 1x loading dye buffer at 90°C for 5min. 
Samples were then loaded into 4-12% Bis-Tris gradient SDS-PAGE gels 
(CriterionTM Precast gel, Bio-Rad) for separation with 1x concentration MOPS 
running buffer (Bio-Rad) at a constant voltage of 85V for 20min followed by 
150V for 40min (until the dye run off the gel). 5μL of Precision Plus Protein 
Dual Colour standard was used as size marker. 
2.2.5.4 Protein transfer and immunoblotting  
Transfer was performed using a standard wet transfer protocol using a 
nitrocellulose membrane (GE Healthcare life sciences). Resolving gel and 
nitrocellulose membrane were placed in-between wet filter papers (Whatman) 
and sponge pads (Bio-Rad) then placed into a transfer cassette (Bio-Rad), 
which was placed into a transfer tank (Bio-Rad Criterion Blotter) filled with 
chilled 1x transfer buffer and a frozen ice pack. Protein transfer was carried out 
at a constant current of 400mA for 60min. Ponceau staining of the 
nitrocellulose membrane was used to confirm transfer of proteins. Membranes 
were de-stained by washing with 1x TBST (Tris-buffered saline, 0.1% Tween 
20) for 10min. The nitrocellulose membrane was blocked in TBS containing 
5% skim-milk powder for 2hr at RT. The primary antibody was diluted to the 
optimal dilution in TBS buffer with 1% BSA and incubated with the membrane 
at 4ºC overnight on a rocking tray. After three washes with TBST, the 
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membranes were incubated with HRP-conjugated secondary antibody for 1hr 
at RT. Signals were visualised with Clarity Western ECL Substrate (Bio-Rad) 
as described by the manufacturer and imaged using ChemiDoc MP (Bio-Rad) 
imaging system. Protein expression was determined by densitometry using 
Image Lab Software (v5.2.1). 
2.2.6 RNA isolation and quantitative real time-polymerase 
chain reaction (qRT-PCR) 
2.2.6.1 RNA extraction 
Cells were grown in 6-well cell culture plates for RNA extraction, washed 
three times with 1x PBS and harvested into 2mL Eppendorf tubes with Trizol 
(1mL/well). Trizol samples were incubated at 37°C for 15min then mixed with 
200mL chloroform and shaken vigorously for 15sec, followed by incubation 
for 3min at RT. Samples were centrifuged at 12,000g for 15min at 4°C. After 
centrifugation, the upper aqueous phase was transferred to a new 1.5mL 
microcentrifuge tube and mixed well with 500µL isopropanol. Samples were 
incubated at RT for 10min, and RNA was pelleted by centrifugation at 12,000g 
at 4°C for 30min. Pellets were washed with 70% ethanol, allowed to dry in air 
for 15-20min, and then dissolved with ~35µL nuclease-free water. Samples 
were stored at -80°C until future use. 
2.2.6.2 DNase treatment 
Turbo-DNase kit (Thermo Scientific) was used for DNA digestion to eliminate 
genomic DNA contamination from the extracted RNA, according to the 
manufacturer’s protocol. Briefly, 10μL of 10x Turbo DNase buffer and 1μL of 
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Turbo DNase were added to 2μg RNA and incubated at 37°C for 30min. To 
inactive DNase activity, 5μL of the inactivation reagent was added for 5min at 
RT with constant mixing. Samples were centrifuged at 10,000g for 1.5min and 
supernatant was collected. RNA precipitation was conducted by incubating 
samples with 50μL 75% isopropanol and 2μL glycogen, and incubated 
overnight at -80˚C. The following day, RNA was centrifugated at 12,000g at 
4°C for 30min, washed with 70% ethanol and resuspended in ~35µL nuclease-
free water. The resulting RNA concentration and purity were determined using 
Thermo Scientific NanoDrop 2000. 
2.2.6.3 Reverse transcription  
Total RNA was converted to cDNA using iScript Select cDNA Synthesis Kit 
(Bio-Rad) before performing qRT-PCR. 1µg of RNA was diluted with 
nuclease-free water to a volume of 15μL. Diluted RNA samples were mixed 
with 5μL iScript reaction buffer and 1μL of reverse transcriptase. A control 
containing all components except RNA was also included. iScript reactions 
were run in an iCycler thermocycler using the following conditions: 25˚C for 
5min, 42°C for 30min, 85°C for 5min and 4°C hold. The cDNA was diluted 5-
fold in nuclease free water and stored at -20°C until required. 
2.2.6.4 Quantitative RT-PCR (qRT-PCR) 
Quantitative RT-PCR was performed on a CFX384 Real-Time PCR Detection 
System (Bio-Rad). Master mixes were prepared with 0.5µL of 5µM forward 
and reverse primers, 5μL iQ SYBR Green Supermix (Bio Rad), 2μL nuclease 
free water, and 2μL cDNA. Quantitative RT-PCR conditions were as follows: 
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95 °C for 3min followed by 40 cycles of 95 °C for 15sec, 55 or 60 °C for the 
annealing temperature (dependent on the primer set used), 30sec and 72 °C for 
30sec. Melt curve was determined by a temperature increase from 60˚C to 95˚C 
in 0.5˚C increments. qRT-PCR reaction primers and annealing temperature are 
listed in Table 2.3. Data were analysed using CFX Manager Software Version 
3.0 (Bio-Rad). Relative gene expression was determined by the ΔΔCT method 
using GAPDH as an internal control for quantification analyses of gene targets. 
2.2.7 Cell cycle analysis 
2.2.7.1 Fixation and staining 
Cell cycle was monitored by measuring DNA content using the DNA-binding 
fluorescent dye propidium iodide (PI). For cell cycle analysis cells were grown 
in 6-well cell culture plates. On the day of harvest, growth media (containing 
dead cells) was collected in a 50mL conical tube, and cells were detached with 
trypsin and added to the same tube containing the media. Cells were 
centrifuged at 1500g for 5min, pellets were resuspended in 500μL PBS, slowly 
dropped into 4.5mL of pre-chilled 70% ethanol and incubated overnight at 
4 °C. Fixed cells were washed with PBS, then pelleted and resuspended in 1mL 
of PI solution (50µg/mL PI 0.1% Triton X-100 and 100µg/mL RNase A) and 
incubated for 30min at RT.  
2.2.7.2 Flow cytometry analysis  
PI-stained cells were analysed on FACS Canto II (BD Biosciences) running 
CellQuest software (BD Biosciences). Prior to sample run, the instrument was 
set up with calibration particles (BD™ CS&T beads) to perform quality control 
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of the instrument’s optics, electronics, and fluidics. A blue laser operating at 
488 nm was used for excitation and PI fluorescence was collected using the red 
channel (560-615nm). A medium flow rate (60 μL/min) was used, and 1 x 105 
nuclei were analysed from each sample. The flow rate and amplification 
settings were kept constant throughout the experiment. A PI fluorescence area 
(PI-A) vs. PI fluorescence width (PI-W) dot plot was drawn on a linear scale to 
eliminate clumps and aggregates using qualitative gating. A PI-A histogram 
was drawn to view nuclear DNA content. Data were processed using FlowJo 
V10.6. 
2.2.8 Chromatin immunoprecipitation (ChIP) coupled with 
PCR (ChIP-PCR) or sequencing (ChIP-seq) 
2.2.8.1 Harvesting and cross-linking 
The MDA-MB-453 or MFM-223 cell lines were seeded into 150mm tissue 
culture dishes (to a confluency of approximately 70%; 4 x dishes per treatment) 
in normal maintenance culture media, allowed to attach for 24-48 hrs, then 
washed with warm PBS and plated in culture media supplemented with 5% 
steroid-stripped FBS for three days, with daily media changes to ensure a 
steroid-free environment, and then treated as designed for each experiment. 
Three independent replicate experiments were performed, representing 
consecutive passages of cells. Cells were cross-linked with 1% formaldehyde 
in solution A for 10min and quenched with 2mM glycine. Cells were washed 
three times with ice-cold PBS and harvested into 1mL ice-cold PBS containing 
1x concentration protease inhibitors cocktail (Roche) using a cell scraper. Cells 
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were centrifuged at 1,300g at 4°C for 3min, the supernatant was removed, and 
cell pellets snap-frozen on dry ice and stored at 80° C. 
2.2.8.2 Lysis and sonication 
Frozen cell pellets were thawed on ice for 30min and resuspended in cell lysis 
buffer (LB1), rotated for 10min at 4°C, pelleted at 2,000g at 4°C for 5min, 
discarding the supernatant. Cell pellets (containing the nuclear content) were 
resuspended in nuclear lysis buffer (LB2), incubated for 10min at 4°C and 
centrifuged at 2,000g for 5min. Chromatin was resuspended in lysis buffer 3 
(LB3) and sonicated to produce chromatin fragments of 100-500bp. Sonication 
was performed with a Diagenode Bioruptor® Plus UCD 300-TO for 10min 
cycling with 30sec ‘ON’ and 30sec ‘OFF’. Sonicated lysate was centrifuged for 
10min at 20,000g at 4°C to remove debris. 1% of the sonicated chromatin was 
taken as input control. The rest of the chromatin samples were 
immunoprecipitated overnight with 5µg of mouse monoclonal TFAP-2β 
antibody (Santa Cruz, # SC-390119) bound to Protein G Dynabeads (Thermo 
Scientific, #10004D), 5µg of rabbit polyclonal AR antibody (Abcam, 
#ab108341) or 2µg rabbit polyclonal H3K27ac antibody (Abcam, # Ab4729) 
bound to Protein A Dynabeads (Thermo Scientific, #10002D). The following 
day, beads were washed six times with ice-cold RIPA buffer followed by one 
wash with cold TE buffer supplemented with 50mM NaCl to remove unbound 
DNA. Protein-DNA complexes were eluted from the beads by resuspension in 
200μL elution buffer. 150μL of elution buffer was also added to the input 
sample and both the input and test (ChIP) samples were incubated overnight at 
65°C to reverse protein-DNA cross links. The following day, the supernatant 
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was collected and diluted with a 200μL elution buffer, ready for DNA 
purification. 
2.2.8.3 DNA purification  
For DNA extraction, 8μL of 1mg/mL RNase A was added to ChIP and input 
samples and incubated at 37°C for 1hr. Proteins were digested by incubation 
with 20mg/mL Proteinase K for 2hr at 55°C. DNA was purified using 400µL 
of phenol-chloroform-isoamyl alcohol (25:24:1), vigorously mixed and spun at 
10,000g for 5min to separate phases. The top aqueous phase was collected into 
a new microcentrifuge tube and DNA precipitation was performed with 2μL 
glycogen and 800μL 100% ethanol overnight at 80°C. DNA was pelleted at 
14,000g for 30min, washed with 70% ethanol and air-dried. The pellets were 
resuspended in 20μL 10mM Tris-HCl pH 8.0. DNA concentration was 
measured using Qubit® 2.0 fluorometer (Invitrogen).  
2.2.8.4 ChIP-PCR and ChIP-seq  
ChIP-PCR reactions were prepared using iQ SYBR Green Supermix (BIO-
RAD) and primers as listed in Table 2.3. Each qRT-PCR reaction contained 
2μL ChIP DNA, 1μL primer mix (0.5μL of 5μM forward and reverse primers 
each), 5μL SYBR green master mix and 2μL of nuclease free water. PCR 
conditions were as follows: 95 °C for 3min followed by 40 cycles of 95°C for 
15sec, 60°C for 30 sec and 72°C for 30sec. Negative controls (without addition 
of DNA) were included in each run. PCR was performed with the CFX384 
Real Time PCR Detection System (Bio-Rad). ChIP-PCR data was analysed 
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using the %Input method, and further depicted as Fold Enrichment over 
negative control (NC). 
For sequencing, 5ng of DNA (ChIP-enriched or input) was used for library 
preparation with an Illumina TruSeq ChIP Library Prep Kit (Illumina) and 
sequenced (75bp single-end reads) at the South Australian Health and Medical 
Research Institute, Genomics Facility, using an Illumina NextSeq 500. All 
computational analyses were performed using Galaxy Bioinformatics Platform 
(Jalili et al. 2020) (for more details see chapter three, section 3.2.2.2) 
2.2.9 Immunohistochemistry   
2.2.9.1 Preparation of tissue for paraffin embedding.  
Extracted tissues were immediately fixed in 10% neutral buffered formalin and 
incubated overnight at 4°C. The following day, tissues were transferred into 
70% ethanol and then processed for dehydration using the Tissue-Tek VIP 
automated tissue processor (Sakura, Torrance, CA). After processing, tissues 
were embedded in paraffin wax using the Leica embedding machine and stored 
at RT until required. Paraffin sections were cut using a Leica sledge microtome 
at 5µm and floated in 37°C water bath. The sections were collected on 
superfrost slides (Thermo scientific) or Adhesive microscope slides 
(TRAJAN), and incubated overnight at 50°C. 
2.2.9.2 Immunohistochemistry staining  
Sections were deparaffinized in three changes of xylene for 5min, followed by 
dehydration using 100% ethanol. The endogenous peroxidase activity was 
128 
 
blocked using 0.9% H2O2 in PBS for 15min followed by two washes in 1x PBS 
for 5min. Slides were subjected to heat‐induced epitope retrieval using 
Decloaking Chamber (BioCare-medical) in 10mM citrate buffer (pH 6.5). Non-
specific immunoglobulin binding was blocked by incubation with 5% goat 
serum in 1x PBS for 30min. The blocking solution was then replaced with the 
required primary antibody at the optimal concentration and incubated overnight 
in a humidified chamber at 4°C. After washing slides twice with 1x PBS, the 
secondary biotinylated antibody was applied for 1hr at RT. Horseradish 
streptavidin-peroxidase conjugate was applied for 1hr, then the sections were 
incubated with the peroxidase substrate, 3‐3′‐diaminobenzidine chromogen 
(DAB) in tris-buffer (pH 7.4) containing 0.01% H2O2 for 6min, to develop a 
brown reaction product. Slides were then washed twice with 1x PBS and 
counterstained with Mayer's hematoxylin for approximately 2min. Once 
stained, the sections were then dehydrated in 100% ethanol and placed in 
xylene. Mounting media was added to the tissue sections and a cover slip 
placed carefully to seal the tissue, minimising bubble formation. Appropriate 
positive and negative (minus primary antibody) controls were included in all 
runs. Slides were scanned using a NanoZoomer 2.0HT Microscopy System 
(Hamamatsu) and visualised using NDPView2 software.  
2.2.9.3 Eosin and hematoxylin staining (H&E) 
Paraffin-embedded tissue sections (5µM) were baked onto superfrost slides for 
45min at 50°C before xylene deparaffinization and rehydration with 100% 
ethanol. Slides were washed three times with 1x PBS and incubated with 
hematoxylin for 5min. Excess hematoxylin was removed from the tissues by 
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several dips in acid alcohol and subsequently rinsed in tap water for at least 
10min. Slides were stained with eosin (0.1%) and after 5min washed 
thoroughly with tap water. The sections were then dehydrated in 100% ethanol, 
placed in xylene, and mounted using coverslips (20 x 20 mm) and DPX 
(Dibutylphthalate Polystyrene Xylene) media. Slides were scanned using a 
NanoZoomer 2.0HT Microscopy System (Hamamatsu) and visualised using 
NDPView2 software.  
2.2.10 Small interfering RNA (siRNA) transfection 
siRNA transfection was performed with Lipofectamine RNAiMax reagent 
(Thermo Scientific) according to the manufacturer's instructions. Briefly, a 
1:100 mixture of Lipofectamine RNAiMAX transfection reagent and pre-
warmed Opti-MEM media was prepared and incubated at RT for 10min. 
siRNA oligomer (20μM) was added to the mixture at final concentrations of 
2.5, 5, and 10nM and incubated for 20min at RT to allow formation of 
liposomes. Nonspecific siRNA (AllStars Negative Control siRNA) was used at 
a concentration of 10nM as a negative control. MDA-MB-453 cells were 
detached from the tissue culture flask using trypsin and counted using 
haemocytometer. For western blot, RNA extraction, and cell cycle analysis, 
500µL of the siRNA-lipofectamine mixture was added to each well of a 6 well 
plate. For reverse transfection, 7.5 x 105 cells were added into 2.5mL of media. 
Cells were harvested after 72hr for protein and cell cycle analysis and after 
48hr for RNA extraction. 
Cell proliferation assay and ChIP-seq were performed in 96-well cell culture 
plates and 150-mm cell culture dishes, respectively. Accordingly, the amount 
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of siRNA-lipofectamine mixture used was changed based on the setup of the 
experiment. For cell proliferation assays, 1.5 x 104 cells were added in 100µL 
media to 20µL of siRNA-lipofectamine mixture/well. Proliferation assay was 
conducted using IncuCyte S3 (as described in section 2.2.4). For ChIP-seq 
experiments, 1.2 x 107 cells in 15mL media were combined with 3mL of 
siRNA-lipofectamine mixture, incubated for 48hr at 37°C in a humified 
incubator with 5% CO2, then treated with vehicle (EtOH) or 10nM DHT for 
4hr and processed as described above in section 2.2.8.  
2.2.11 In situ proximity ligation assay (PLA) 
2.2.11.1 Sample preparation 
The PLA assay was performed on formalin fixed paraffin embedded tumour 
tissues and 2D adherent tissue culture cells using a Duolink II Detection Kit 
(Sigma). For tumour tissues, the standard IHC protocol was followed up until 
the protein blocking step. For 2D adherent cells, MDA-MB-453 cells were 
seeded on glass coverslips (20 x 20 mm) at a density of 3.5 x 105 in 6-well cell 
culture plates and left to attach for 48hr. Where appropriate, MDA-MB-453 
cells were treated with vehicle (EtOH) or DHT for 6hr prior to collection. Cells 
were fixed in 10% neutral buffered formalin for 10min at RT. Cellular 
membranes were permeabilised with 0.1% Triton X-100 for 1hr at RT and 
washed three times for 5min in 1x PBS.  
Tumour tissues and cell line samples were protein blocked by adding 10% 
Donkey serum in PBS (matching the host species of the labelled secondary 
antibody) and incubated for 30min at RT in a humidity chamber. The blocking 
solution was then replaced with a 1:400 dilution of rabbit anti-AR (LifeSpan 
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Biosciences, #B3326) and 1:400 dilution of mouse anti-TFAP-2β (Santa Cruz, 
# SC-390119) antibodies and incubated overnight in a humidified chamber at 
4°C. After three washes with 1x PBS, the samples were incubated with PLA 
probes supplied with the kit, diluted 1:5 in Duolink diluent for 1hr at 37°C in a 
humidity chamber. Samples were washed twice for 5min in 1x wash buffer A. 
PLA probes were ligated by incubating with ligase enzyme diluted 1:40 in 
ligation buffer for 30min at 37°C in a humidity chamber. Samples were again 
washed in 1x wash buffer A before incubation with polymerase enzyme that 
was diluted 1:80 in amplification buffer for 100min at 37°C in a humidity 
chamber. Following incubation, samples were washed twice for 10min in 1x 
wash buffer B and then washed once in 1:100 diluted wash buffer B for 1min. 
After that, samples were stained with DAPI (1/1000 in PBS) for 1min, washed 
twice for 5min in PBS in the dark, mounted with DAKO mounting medium, 
and stored in the dark at RT until analysis. The signal was visualized as a 
distinct fluorescent focus and was captured using Texas red and DAPI filters 
on the Olympus FV3000 confocal microscope (Adelaide Microscopy, The 




2.2.11.2 PLA Image Analysis using ImageJ. 
Analysis of PLA images was performed as previously described (Law et al. 
2017). Images from single scans were analysed in ImageJ to calculate the 
number of PLA puncta. Images (at least four images/replicate) were first 
transformed to 8-bit, and a threshold was then selected manually to 
discriminate PLA puncta from background fluorescence (Image > Adjust > 
Threshold). Once selected, this threshold was applied uniformly to all images 
in the sample set. The built-in ImageJ macro “Analyze Particles” was then used 
to count and characterise all objects in the threshold image. 
2.2.12 Ex vivo explant of normal breast tissue. 
Ethical approval for this study was granted by the University of Adelaide 
Human Research Ethics Committee (approval#: H-2015-175). Normal breast 
tissues were obtained (with a written informed consent form) from women 
undergoing breast reduction surgery at the Flinders Medical Centre, Adelaide, 
South Australia. Tissues were cultured ex vivo as previously described 
(Centenera et al. 2018; Dean et al. 2012). In brief, tissues were transported on 
ice to the laboratory and washed with phenol red free RPMI 1640 medium to 
remove blood. Adipose tissue was removed using a sterile scalpel, and the 
remaining connective tissue containing glandular elements was dissected into 
approximately 1mm3 pieces. Tissue pieces were placed onto gelatin dental 
sponges (Ethicon) pre-soaked in phenol red free RPMI 1640 media 
supplemented with 10%FBS, 2mM L-glutamine, 10µg/mL human recombinant 
insulin, 10µg/mL hydrocortisone, 1x concentration antimycotic-antibiotic and 
100nM E2 and incubated at 37°C with 5% CO2. After 24hr, the medium was 
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removed and replaced with a culture medium supplemented with treatments, 
followed by culture for a further 48hr. Four tissue pieces from each case were 
randomly allocated to each treatment on a single sponge. Cultured tissue pieces 
were fixed in 10% neutral-buffered formalin at 4°C overnight, dehydrated, 
embedded in paraffin wax using the Tissue-Tek VIP automated tissue 
processor (Sakura, Torrance, CA) and used for H&E and Ki-67 IHC staining.  
2.2.13 Mammary intraductal (MIND) xenografts 
2.2.13.1 Ethics approval and animals 
Animal experiments were approved by the University of Adelaide Animal 
Research Ethics Committee (approval#: M-2018-088). Female NGS (NOD 
scid gamma mouse) mice were purchased from Animal Research Centre 
(Perth, Western Australia). All the animals used in this study were between 10 
–12 weeks of age. Mice were housed at the Adelaide Health and Medical 
Sciences BioResources Facility, (The University of Adelaide). Mice were kept 
in a 12-hour light-dark cycle, temperatures of 19-23°C with 40-60% humidity, 
fed and watered ad-libitum, under pathogen-free conditions and were carefully 
monitored throughout the experiment, as per ethically approved clinical 
monitoring guidelines.   
2.2.13.2 MIND injection of breast cancer cells 
The MIND model as established by Professor Iggo, as previously described 
(Richard et al. 2016; Sflomos et al. 2016). The day before injection, the mice 
were anesthetised using isoflurane (4-5%) and the fur coat on the lower 
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abdomen around the fourth inguinal nipples was removed using hair removal 
cream (Veet). The next day, the nipples were surgically cleaned with iodine 
solution followed by 100% ethanol, and the tip of the nipples was cleaved with 
spring scissors. A total of 2 x 105 LTP labelled MDA-MB-453 cells were 
resuspended in 10µL normal growth media and injected into one of the fourth 
inguinal mammary ducts of NSG mice using a 50-gauge blunt-ended Hamilton 
syringe. Once all the 4th glands were injected, a topical analgesic (Lidocaine) 
was applied to the nipple for analgesic, and the mouse was placed on a heating 
pad for recovery to compensate a loss of body temperature. Paracetamol 
analgesic (300mg/kg) was given to the mice and removed 3 days post injection.  
Tumours were allowed to establish for 5 days, and then mice allocated by 
simple randomisation to receive vehicle (n =10) or D-11 (10 mice received 8 
doses of 200mg/kg/day and then 7 doses of 150mg/kg/day due to toxicity 
concerns) for 15 consecutive days. Tumour growth was monitored every week 
by injection of mice with 100μL of D-luciferin (30mg/mL) followed by 
bioluminescent imaging with the IVIS Lumina X5 imaging system 
(PerkinElmer). Photon counts per second were recorded using IVIS, and the 
injected mammary glands were harvested for IHC at the completion of the 
experiment. Spleen and liver tissues were collected and stained with H&E for 
pathological analysis of tissues. 
2.2.14 Statistical analysis 
Statistics were performed using Graphpad Prism 9.0. Two-tailed Student t 
tests, one-way or two-way ANOVA tests were used as indicated in the results 
sections. The half-maximal inhibitory concentration (IC50) of CDK9i D-11 was 
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determined from the generated concentration-response curves using non-linear 
regression curve fit in GraphPad 9 software. All data are expressed as the mean 
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NEGATIVE BREAST CANCER CELL LINES WITH 





Molecular apocrine and some TNBC tumours are sensitive to androgens as 
they express high levels of AR and target genes known to be regulated by AR 
in prostate cancer (Doane et al. 2006; Farmer et al. 2005; Lehmann et al. 2011). 
Although these tumours express high levels of AR, how AR signalling impacts 
their growth remains an area of controversy. The potent androgen DHT 
stimulates proliferation of the MDA-MB-453 and HCC-202 breast cancer cell 
lines, considered models of molecular apocrine breast cancer (Cochrane et al. 
2014; Doane et al. 2006; Naderi & Hughes-Davies 2008; Ni et al. 2011; Park, 
IH et al. 2019), suggesting an oncogenic role. Nevertheless, this proliferative 
response to androgen is not seen in all models of ERα-negative/AR-positive 
breast cancer. Activation of AR by DHT inhibits proliferation of the TNBC 
cell lines MFM-223 and CAL-148 (Hackenberg et al. 1993; Thakkar et al. 
2016; Thorek et al. 2019), which are both genetically similar to MDA-MB-453 
as they transcriptionally cluster with this cell line due to high expression of AR 
and known AR target genes (Lehmann et al. 2011). The precise molecular 
mechanisms by which AR can induce divergent proliferative effects in ERα-
negative breast cancer cells is unknown. This chapter bioinformatically 
assessed data generated from three contemporary genomic technologies to 
137 
 
characterise AR activity associated with proliferative versus anti-proliferative 
cellular responses in ERα-negative/AR-positive breast cancers, with the view 
to understanding the mechanistic basis of oncogenic versus tumour suppressive 
effects. The following paragraphs introduce the methodologies used to generate 
the data analysed for this chapter: RNA-seq, ChIP-seq and RIME. 
RNA sequencing (RNA-seq) uses the capabilities of high-throughput 
sequencing technology to provide insight into genome-wide transcriptional 
profiles (termed the transcriptome) (Han et al. 2011). RNA-seq is widely 
regarded as superior to other gene expression analysis approaches (Han et al. 
2011). Unlike hybridisation-based approaches (e.g. microarrays), RNA-seq 
does not require transcript-specific probes, thereby avoiding hybridisation 
issues and offering unbiased detection of known and unknown transcripts 
(Kukurba & Montgomery 2015; Wang, Zhong, Gerstein & Snyder 2009). 
Additionally, RNA-seq allows genome-wide analysis of transcription at single 
nucleotide resolution with low background signal, as the cDNA fragments 
generated from an RNA sample can be unambiguously mapped to unique 
regions on the genome (Kukurba & Montgomery 2015; Wang, Zhong, Gerstein 
& Snyder 2009). The benefits of this gene expression analysis technology have 
been evolving to better characterise gene expression profiles of breast cancer 
cells under different experimental conditions (Bi et al. 2020; Moore et al. 
2012b). For example, a previous study from our laboratory used microarray 
technology to examine gene expression changes in response to DHT and the 
synthetic progestin, MPA, in the MDA-MB-453 cell line (Moore et al. 
2012b). A recent study by Bi and colleagues used RNA-seq technology to 
screen transcriptomes of parental and tamoxifen-resistant (TAMR) MCF-7 
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breast cancer cells to identify gene expression changes associated with 
tamoxifen resistance in ERα-positive breast cancer (Bi et al. 2020). Herein, we 
used RNA-seq technology to examine AR transcriptional targets in two ERα-
negative/AR-positive cell lines, MDA-MB-453 and MFM-223, with similar 
expression levels of AR but divergent growth responses to AR agonists.   
Chromatin immunoprecipitation sequencing (ChIP-seq) is a powerful 
method for identifying genome-wide chromatin binding sites – termed the 
cistrome - of DNA-associated proteins (Schmidt et al. 2009). Before ChIP-
seq, chromatin immunoprecipitation coupled with microarray (ChIP-chip) 
was the method for studying protein–DNA interactions (Buck & Lieb 2004). 
However, due to limitations of the ChIP-chip technology including low 
resolution, high signal to noise ratio, and a dependence on hybridisation 
(Laajala et al. 2009; Trapnell et al. 2010), ChIP-seq has become the 
technique of choice amongst the research community as it has many 
advantages (Cao, Jia et al. 2016). Like RNA-seq, ChIP-seq has high 
resolution at the single base-pair level and no limitation on genome coverage 
(Ho et al. 2011). Moreover, ChIP-seq has a higher signal-to-noise ratio 
compared to ChIP-chip due to the absence of the hybridisation step, and can 
work from a much smaller amount of starting material (Ho et al. 2011). The 
basic protocol of ChIP-seq involves fixation of cells or tissue with 
formaldehyde to form covalent linkages between DNA-binding proteins and 
DNA, cell lysis, chromatin purification and subsequent fragmentation, 
followed by isolation of specific DNA–protein complexes through 
immunoprecipitation with protein-specific antibodies for a factor of interest 
(Furey 2012). The DNA isolated from the immunoprecipitated complexes is 
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then amplified by a polymerase chain reaction (PCR) and sequencing-
specific adapters ligated to the end products to form a library (Furey 2012). 
After this step, the amplicons are sequenced using next generation 
sequencing (NGS) technology (Mundade et al. 2014). The reads resulting 
from sequencing are mapped to the genome, and location of the sequenced 
DNA is identified, marking regions of protein-bound DNA for the target of 
interest (Mundade et al. 2014). ChIP-seq technology has been used to 
generate cistromes representing ERα (Carroll et al. 2006; Chi et al. 2019; 
Piggin et al. 2020; Ross-Innes et al. 2012; Singhal et al. 2016) and AR (Ni et 
al. 2011; Robinson, JL et al. 2011) in breast cancer cells. Through ChIP-seq 
technology Carroll and colleagues showed that ER cistrome was different in 
good versus poor outcome primary breast tumours and in endocrine sensitive 
versus resistant models (Ross-Innes et al. 2012). Cistrome analysis also 
furthered mechanistic understanding of AR signalling in the MD-MB-453 
cell line (Ni et al. 2011; Robinson, JL et al. 2011). The study by Robinson et 
al  (2011) mapped AR binding events for the first time in breast cancer cells 
and observed a greater overlap between the AR cistrome of MDA-MB-453 
cells and the ERα cistrome of MCF-7 breast cancer cells compared to the AR 
cistrome of LNCaP prostate cancer cells  (Robinson, JL et al. 2011). In 
contrast, Ni and colleagues found a larger overlap between the AR cistrome 
of MDA-MB-453 cells and the AR cistrome of LNCaP cells than the ERα 
cistrome of MCF-7 cells (Ni et al. 2011). Regardless of this discrepancy, 
which could be attributed to differences in experimental conditions, the 
studies concur that the potential oncogenic effect of AR in MDA-MB-453 
cells involves AR acting like ERα in a breast cancer context but also acting 
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like AR in a prostate cancer context (Hickey, T et al. 2012). By using ChIP-
seq technology, in this study, we investigated the DHT-stimulated AR 
cistromes of MDA-MB-453 and MFM-223 breast cancer cells.   
Rapid immunoprecipitation (coupled with) mass spectrometry (MS) of 
endogenous protein (RIME) is an unbiased approach for identifying 
interacting proteins (defined as the interactome) of a chromatin-bound factor 
of interest (D’Santos et al. 2015). RIME is used to purify endogenous 
protein, rather than the use of exogenous tagged approaches and can be used 
to identify protein complexes from limited amounts of starting material 
(D’Santos et al. 2015). The basic RIME protocol is similar to the first stages 
of the ChIP-seq protocol and involves formaldehyde crosslinking performed 
prior to antibody-based immunoprecipitation of endogenous protein/DNA 
complexes, with subsequent release of DNA, peptide digestion and MS 
analysis (D’Santos et al. 2015; Mohammed et al. 2016). The RIME approach 
has been used to characterise composition of ERα interactomes, identifying 
novel ERα interacting proteins in ERα-positive breast cancer cells (D’Santos 
et al. 2015; Mohammed et al. 2013; Mohammed et al. 2015). Moreover, 
RIME coupled with an amino acid labelling technique (Stable isotope 
labelling using amino acids in cell culture; SILAC) has allowed quantitative 
characterisation of changes to the ERα and PR associated interactomes to 
identify novel coregulators in agonist and antagonist-liganded conditions in 
ERα-positive breast cancer cells (D’Santos et al. 2015; Mohammed et al. 
2013; Mohammed et al. 2015). A recent study has introduced another 
modified RIME assay called quantitative multiplexed RIME (qPLEX-RIME) 
to monitor and quantify the dynamics of chromatin-associated complexes 
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(Papachristou et al. 2018). qPLEX-RIME uses Tandem Mass Tags (TMT), 
chemical isobaric reagents, to label RIME-generated peptides, which allows 
the simultaneous analysis of multiple conditions and biological replicates in 
a single experiment (Papachristou et al. 2018). In the latter study, qPLEX-
RIME was applied to discover temporal changes to the ERα interactome in 
MCF-7 cells treated with tamoxifen and to identify the ERα interactome in 
patient-derived xenograft (PDX) breast tumours and primary human breast 
cancer tissues (Papachristou et al. 2018). Our study is the first to use the 
RIME approach to investigate differences in the AR interactomes of MDA-
MB-453 & MFM-223 cells. 
This part of my PhD project implemented these contemporary techniques 
(RNA-seq, ChIP-seq and RIME) to interrogate AR action in two models of 
ERα-negative/AR-positive breast cancer with divergent proliferative 
responses to the AR ligand DHT. By examining the AR-associated 
interactomes, cistromes and transcriptomes, this chapter aimed to identify 
candidate factors that mediate oncogenic versus tumour suppressive AR 






3.2.1.1 Treatment and sample preparation 
RNA-seq data was previously generated by the host laboratory using the 
following protocol. MDA-MB-453 and MFM-223 cells were cultured in media 
supplemented with 5% steroid-stripped FBS and treated with either vehicle 
(EtOH) or 10nM DHT for 6hr. Six independent replicates representing 
consecutive passages of cells were generated per treatment condition for each 
cell line. Total RNA was extracted using the RNeasy® kit (Qiagen) according 
to the manufacturer’s instructions. In short, cells were harvested by scraping 
into RLT buffer containing 1% (v/v) 2- mercaptoethanol. One volume of 70% 
ethanol was added, and the lysate was homogenized by pipetting. The lysates 
were transferred to a RNeasy spin column and centrifuged at 9,000g for 15sec. 
The flow through was discarded and the collection tube was replaced. Samples 
were washed with RW1 buffer and centrifuged at 9,000g for 15sec. The 
RNeasy column was placed into a new collection tube, buffer RPE was added, 
and the sample was centrifuged as above. RNA was eluted with 30-50μL of 
RNase-free water. The Turbo-DNase kit (Thermo Scientific) was used for 
DNA digestion to eliminate genomic DNA contamination from the extracted 
RNA according to the manufacturer’s protocol (as described in chapter 2 
section 2.2.6.2). Concentration and quality of the RNA samples were measured 
using the Thermo Scientific NanoDrop 2000. Sequencing libraries were 
prepared using the Illumina TruSeq Stranded mRNA Library Prep High 
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Throughput Kit according to the manufacturer’s protocol starting with 1μg 
total RNA. Briefly, purified mRNAs were fragmented and converted to cDNA 
with reverse transcriptase. The resulting single-stranded cDNAs were 
converted to double-stranded cDNAs and subjected to end-repair, A-tailing, 
and adapter ligation. The constructed libraries were amplified using 15 cycles 
of PCR (98°C for 10sec, 60°C for 30sec,72°C for 30sec,72°C for 5min, and 
hold at 4°C). Samples were sequenced (40bp single end reads) at the Genomics 
Core Facility, Cancer Research UK (CRUK), Cambridge Institute, UK, using 
an Illumina NextSeq.   
3.2.1.2 RNA-seq data analysis 
Bioinformatic analysis of RNA-seq data was conducted using R program 
(v2.15.1). Sequenced regions were aligned to Human genome 19 (hg19) using 
TopHat v2.0.9 (Trapnell et al. 2010). The reads were quantified into gene 
counts using HT-Seq v0.6.0. Read counts were normalised and tested for 
differential gene expression by the edgeR package from Bioconductor (Chen, 
Y et al. 2014). Differential expression analysis was conducted using DESeq 
(Anders & Huber 2010). A gene was considered to be differentially expressed 
if it exhibited a fold change (FC) of greater than 1.5 (up-regulated gene) or less 
than 0.6 (down-regulated gene) and if the gene had a p-value less than 0.05. 
Heat maps and volcano graphs were prepared using RStudio (v1.3.959). 
3.2.1.3 Functional enrichment analysis of gene ontology 
To identify biological processes associated with differentially expressed genes 
in MDA-MB-453 and MFM-223 cells, I performed functional enrichment 
analysis of gene ontology using the Gene set enrichment analysis (GSEA) 
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website (http://www.broad.mit.edu/gsea/index.jsp) and the molecular signature 
database v7.1 (MSigDB) as the reference gene set (Liberzon et al. 2011). 
MSigDB hosts an extensive collection of genes that were grouped based on 
certain criteria such as biological role, canonical pathways, regulatory target 
genes and cellular component.  
3.2.2 ChIP-seq 
 
3.2.2.1 Treatment and samples preparation 
ChIP-seq data was previously generated by the host laboratory using the 
following protocol. The MDA-MB-453 or MFM-223 cell lines were seeded 
into 150mm tissue culture dishes at a density of 8 x 106 (4x dishes per 
treatment) in normal maintenance culture media, allowed to attach for 24-48hr, 
then washed with warm PBS and plated in culture media supplemented with 
5% steroid-stripped FBS for three day, with daily media changes to ensure a 
steroid-free environment, prior to treatment with either vehicle (EtOH) or DHT 
(10nM) for 4hr. Treated cells were immediately cross-linked with 1% 
formaldehyde for 10 min, quenched for 2min with 0.2M glycine, washed 
several times with cold PBS, and scraped into 1mL of cold PBS containing 1x 
concentration of a protease inhibitor cocktail. Cells were washed twice in cold 
PBS containing the protease inhibitor, liquid removed, and pellets frozen at -
80C until further processing. For immunoprecipitation (IP), 100 µL of 
Dynabeads® Protein A beads were pre-absorbed with 5µg of rabbit polyclonal 
AR antibody (Abcam ER179; ab108341). Chromatin isolation and 
fractionation, IP and DNA purification were performed as described in chapter 
two, section 2.2.8. Three independent replicate experiments were performed, 
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representing consecutive passages of cells. 5ng of DNA (ChIP-enriched or 
input) was used for library generation with an Illumina TruSeq ChIP Library 
Prep Kit (Illumina) and sequenced (75bp single-end reads) at the South 
Australian Health and Medical Research Institute- Genomics Facility using an 
Illumina NextSeq 500.  
3.2.2.2 ChIP-seq data processing  
Quality control, alignment, and peak calling 
All computational analyses were performed using the Galaxy Bioinformatics 
Platform (Jalili et al. 2020). Quality control assessment for the raw sequencing 
data (FASTQ) was conducted using FastQC (Galaxy v0.72+galaxy1). FastQC 
checked whether the raw sequencing reads contained PCR primers and 
adaptors and provided information about the base quality score (Brown, J, 
Pirrung & McCue 2017). The base quality score, also known as a Phred or Q 
score is an integer value representing the estimated probability of an error, i.e., 
that the base is incorrect (Wan, Anh & Asai 2012). The score generally range 
from 2 to 40 with higher scores indicating greater confidence in the call (Wan, 
Anh & Asai 2012). All reads were trimmed for adapter sequences and poor-
quality bases using the default parameters of Filter by quality tool (Galaxy 
v1.0.2+galaxy0). Sequenced regions were aligned to hg19 using the Bowtie2 
default parameters (Langmead et al. 2009), mapped reads with a minimum 
mapping quality (MAPQ) <10 and duplicate reads were removed using filter 
SAM/BAM tools (Galaxy v1.8+galaxy1). To identify genomic regions that 
were enriched with aligned reads (peak calling), I used the MACS2 tool 
(Galaxy v2.1.1.20160309.6) with a pooled input sample as the control.  
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Consensus bed files 
Consensus bed files containing peaks that appeared in at least two of the three 
replicates (rep) of a particular condition were generated. Intersect-intervals 
Bedtool (Galaxy v2.29.0) was used to intersect overlapping pieces of intervals 
between rep 1 and rep 2 (generating file A), rep 1 and rep 3 (generating file B), 
and rep 2 and rep 3 (generating file C), of a given treatment with a minimum 
overlap of 1bp. After that, intersected intervals (File A, B, & C) were 
concatenated together using Concatenate (Operate on Genomic Intervals, 
Galaxy v0.1.0) and merged to remove any duplicate reads using 
Bedtools/combine overlapping-nearby intervals into a single interval (Galaxy 
v2.29.2). Consensus files were used for downstream analysis.  
Peak annotation and motif analysis 
 
Regions of AR chromatin binding (peaks) were annotated with respect to 
neighbouring genes (≤100 kb from the transcription start site) using 
CisGenome (v2). Peak annotation results were integrated with the outcomes of 
the differential expression analysis using Join two files (Galaxy Version 1.1.2) 
and Filter data (Galaxy Version 1.1.1) tools. Motif analysis was conducted 
using MEME-ChIP online tool, v5.1.1 (Machanick & Bailey 2011). As 
MEME-ChIP needs FASTA sequence as an input file, peak summits were 
extended +/-250bp around the summit using bedtools and FASTA sequence for 
each centered interval was extracted using Extract Genomic DNA tool (Galaxy 
V3.0.3+galaxy2). Extended FASTA files were used as an input for MEME-




 Presentation of ChIP-seq results 
A principal component analysis (PCA) plot and heatmaps were generated from 
multiBigwigSummary using Generate PCA plots (Galaxy v3.3.2.0.0) and 
plotHeatmap (Galaxy Version 3.3.2.0.1) tools, respectively. ChIP-seq data was 
visualized using the Integrative Genomics Viewer (IGV) (Robinson, JT et al. 
2011).  
3.2.3 RIME 
3.2.3.1 Sample preparation 
RIME was previously performed by my supervisor, A/Prof Theresa Hickey, 
while she was working in the Carroll laboratory (Cancer Research UK, 
Cambridge Institute) as described (Paltoglou et al. 2017). Briefly, MDA-MB-
453 and MFM-223 cells were plated at 8 x 106 in maintenance culture media in 
6 x 150 mm tissue culture dishes per condition. After 48hr, cells were cross-
linked with 1% EM-grade formaldehyde for 7min, quenched with 2mM 
glycine for 2min, washed several times with ice-cold PBS, and harvested into 
ice-cold PBS containing a protease inhibitor cocktail using a cell scraper. Two 
cell pellets were created for each experiment, representing 6 plates of cells 
each, one for the AR IP and the other for an IgG control. Two independent 
replicates were prepared for MDA-MB-453, the first line to undergo 
investigation, but three independent replicate experiments were subsequently 
performed for MFM-223 cells. These replicates represented consecutive 
passages of cells. For IP, Dynabeads® Protein A beads were pre-absorbed with 
10µg of rabbit polyclonal AR antibody (Santa Cruz Biotechnology, AR N20: 
sc-816) or anti-Rabbit IgG (Santa Cruz Biotechnology, sc-2027). For 
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chromatin isolation, cell pellets were resuspended in LB1 (50mM HEPES-
KOH (pH 7.5), 140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40 and 
0.25%Triton X-100) followed by rotation mixing for 10 min at 4°C. Then, 
nuclei were pelleted and resuspended in LB2 buffer (10mM Tris-HCL (pH 
8.0), 200mM NaCl, 1 mM EDTA and 0.5mM EGTA) and rotated at 4°C for 
5min. The samples were then resuspended in LB3 buffer (10mM Tris-HCl (pH 
8), 100mM NaCl, 1mM EDTA, 0.5mM EGTA, 0.1% Na-deoxycholate and 
0.5% N-lauroylsarcosine) and sonicated in a water bath sonicator (Diagenode 
Bioruptor). The bead-bound antibody and sonicated chromatin were incubated 
overnight at 4°C. The following day, beads were washed 10 times with ice-
cold RIPA buffer followed by one wash in freshly prepared 100mM AMBIC 
(ammonium bicarbonate) to remove unbound proteins. A 10μL trypsin solution 
(15ng/μL) prepared in 100mM AMBIC was added to the beads followed by 
overnight incubation at 37°C. The next day, trypsin solution was added for a 
second digestion step followed by incubation for 4h at 37°C. At the end of the 
second digestion step, the tubes were placed on a magnet and the supernatant 
solution was collected and acidified by the addition of 2μL 5% formic acid. 
Digested peptides were analysed at the Proteomics Core Facility, Cancer 
Research UK (CRUK) Cambridge Institute, UK, using an LTQ Orbitrap MS 
system (Thermo Scientific) as described (Paltoglou et al. 2017). 
3.2.3.2 RIME data analysis 
MS peptides reads were identified via the SwissProt human database using the 
Mascot search engine v2.3.0. Only co-precipitating proteins that occurred in all 
independent biological replicates were considered. These proteins were 
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identified using the ‘comparing values of two-three lists’ tool of BaRC 
(Bioinformatics & Research Computing) and then further filtering was 
achieved by excluding proteins that appeared in matching IgG controls. The 
molecular function of AR co-regulators was determined using Metascape (A 
Gene Annotation & Analysis Resource) (Zhou, Yingyao et al. 2019).  
3.3 Results 
3.3.1 Transcriptional targets of AR in MDA-MB-453 and 
MFM-223 cells 
3.3.1.1 mRNA expression of known AR target genes in the RNA-seq 
datasets 
Results of the RNA-seq experiments were firstly examined to validate changes 
in mRNA expression of genes that are known to be regulated by androgens in 
breast and/or prostate cancer. FKBP5 acts as a co-chaperone that modulates 
steroid hormone receptor activity (Fries, Gassen & Rein 2017). FKBP5 
expression is often used as an indicator of functional AR signalling, as it 
reflects better than any other AR target gene, the presence of residual androgen 
after either short or long-term androgen deprivation therapy in prostate cancer 
(Zhou, Ye, Bolton & Jones 2015). Our results showed that treatment of MDA-
MB-453 cells with DHT significantly increased FKBP5 mRNA expression 
(FC=4.14, p-value= 6.6E-11) in comparison to vehicle treated cells. Similar 
results were observed in DHT-treated MFM-223 cells (FC=3.29, p-value= 
9.6E-15). C1orf116 is highly expressed in prostate cancer tissues and has been 
shown to be up-regulated by androgens in prostate cancer cell line models 
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(Steketee et al. 2004). Our RNA-seq data showed that DHT significantly 
induced mRNA expression of C1orf116 by nine and four-fold in MDA-MB-
453 and MFM-223 cells, respectively. Other genes which have been previously 
shown to be upregulated by DHT or the synthetic androgen R1881 in MDA-
MB-453 cells via microarray, such as SEC14L2, RANBP3L, UGT2B28, and 
WNT7B (Moore et al. 2012b; Ni et al. 2013; Ni et al. 2011), also demonstrated 
increased mRNA levels upon DHT treatment in MDA-MB-453 and MFM-223 
cells (Table 3.1). KLK3 is a key downstream target gene of the AR in normal 
and malignant prostate tissues and is a serum biomarker to monitor prostate 
cancer progression (Saxena et al. 2012). Exposure of MDA-MB-453 cells to 
DHT did not induce expression of KLK3, an observation in agreement with 
previous studies that have reported that KLK3 is not induced by androgens in 
this cell line (Magklara, Brown & Diamandis 2002; Magklara et al. 2000; 
Moore et al. 2012b). Interestingly, in MFM-223 cells, DHT caused a ~19 fold 
increase in KLK3 mRNA level relative to the vehicle (Table 3.1). CLDN8 
encodes a protein that forms tight junctions in cell membranes (Ashikari et al. 
2017; Zhang, Y et al. 2020) and is associated with several signalling pathways 
implicated in epithelial cell proliferation and has been identified as an 
androgen-regulated gene in prostate cancer (Tsukita et al. 2008). CLDN8 
expression was significantly increased (FC=9.44, p-value=8.3E-07) upon DHT 
treatment in MDA-MB-453 cells (Table 3.1).  
Collectively, these examples provide confirmation that the RNA-seq data used 
in this study demonstrates responses to DHT treatment that are consistent with 
androgenic responses of previous studies in prostate, validating its use for 
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characterising transcriptomic differences that might underscore differential 




Table 3.1: mRNA expression of known AR target genes in response to DHT in 
MDA-MB-453 & MFM-223 cells. Six independent replicates representing 
consecutive passages of cells were generated per treatment condition for MDA-
each cell lines. p-value was generated using One Way ANOVA. 




DHT versus vehicle 
MFM-223 
DHT versus vehicle 
FC p-value FC p-value 
ENSG00000096060 FKBP5 4.14 6.6E-11 3.29 9.6E-15 
ENSG00000182795 C1orf116 9.44 6.4E-12 3.89 2.8E-16 
ENSG00000100003 
 
SEC14L2 41.44 1.1E-13 5.29 2.1E-16 
ENSG00000164188 
 
RANBP3L 18.52 1.2E-11 16.36 5.5E-18 
ENSG00000135226 
 
UGT2B28 32.09 1.1E-08 14.21 2.34E-07 
ENSG00000142515 
 
KLK3 ND ND 19.91 5.58E-05 
ENSG00000156284 
 
CLDN8 9.44 8.3E-07 ND ND 
 




3.3.1.2 Differential expression analysis of RNA-seq data 
To identify differentially expressed genes (DEG) between vehicle and DHT 
treatments, the DESeq workflow was used. Hierarchical clustering of genes 
regulated by DHT versus vehicle was performed to check if the replicates of 
each treatment group had similar gene expression profiles. As shown in Figure 
3.1, replicates of each treatment condition were clustered together in each cell 
line. Using the filtering criteria of fold change (FC) ≥1.5 and p-value of <0.05, 
443 genes were up-regulated in the DHT treatment group compared with the 
vehicle group in MDA-MB-453 cells (Figure 3.2A). For the down-regulated 
genes, filtering criteria of FC < 0.6 and p-value of <0.05 were used. DHT 
significantly down-regulated expression of 304 genes in MDA-MB-453 cells 
compared with the vehicle (Figure 3.2A). In the MFM-223 cell line, DHT 
significantly induced mRNA expression of 393 genes (FC ≥1.5) and down-
regulated mRNA levels of 323 genes (FC < 0.6) compared with the vehicle 
(Figure 3.2B). Unique and shared genes between MDA-MB-453 and MFM-
223 cell lines were also assessed. About 15.2% (110 genes) of DHT up-
regulated genes were common between MDA-MB-453 and MFM-223 cell 
lines (Figure 3.2C, Appendix 2A). DHT down-regulated genes showed less 
overlap, with only 37 genes (6.2%) shared between MDA-MB-453 and MFM-
223 cells (Figure 3.2D, Appendix 2B). Whereas some genes were up or down 
regulated by DHT in both cell lines, the majority of DHT-regulated genes were 
modulated in only one of the two cell lines (Figure 3.2 C-D). In MDA-MB-453 
cells, 333 genes (45.9%) were uniquely up-regulated, and 267 genes (45.3%) 
were uniquely down-regulated by DHT. In MFM-223 cells, treatment with 
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Figure 3.1: Heat maps depict the clustering of top 200 differentially expressed 
genes (DHT versus vehicle) in (A) MDA-MB-453, and (B) MFM-223 cells. 
Note that the Veh treatment group for MFM-223 cells only has 5 independent 
replicates representing consecutive passages of cells because the sequencing 

















Figure 3.2: RNA-seq analysis of AR transcriptomes in MDA-MB-453 & 
MFM-223 cells. Volcano plots showing distribution of gene expression for 
DHT in MDA-MB-453 (A) and MFM-223 (B) cells compared to vehicle 
control. Blue or orange points represent significantly up-regulated genes (Sig. 
Up) with FC ≥1.5 & p-value <0.05; pink or green points represent significantly 
down-regulated genes (Sig. Down) with FC< 0.6 and p-value <0.05; petrol 
blue or light gray points represent genes with 1.5 > FC ≥ 0.6 (p-value <0.05) 
and/or p-value ≥ 0.05. (C-D) Venn diagrams showing the number of genes 





regulated (FC< 0.6 and p-value <0.05) by DHT in MDA-MB-453 and MFM-
223 cells. 
3.3.1.3 Functional annotation of DHT-regulated genes in MDA-MB-
453 versus MFM-223 cells 
DHT-regulated genes unique to MDA-MB-453 cells 
Functional enrichment analysis of Gene Ontology (GO) terms was performed 
to provide a global view about biological processes associated with DHT-
regulated genes in MDA-MB-453 versus MFM-223 cells (Figure 3.3 and 
Appendix 2C-F). Genes that are uniquely regulated by DHT in MDA-MB-453 
and MFM-223 cells, potentially contribute to the divergent proliferative effects 
of this ligand in those two cell lines. Therefore, this section will first discuss 
GO terms of unique DHT-regulated genes, and then will address common 
genes. The identified DHT up-regulated genes that were unique to the MDA-
MB-453 cell line fit mainly into four categories: (1) response to steroid 
hormones; 2) metabolism; 3) development and (4) growth (Figure 3.3A and 
Appendix 2C). In particular, DHT treatment significantly increased the 
expression of many genes associated with lipid metabolism in MDA-MB-453 
cells including FAR2, ACSL4, ACSL1, PDSS1, ALDH1A3, PLCB2, PLCH2, 
and HSPG2. Genes associated with other metabolic processes were also 
enriched by DHT in this cell line, including amino acid, ribonucleoprotein, and 
carbohydrate metabolism. Examples of genes that were involved in these 
pathways are listed in Appendix 2C.  
Genes associated with developmental processes such as epithelium & 
mesenchymal tissue development and major organ system development (such 
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as nervous, reproductive, circulatory, and immune system development) were 
also induced by DHT in MDA-MB-453 cells. Among these genes are EPHA2, 
FGFR2, EPHA7, DDN, AFF3, NAV2, ISX (Appendix 2C). The RNA-seq 
results also revealed DHT-induced expression of genes associated with cell 
survival/growth including CAMKK1 (Brzozowski & Skelding 2019; Karacosta 
et al. 2012; Massie et al. 2011), ALKBH2 (Fujii et al. 2013; Pilžys et al. 2019), 
TOX3 (Dittmer et al. 2011; Seksenyan et al. 2015), SGK1 (Lang et al. 2010; 
Shanmugam et al. 2007),  and WNT4 (Ni et al. 2011).   
On the other hand, the GO analysis showed that DHT significantly suppressed 
mRNA levels of several genes that are associated with cell motility, adhesion, 
wound healing, and invasion pathways (Figure 3.3B) in MDA-MB-453 cells. 
Examples of these genes are: COL5A3, CCR2, FBLN5, MMP-7, MMP-14, 
VTN, ADGRB1, SDK1, MCMAM, CDH13 and many other genes listed in 
Appendix 2D. Moreover, the data showed that DHT treatment decreased the 
expression of genes with purported tumour suppressor activity including DLC1 
(Plaumann et al. 2003; Song, YF et al. 2006; Ullmannova-Benson et al. 2009), 
FBXW7 (Sailo et al. 2019; Yeh, C-H, Bellon & Nicot 2018), and SFRP1 
(Klopocki et al. 2004). The fold change and p-values for all genes discussed in 





















Figure 3.3: Functional annotation of genes uniquely regulated by DHT in the 
MDA-MB-453 cell line compared to the MFM-223 cell line. Bar graph (A) 
shows the biological processes associated with DHT up-regulated genes, while 
bar graph (B) shows biological pathways associated with DHT down-regulated 





DHT-regulated genes unique to MFM-223 cells 
In MFM-223 cells, activation of AR by DHT induced mRNA levels of genes 
involved in ion and transmembrane transport, cell motility, response to 
hormones and regulation of proliferation & cell death (Figure 3.4A & 
Appendix 2E). We further investigated the genes that were enriched in 
regulation of proliferation & cell death pathways. Among these genes, we 
identified the transcriptional repressor ZBTB16 and negative regulator of 
growth factor signalling LRIG1. ZBTB16 and LRIG1 are tumour suppressor 
genes in several human cancers including breast, prostate, bladder, colon, 
cervical, and lung (Cao, JingPing et al. 2013; Hedman & Henriksson 2007; 
Kikugawa et al. 2006; Krig et al. 2011; Li, Q et al. 2019; Lindquist et al. 2014; 
Ljuslinder et al. 2007). DHT also induced expression of other genes that have 
tumour suppressor activity in different types of cancer including RGS2 (Cao, X 
et al. 2006), ZNF689 (Hu, Ruozhen et al. 2011), SPDEF (Cheng, X-H et al. 
2014), TNFAIP3 (Honma et al. 2009), IGFBP3 (Cai, Dozmorov & Oh 2020), 
HIPK2 (Feng, Yuanyuan et al. 2017), HPGD (Wolf, I et al. 2006) and Nkx 3.1 
(Bhatia-Gaur et al. 1999).  
Genes that were significantly and uniquely repressed by DHT in MFM-223 
cells were involved mainly in development and homeostasis regulation (Figure 
3.4B & Appendix 2F). Moreover, DHT decreased mRNA expression of genes 
involved in cell survival or with purported oncogenic activity such as LGR5 
(Xu, L et al. 2019; Yang, L et al. 2015), TM4SF18 (Allioli et al. 2011; Cao, Jia 
et al. 2016; Huang, Y-K, Fan & Qiu 2016; Sun, Y et al. 2015; Zukauskas et al. 
2011), and BCL2 (Dawson et al. 2010; Merino et al. 2016). The fold change 
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Figure 3.4: Functional annotation of genes uniquely regulated by DHT in the 
MFM-223 cell line compared to the MDA-MB-453 cell line. Bar graph (A) 
shows the biological processes associated with DHT up-regulated genes, while 
bar graph (B) shows biological pathways associated with DHT down-regulated 





DHT-regulated genes common to MDA-MB-453 and MFM-223 cells 
Since the number of genes that were regulated by DHT in both cell lines was 
low (up-regulated genes =110 and down-regulated genes =37), Gene Ontology 
analysis did not show significant enrichment of these genes in specific 
biological processes. However, among the most significantly up-regulated 
genes are UGT2B28, UGT2B11, CYP4F8, and SLC26A3 (Appendix 2A). 
UGT2B28 and UGT2B11, encode proteins that maintain intracellular steroid 
hormone homeostasis by inactivating steroids through the addition of a sugar 
moiety to a hydroxyl group (glucuronidation) within the steroid molecule 
(Barbier et al. 2008; du Toit & Swart 2016). The glucuronidation of androgens 
renders them unable to bind the AR, allowing the secretion of conjugated 
steroids (Barbier et al. 2008; du Toit & Swart 2016). CYP4F8 encodes a 
member of the cytochrome P450 superfamily of enzymes that catalyse 
synthesis of cholesterol, steroids and other lipids (Vainio et al. 2011). CYP4F8 
silencing significantly reduced cell viability in  LNCAP prostate cancer cells 
(Vainio et al. 2011). SLC26A3 is a transmembrane glycoprotein that transports 
chloride ions across the cell membrane in exchange for bicarbonate ions 
(Dorwart et al. 2008). While the role of SLC26A3 as an AR target gene has not 
yet been studied, AR signalling has shown to be able to enhance transcription 
of members of the solute carrier family that transport lipid molecules, glucose, 
amino acids, and other nutrients such as SEC14L2, SLC1A3, SLC16A6 and 
SLC2A5 (Moore et al. 2012b; Sakakibara et al. 2021; Xu, Y et al. 2006). 
Moreover, DHT significantly up-regulated expression of C-MYC and WNT7B 
in both MDA-MB-453 and MFM-223 cells. Previous studies have examined 
the role of C-MYC and WNT7B  genes in AR signalling in MDA-MB-453 (Ni 
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et al. 2013; Ni et al. 2011). As previously discussed in Chapter 1 (Section 
1.4.8), DHT stimulates the expression of WNT7B and HER3 in MDA-MB-453 
cells, leading to activation of the Wnt/β-catenin and HER2 signalling 
pathways, which are required for androgen-induced growth of these cells (Ni et 
al. 2011). DHT-induced HER2 signalling also induces PI3K/AKT pathway 
activation, which in turn leads to degradation of MAD1 (MXD1), which 
disrupts the MAD1–MAX complex (Ni et al. 2013). This allows MAX to 
interact with MYC, leading to enhance oncogenic function of MYC (Ni et al. 
2013). Here, we also showed that DHT stimulates expression of the MYC and 
WNT7B in MFM-223 cells, which their growth is inhibited by DHT. This may 
indicate that MYC and WNT7B signalling are not the main signalling 
pathways mediating oncogenic effects of AR in ERα-negative/AR-positive 
breast cancer or it may also indicate that MFM-223 cells lack some factors that 
mediate oncogenic effects of those signalling pathways.  
In both MDA-MB-453 and MFM-223 cell lines, DHT significantly suppressed 
mRNA levels of genes associated with cell migration including CCR1, CXCR4, 
WNT6, GBP2, AMIGO2, and LURAP1L. Moreover, the AR gene itself was 
significantly down-regulated by DHT in MDA-MB-453 and MFM-223 cells. 
Negative autoregulation of AR mRNA by androgens has been reported for 
prostate (Wolf, DA et al. 1993; Yeap, Krueger & Leedman 1999) and breast 
cancer cell lines (Hall, R et al. 1994; Hall, RE et al. 1992; Yeap, Krueger & 
Leedman 1999).  
Moreover, few genes were found to be regulated in the opposite way by DHT 
in MDA-MB-453 and MFM-223 cells (Table 3.2). An example of a gene that 
was up-regulated by DHT in MDA-MB-453 cells but down-regulated in MFM-
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223 cells is PLCB2. PLCB2 catalyse the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) and generates 2 important downstream materials: 
diacylglycerol (DAG) and inositol1,4,5-trisphosphate (IP3) (Lopez et al. 2001). 
DAG and IP3 involve in a great diversity of signalling pathways, such as the 
Ras signalling pathway and Rho signaling pathway (Lopez et al. 2001; Wang, 
X et al. 2018). PLCB2 knockdown inhibits proliferation of PC3 and DU145 
prostate cancer cell lines via the PTEN/AKT signalling pathway (Wang, X et 
al. 2018). An example of a gene that was down-regulated by DHT in MDA-
MB-453 cells but up-regulated in MFM-223 cells is CXCR7. CXCR7, a 
chemokine receptor able to bind the chemokines CXCL12/SDF-1 and 
CXCL11, the primary regulator for cell migration, invasion, and expression of 
metalloproteinase (Sun, X et al. 2010). Similar to the effect of DHT on mRNA 
expression of CXCR7 in MDA-MB-453 cells, treatment of LNCaP prostate 
cancer cells with 1 nM DHT for 48 hr reduced the expression of CXCR7 by 
70% (Yu, L, Yu & Wang 2015). The fold change and p-values for all genes 




Table 3.2: mRNA expression of genes regulated in the opposite way by DHT 
in MDA-MB-453 and MFM-223 cells.  
Ensembl gene ID Gene symbol 
MDA-MB-453 
DHT versus vehicle 
MFM-223 
DHT versus vehicle 
FC p-value FC p-value 
ENSG00000143153 ATP1B1 2.182048 5.73E-07 0.5163 6.56E13 
 
ENSG00000211448 DIO2 2.916672 0.009179 0.516783 
 
0.002321 
ENSG00000137841 PLCB2 4.789161 2.31E-05 0.445167 8.74E-07 
ENSG00000163638 ADAMS9 
 
0.404246 0.019345 2.231762 0.026749 
ENSG00000122786 CALD1 0.299778 
 




0.502467 0.037541 2.080464 0.000128 








3.3.2 Genome-wide identification of AR binding sites (ARBS) in 
MDA-MB-453 versus MFM-223 cells 
3.3.2.1 Overview of AR ChIP-seq data  
To examine whether differences in the DHT-regulated transcriptomes in MDA-MB-453 
and MFM-223 cells are due to differences in their AR cistromes, the unpublished AR 
ChIP-seq data of MDA-MB-453 and MFM-223 cells treated with vehicle or 10 nM DHT 
for 4 hours was analysed. An overview of the number of the reads that passed through the 
quality control assessment steps, mapping efficiency, and number of called ChIP peaks 
for each sample are shown in Appendix 2G. Overall, all samples had a base quality score 
(Phred score) ≥ 34 and unique aligned rate (%) ≥ 74, indicating the high quality of the 
data. PCA was used to check if the replicates of each treatment condition had similar peak 
profiles. There was a strong correlation between ChIP-seq replicates in each treatment 
group; PCA identified two distinct clusters separated along PC2 in each cell line 
corresponding to the vehicle and DHT treatments (Figure 3.5A). To compare the DHT-
stimulated AR cistromes associated with the MDA-MB-453 and MFM-223 cell lines, I 
created consensus peak-sets containing reproducible binding regions identified in at least 
two of the three replicates for each condition (i.e., vehicle and DHT). As expected, the 
consensus AR cistrome was markedly expanded in the presence of DHT in both cell lines 
due to ligand-induced receptor activation (Figure 3.5B). AR was recruited to 18,777 
consensus DNA binding sites in MDA-MB-453 cells and 14,493 consensus binding sites 
in MFM-223 cells (Figure 3.5B). Among these AR binding sites (ARBS), 11,043 MDA-
MB-453 specific ARBS (MDA-MB-453 unique sites) that were not called as peaks in the 
MFM-223 cell line, 6,759 MFM-223 specific ARBS (MFM-223 unique sites), and 7734 
common ARBS (Figure 3.5 C and Figure 3.6). Figure 3.6B shows examples of AR bound 
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Figure 3.5: Genome-wide mapping of AR chromatin binding by ChIP-seq in 
MDA-MB-453 and MFM-223 cells. PCA plots and Venn diagrams displaying 
differences and similarities between replicate treatment samples and overlap of 
consensus AR cistromes between Vehicle (Veh) and DHT treatments in (A) 
MDA-MB-453 and (B) MFM-223 cells. (C) Venn diagram displaying overlap 








Figure 3.6: Comparison of AR ChIP-seq data in MDA-MB-453 versus MFM-
223 cells. (A) Heatmaps and corresponding read density plots showing 
consensus ChIP-seq signals (fragments /kilobase pair/per million reads 
(FPKM)) and the number of common, MDA-MB-453 unique and MFM-223 
unique AR binding sites with 10 nM DHT. (B) Genome browser images of 
AR-DNA binding sites associated with established AR target genes FKBP5 





3.3.2.2 Genomic annotation and transcriptional regulation of AR 
binding sites 
To examine whether unique and common AR-DNA binding sites correspond to 
the DHT-induced gene expression differences in MDA-MB-453 and MFM-223 
cells, neighbouring genes associated with ARBS were identified using the 
CisGenome's annotation functions and integrated the results with the outcomes 
of the differential expression analysis. Approximately 65% of the MDA-MB-
453 unique DHT-regulated (Log2 FC≥1, P <0.05) genes were associated with 
MDA-MB-453 unique ARBS. Examples of these genes are FAR2, HAAO, 
ALDH1A3, BAG2, CLDN8, DDC, TOX3, EPHA4, CXCR4, MMP13, and 
PAX7. Figure 3.7A shows IGV representative images of MDA-MB-453 unique 
ARBS at MDA-MB-453 unique DHT-regulated genes. However, the results 
were starkly different in MFM-223 cells, with less than 15% of the MFM-223 
unique DHT-regulated genes exhibiting association with MFM-223 unique 
ARBS. These results were exemplified by visualisation of the ChIP-seq data 
using IGV software to show that AR was able to bind to chromatin at the same 
loci in both cell lines, but the associated genes was only regulated by DHT in 
MFM-223 cells. Interestingly, the tumour suppressor genes ZBTB16 and 
LRIG1 were among this set of genes. Figure 3.7B & 3.7C gives examples of 





















 Figure 3.7: IGV images of AR binding sites in MDA-MB-453 and MFM-223 
cells. (A) MDA-MB-453 unique AR binding sites associated with genes 
uniquely upregulated by DHT in MDA-MB-453 but not MFM-223 cells. (B) 
MFM-223 unique AR binding sites associated with genes uniquely upregulated 
by DHT in MFM-223 cells but not MDA-MB-453 cells. (C) AR binding sites 
present in both cell lines that are associated with tumour suppressor genes 





3.3.2.3 Motif analysis of the AR cistromes 
Motif analysis of AR binding sites represents a starting point to identify 
candidate co-factors that may interact and facilitate or inhibit AR action. Motif 
analysis of AR cistromes representing MDA-MB-453 and MFM-223 cells 
treated with DHT was performed using the MEME tool (Machanick & Bailey 
2011). As expected, we detected AR and FOXA1 motifs as the most highly 
enriched motifs in both cell lines (Figure 3.8). The function of FOXA1 as a 
pioneer factor that engages and reconfigures condensed chromatin to facilitate 
DNA binding of other transcription factors makes it an intimate companion to 
AR (Robinson, JL et al. 2011; Sahu et al. 2011). The AR and FOXA1 
cistromes in MDA-MB-453 cells have been shown to have a very large overlap 
(Robinson, JL et al. 2011), but the FOXA1 cistrome in MFM-223 cells has not 
been performed yet. Other transcription factor motifs were also found to be 
commonly enriched in both cell lines, including motifs for GATA, SOX and 
IRX family members. More importantly, we found that the third most 
significantly enriched motif (after AR and FOXA1) in the AR cistrome of 
MDA-MB-453 cells was that for Transcription factor AP-2 (TFAP-2) (Figure 
3.7). TFAP-2 is a family of sequence‐specific DNA binding transcription 
factors that orchestrate a variety of processes including development, growth, 
and tissue differentiation (Ikram et al. 2016; Knight et al. 2005; Wenke & 
Bosserhoff 2010). TFAP-2 motifs were enriched in the AR cistrome of MDA-
MB-453 cells but were not enriched in the AR cistrome of the MFM-223 cell 
line. To further explore disparities in the expression profiles of AR co-factors 
among these two cell lines, we utilized the RIME technique to study 





























Figure 3.8: The top motif matrices predicted by motif analysis by MEME in 
(A) MDA-MB-453 cells and (B) MFM-223 cells. AR, FOXA1, GATA3, and 
IRX were enriched in both cell lines. TFAP-2 was found to be the third top 
motif matrices enriched in MDA-MB-453 cell line and was not enriched in the 
MFM-223 line. The motif distribution graph plots to the right show the 
position of significant motif matches within the input sequences. The vertical 
line in the center of the graph corresponds to the center of the sequences. E-




3.3.3 Endogenous AR interactome profiling in MDA-MB-453 and 
MFM-223 cells 
To identify cooperating factors that are involved in the regulation of AR 
signalling in ERα-negative/AR-positive breast cancer cell lines, unpublished 
AR interactome data of MDA-MB-453 and MFM-223 cells generated using the 
RIME technique was analysed. The RIME experiment was performed by my 
supervisor, A/Prof Theresa Hickey, while she was working in the Carroll 
laboratory (Cancer Research UK, Cambridge Institute) when the RIME 
technique was first being developed. To define a high confidence interactome, 
only proteins that occurred in all independent biological replicates were 
considered and any protein that appeared in matching IgG controls was 
excluded. Using these criteria, 131 MDA-MB-453 specific, 81 MFM-223 
specific, and 21 shared AR interacting proteins were identified. The AR itself 
was detected with high confidence in all AR-IP replicates in both cell lines, 
with 18 unique AR peptides routinely identified, which served as a positive 
control for experimental success. Within the shared AR interactor list, I 
identified SWI/SNF related proteins (SMCE1, SMRC2, SMRD2, and 
ARID1A), ELAVL1 which increases stability of mRNA, the transcription 
factor GATA3 (a known interactor of ERα) and other transcription factors 
including JUNB and TRPS1.  
In the MDA-MB-453 cell line, the FOXA1 pioneer factor was identified as an 
AR interactor, consistent with previous studies highlighting the importance of 
FOXA1 for AR–chromatin interactions in this cell line (Robinson & Carroll 
2012; Robinson, JL et al. 2011). Although FOXA1 motifs were enriched in the 
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AR cistrome of MFM223 cells, FOXA1 was not identified in the RIME data 
associated with this cell line. Several MDA-MB-453 specific AR interacting 
proteins were associated with chromatin organisation and RNA processing 
(Figure 3.9A). Other members of the MDA-MB-453 AR interactome were 
involved in DNA repair (PAXX, PNKP, PRMT1, and UBA1), metabolic 
processes (e.g., ALDH16A1, BOLA2, DLD, and COPG1) transcriptional 
repression (PHB2, CTBP2, and CTBP2) and general transcription (GTF2I, 
TLF3, and STAT1). Approximately 7 proteins of the MDA-MB-453 AR 
interacting partners were involved in cell cycle/growth (Figure 3.9A). 
Examples of cell cycle regulation/progression proteins are CCD68, LAP2A, 
and NUDC. Importantly, among the novel differential precipitating factors, we 
found TFAP-2β, a member of the TFAP-2 transcription factor family, which 
we demonstrated to be enriched at AR-DNA binding sites by motif analysis in 
MDA-MB-453 but not MFM-223 cells (section 3.3.2.3). The identified MFM-
223 specific AR interactors were involved mainly in chromatin remodeling, 
DNA occupancy, RNA processing/splicing, and chaperone-mediated protein 
folding (Figure 3.9B). Other members of the MFM-223 AR interactome were 
involved in the regulation cell growth/death (ANXA7, and YWHAZ), response 















Figure 3.9: AR interacting proteins identified by RIME in MDA-MB-453 and MFM-223 cells. Unique AR co-regulators 
identified in (A) MDA-MB-453 & (B) MFM-223 cell lines were categorised according to their molecular function. The 
miscellaneous group contains proteins associated with chaperone-mediated protein folding, transport, homeostasis, and redox 












3.4 Discussion  
How AR signalling can exert divergent proliferative effects in different models 
of ERα-negative breast cancer is not fully understood. This study aimed to 
define novel features of AR signalling that may underpin the mechanistic basis 
for divergent proliferative effects, in an effort to facilitate future development 
of biomarkers that may inform rational clinical AR target strategies for this 
disease sub-group.  
When comparing the activated AR transcriptome of MDA-MB-453 with 
MFM-223 cells, we observed that DHT regulates distinct sets of genes that are 
associated with distinct biological functions (Figure 3.3 & 3.4). DHT 
significantly enhanced the expression of genes associated with tumour 
progression pathways in the MDA-MB-453 model, including lipid metabolism, 
development as well as cell survival and growth (Figure 3.3A). Expression of 
many lipid metabolism genes including FAR2, ACSL4, ACSL1, PDSS1, 
ALDH1A3, PLCB2, PLCH2, and HSPG2 was also significantly and uniquely 
stimulated in MDA-MB-453 cells upon exposure to DHT. Lipid metabolism 
represents one of the key androgen-regulated processes in prostate cancer cells 
and alteration in lipid metabolism is a hallmark of prostate cancer (Barfeld et 
al. 2014; Butler, LM, Centenera & Swinnen 2016; Mah et al. 2019), whereby 
increased lipogenesis accompanied by overexpression of lipid metabolic genes 
are characteristic of primary and advanced disease (Chen, M et al. 2018; 
Iglesias-Gato et al. 2016; Zadra & Loda 2017). Therefore, as the similarities 
between molecular apocrine tumours and AR-positive prostate cancers that are 
also typically ER-negative are well described (Ni et al. 2011; Robinson, JL et 
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al. 2011), it is reasonable to argue that lipid metabolism pathways might also 
have a critical role in the growth of this disease sub-type and might 
differentiate AR signalling in molecular apocrine compared to a triple negative 
breast cancer sub-type. The ability of AR to promote growth of MDA-MB-453 
cells could also be attributed to its ability to enhance transcription of 
development/ growth associated genes with purported oncogenic activity such 
as EPHA2 (Kinch, Carles-Kinch & metastasis 2003; Song, W et al. 2017), ISX 
(Wang, S-N et al. 2016), FGFR2 (Lei, Haipeng & Deng 2017), TOX3 (Yu, Xin 
& Li 2015) and WNT4 (Lei, Haipeng & Deng 2017). In MFM-223 cells, which 
are growth inhibited by AR signalling, DHT uniquely induced expression of 
genes with anti-tumour activity including ZBTB16 and LRIG1. ZBTB16 is an 
important transcriptional repressor, involved in various biological processes 
including cell death (Wei et al. 2018). Ectopic expression of ZBTB16 inhibited 
proliferation, metastasis, and induced apoptosis of breast and prostate cancer 
cell lines (Cao, JingPing et al. 2013; He, J et al. 2020; Jiang, F & Wang 2004; 
Kikugawa et al. 2006). Conversely, inhibition of ZBTB16 expression by siRNA 
or shRNA in LNCaP cells results in outgrowth (Hsieh et al. 2015; Jin et al. 
2013). I show for the first time that ZBTB16 expression is significantly 
stimulated by DHT (FC=29.27, p-value= 6.4E-21) in MFM-223 cell line but 
not the MDA-MB-453 cell line, which may play a role in mediating divergent 
growth effects. LRIG1 is a negative regulator of growth factor signalling and a 
proposed tumour suppressor in several human cancers including breast, 
bladder, colon, cervical, and lung (Hedman & Henriksson 2007; Krig et al. 
2011; Li, Q et al. 2019; Lindquist et al. 2014; Ljuslinder et al. 2007). The 
RNA-seq data in this chapter showed that treatment of MFM-223 cells with 
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DHT caused a high induction (FC=7, P-value=0.0) in mRNA levels of LRIG1 
but had no effect in MDA-MB-453 cells, suggesting that this gene may also 
play a role in mediating divergent growth effects of AR signalling in these 
models. 
As only 6% of DHT down-regulated genes were shared between MDA-MB-
453 and MFM-223 cells (Figure 3.2D), the unique DHT down-regulated genes 
and their functions in each cell line were investigated. Many cell-motility 
related genes demonstrated a reduction in mRNA expression in DHT-treated 
MDA-MB-453 cells (Figure 3.3B). More importantly, DHT impaired 
transcription of genes with proposed tumour suppression activity such as DLC1 
(Plaumann et al. 2003; Ullmannova-Benson et al. 2009) and FBXW7 (Xu, L et 
al. 2019; Yang, L et al. 2015). DLC1 is a bona fide tumour suppressor gene 
that is downregulated via genetic and epigenetic mechanisms in a variety of 
cancers, including breast cancer (Plaumann et al. 2003; Song, YF et al. 2006; 
Ullmannova-Benson et al. 2009). DLC1 loss in cancer leads to constitutive 
activation of RhoA RhoGTPases and Cdc42 (Plaumann et al. 2003; 
Ullmannova-Benson et al. 2009). This results in increased cell proliferation, 
changes in cell morphology, and inhibition of apoptosis (Plaumann et al. 2003; 
Sekimata et al. 1999). FBXW7 controls proteasome-mediated degradation of 
oncoproteins such as cyclin E, C-MYC, MCL1, and mTOR (Sailo et al. 2019; 
Yeh, C-H, Bellon & Nicot 2018). In contrast, the mRNA levels of genes 
involved in cell proliferation and development processes were decreased in 
MFM-223 cells treated with DHT (Figure 3.4B). Among these genes, we 
identified LGR5 and BCL2. LGR5 is a receptor for the R-spondin (RSPO), 
which, when bound, acts in cooperation with Wnt receptors to potentiate 
183 
 
Wnt/β-catenin signalling (Yang, L et al. 2015). LGR5 promoted cell mobility, 
tumour formation, and epithelial‐mesenchymal transition in breast cancer cells 
by activating Wnt/β‐catenin signaling (Xu, L et al. 2019; Yang, L et al. 2015). 
BCL2 contributes to cancer formation and progression by blocking apoptosis 
(Lindeman & Visvader 2013). Collectively, RNA-seq analysis provides 
compelling evidence that DHT enhances MDA-MB-453 cell proliferation by 
activating transcription of genes with oncogenic effects but inhibiting MFM-
223 cell growth by increasing mRNA levels of tumour suppressor genes. 
Comparing DEGs to AR binding sites revealed that 65% of genes uniquely 
regulated by DHT in the MDA-MB-453 cell line were associated with DHT-
stimulated AR binding sites found only in this cell line, which suggests direct 
AR regulation of these molecular determinants. In contrast, a relatively small 
number of genes uniquely regulated by DHT in the MFM-223 line were 
associated with AR binding sites unique to this cell line. Instead, the peak 
annotation analysis showed that about 42% of these genes are associated with 
AR binding sites common to both lines, suggesting that the MDA-MB-453 cell 
line lacks the factors that required to activate these sites. These results 
highlight the importance of MDA-MB-453 unique AR binding sites in MDA-
MB-453 and indicate that these sites could be the main mediator of differential 
proliferative effects of DHT.  
As activity of the AR cistrome is modulated by a number of potential 
interaction factors, differences in the AR binding profile observed or their 
transcriptional activity might result from disparities in composition of the AR 
interactome. To test this hypothesis, I started with motif enrichment analysis of 
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the AR cistromes in MDA-MB-453 and MFM-223 cells. AR, FOXA1, and 
GATA motifs were enriched in the AR cistromes of both cell lines (Figure 
3.8). FOXA1 acts as a cell-type specific pioneer factor that facilities 
recruitment and binding of ER and AR to their cis-regulatory elements across 
the genome (Lupien et al. 2008). Among all GATA family members, GATA3 
is required for normal development of the mammary gland where it is 
estimated to be the most abundant transcription factor in luminal epithelial 
cells (Takaku, Grimm & Wade 2015). In breast cancer, GATA3 expression is 
highly correlated with ERα expression and with the luminal transcriptional 
program (Kong et al. 2011). Little is known about GATA3 and AR interaction 
in breast cancer, and there is an ongoing study by another student in our lab on 
GATA3 in ERα-negative/AR-positive breast cancer. The motif analysis 
revealed the enrichment of the TFAP-2 transcription factor motif in the MDA-
MB-453 but not the MFM-223 AR cistrome (Figure 3.8). TFAP-2 was the third 
most significantly enriched motif (after AR and FOXA1) in the AR cistrome of 
MDA-MB-453 cells. The TFAP-2 transcription factors are required for normal 
development and morphogenesis of several organs including the breast 
(Pellikainen & Kosma 2007). This motif analysis suggested that one of the 
TFAP-2 family members could be a key differential AR interacting protein in 
these models.  
The composition of AR protein complexes was investigated more broadly 
using an unbiased proteomic approach called RIME. Only 10% of all AR 
interacting partners were shared between MDA-MB-453 and MFM-223 
models, indicating a large difference in the AR interactomes. Nevertheless, 
multiple chromatin remodeling, general transcription, and RNA 
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processing/splicing factors were precipitated with AR in both cell lines (Figure 
3.9), and likely represent factors needed to facilitate the activity of 
transcription factors in a non-specific manner. These factors regulate 
transcriptional activity of AR via recognition of AREs and regulating pre-
mRNA splicing of its target genes (Chmelar et al. 2007). Consistent with the 
motif analysis, GATA3 was identified in the MDA-MB-453 and MFM-223 AR 
interactomes. FOXA1 pioneer factor was identified as an AR interactor by AR 
RIME analysis and motif analysis of AR-DNA binding sites in MDA-MB-453 
cells. However, in MFM-223 cell line, FOXA1 motifs were enriched in the AR 
cistrome but FOXA1 was not identified in the RIME. Other members of the 
AR interactome are involved in transcriptional repression such as CTBP2 in 
MDA-MB-453 and CBX5 in MFM-223. As a transcriptional corepressor, 
CTBP2 is known to repress tumour-suppressor genes and AR corepressors in 
prostate cancer cells, such as NCOR and RIP140, by binding with AR to the 
promoter and enhancers of these genes (Takayama et al. 2014). In contrast, 
CBX5 has been implicated in chromatin packing and epigenetic repression 
(Pongas et al. 2017). While the AR interacting proteins in MFM-223 cells are 
mainly involved in chromatin remodeling, DNA occupancy and RNA 
processing/splicing functions, the AR interaction partners in MDA-MB-453 are 
more diverse in the molecular functions they regulated. Factors involved in cell 
cycle regulation such as HCFC1, which facilitates G1 to S phase transition 
(Xiang et al. 2020), LAP2A, which stabilises Retinoblastoma (Rb) (Gesson, 
Vidak & Foisner 2014), and NUDC, which is involved in spindle formation 
during mitosis and in microtubule organization during cytokinesis (Chuang et 
al. 2013), were isolated from AR protein complexes uniquely in MDA-MB-453 
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cells. Consistent with previous studies that functionally link AR action with 
DNA damage repair (Bartek, Mistrik & Bartkova 2013; Polkinghorn et al. 
2013), DNA repair proteins PAXX, PNKP, PRMT1 and UBA1 were also 
found in MDA-MB-453 cells. AR transcriptional activity is known to be 
modulated by kinases as well as phosphatases (Chen, S et al. 2009). Some of 
the identified MDA-MB-453 AR interacting proteins may regulate AR 
function by the means of phosphorylation or dephosphorylation. For example, 
CDK1 has been shown to stimulate AR activity through phosphorylation of 
serine 81 in the N-terminal domain (Chen, S et al. 2006; Skraškova et al. 
2016). A study by Chen and colleagues showed that phosphorylation of AR by 
CDK1 at S81 in vitro is associated with prevention of AR degradation, thereby 
increasing AR stability and increasing AR protein expression (Chen, S et al. 
2006).  
Of notable significance, this chapter is the first to describe the interaction of 
AR with the TFAP-2β transcription factor in MDA-MB-453 but not MFM-223 
cells. TFAP-2β is a member of the TFAP-2 family that was detected as 
significantly enriched by motif analysis of the AR cistrome in MDA-MB-453 
cells (section 3.3.2.3). By activating its target genes, TFAP-2β plays important 
roles in regulating vertebrate development, cell growth, survival and 
differentiation (Ikram et al. 2016; Knight et al. 2005; Wenke & Bosserhoff 
2010). TFAP-2β is thought to be oncogenic in various cancer entities, 
including rhabdomyosarcoma (Ebauer et al. 2007), lung adenocarcinoma (Fu, 
L et al. 2014), and thyroid cancer (Fu, X et al. 2019). Moreover, clinical studies 
using human breast tissues have reported nuclear TFAP‐2 expression in benign 
breast epithelium in which both TFAP‐2α and TFAP‐2β have been located in 
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the ductal epithelium (Friedrichs et al. 2005; Hurst, Haffty & Williams). As a 
transcription factor involved in many different molecular signalling pathways 
and as a novel AR interacting partner in the context of AR oncogenic effects, 
we sought to investigate the role of TFAP-2β in ERα-negative/AR-positive 
breast cancers. Chapter four presents in silico validation and wet lab 
experiments conducted to test the hypothesis that TFAP-2β is a critical 
regulator of the molecular apocrine breast cancer growth and may be a 






TFAP-2Β IS CRITICAL FOR THE GROWTH OF 




TFAP-2β is a member of a sequence-specific DNA binding transcription factor 
family, which comprises five different but closely related proteins (TFAP-2α, -
2β, -2γ, -2δ, -2ε) transcribed from different genes (TFAP2A-E), each having a 
molecular weight of approximately 50kDa (Eckert et al. 2005; Pellikainen & 
Kosma 2007). As a member of the TFAP-2 family, the TFAP-2β protein has a 
highly conserved helix-span-helix motif at the carboxyl terminus, which, 
together with a central basic region, mediates factor dimerisation and DNA 
binding (Eckert et al. 2005; Pellikainen & Kosma 2007). A third, less 
conserved region toward the amino terminus contains a short proline-rich 
sequence important for transactivation (Eckert et al. 2005). TFAP-2 proteins 
form homo- or heterodimers, bind to the consensus sequence 5'-
GCCNNNGGC-3' and transactivate genes involved in a large spectrum of 
important biological functions including development, growth, differentiation 
and metabolism (Satoda et al. 2000; Wenke & Bosserhoff 2010). Functional 
missense mutations in TFAP-2β basic domain have been implicated in the 
human condition Char Syndrome (Satoda et al. 2000), an autosomal disorder 
characterised by abnormal heart, limb, and facial development (Satoda et al. 
1999; Zhao, F et al. 2001). In mice, homozygous deletion of TFAP-2β has been 
reported to cause congenital polycystic kidney disease due to excessive 
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apoptosis of renal epithelial cells, ultimately resulting in terminal renal failure 
(Moser et al. 1997). Scientific studies have also revealed a diverse range of 
biological functions related to TFAP-2β (Hara et al. 2019; Ikram et al. 2016; 
Joost et al. 2019; Nordquist et al. 2009). Small interfering RNA-mediated 
knockdown of TFAP-2β in corneal endothelial cells decreased expression of 
the corneal endothelium–specific proteins type VIII collagen α2 (COL8A2) 
and zona pellucida glycoprotein 4 (ZP4), and suppressed cell proliferation 
(Hara et al. 2019). TFAP-2β is also involved in neuronal differentiation 
through up‐regulation of the catecholamine biosynthesising enzyme genes 
DBH (dopamine beta-hydroxylase) and TH (tyrosine-hydroxylase), and down‐
regulation of MYCN and REST, master neuronal gene repressors (Ikram et al. 
2016). TFAP-2β can regulate adipocyte metabolism by facilitating glucose 
uptake and lipid accumulation (Joost et al. 2019; Nordquist et al. 2009; Ugi et 
al. 2010). Since TFAP-2β is implicated as a mediator of these diverse 
biological functions, there has been interest in studying the role of this 
transcription factor in relation to cancer. 
TFAP-2β has been shown to be oncogenic in various cancer types, including 
rhabdomyosarcoma (Ebauer et al. 2007), lung adenocarcinoma (Fu, L et al. 
2014), and thyroid cancer (Fu, X et al. 2019). Little is known about the role of 
TFAP-2β in mammary gland development and breast disease, including breast 
cancer. Higher TFAP-2β levels have been shown to distinguish lobular from 
ductal breast carcinomas and siRNA-mediated knockdown of TFAP-2β 
diminished proliferation of lobular breast cancer cell lines in vitro (Raap et al. 
2018), suggesting an oncogenic role in this disease sub-type. TFAP-2β is also 
strongly expressed in apocrine metaplasia, a common benign feature of the 
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aging human mammary gland (Raap et al. 2018). Using an unbiased proteomic 
approach (RIME), this study identified TFAP-2β as a novel AR interacting 
protein in MDA-MB-453 breast cancer cells (Chapter 3), a cell line commonly 
used as a model of molecular apocrine breast cancer (Doane et al. 2006; 
Farmer et al. 2005; Naderi & Hughes-Davies 2008; Ni et al. 2011; Robinson, 
JL et al. 2011). This chapter aimed to examine the biological role of TFAP-2β 
in the molecular apocrine sub-type and determine whether TFAP-2β is a 





4.2.1 Analysis of TFAP2B expression in published gene 
expression datasets 
Relative TFAP2B expression levels were assessed by analysing gene-
expression microarray datasets derived from cases of breast cancer that formed 
part of the phase III clinical trial by the European Organisation for Research 
and Treatment of Cancer (EORTC; NCT00017095), a trial that tested whether 
p53 mutant tumours respond better to anthracycline-based chemotherapy 
(Bonnefoi, Hervé et al. 2011). Classification of breast tumours into luminal, 
basal, and molecular apocrine subtypes was performed using PAM50 
classification of breast cancer as well as sub-type specific signature genes as 
described elsewhere (Farmer et al. 2005; Iggo 2018).  
4.2.2 Plasmid construction and virus production 
TFAP-2α (pDRM13) and TFAP-2β (pDRM14) vectors were generated from 
pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene, #12252) by Gibson assembly 
(Thermo Scientific). The structure of the plasmids is listed in Appendix 1C-D. 
A doxycycline-inducible TFAP-2β vector (pDRM23) was generated from 
pCW57.1 (Addgene #41393) by Gateway cloning (Invitrogene) from an entry 
vector (pDRM21) containing the TFAP-2β open reading frame (orf). The insert 
in pDRM21 was derived from an RZPD clone (IRATp970A0639D). A 
doxycycline-inducible empty vector (EV, pDRM51) was made by self-ligation 
of pCW57.1 cut with BsrGI restriction enzyme to serve as a negative control. 
The NLS-tomato entry vector (pDRM89) was constructed by Gateway cloning 
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by inserting an SV40 NLS-tagged tdTomato gene into the pJS64 plasmid, a 
Gateway destination vector based on the pRRLSIN.cPPT.PGK-GFP.WPRE 
backbone (Addgene #12252) containing the MND promoter (Halene et al. 
1999) driving expression of the transgene and a PGK-hygroR cassette for 
selection.  Lentiviral particles were produced by transfection of HEK 293T/17 
cells with vector plasmid (pDRM13, pDRM14 or pDRM23) and packaging 
plasmids (psPAX2, Addgene, #12260; pMD2-G Addgene, #12259). Plasmid 
DNA was mixed with polyethylenimine (PEI MAX Transfection Grade Linear 
Polyethylenimine Hydrochloride MW 40,000, Polysciences GmbH, #24765-1), 
at a ratio of 1:3, allowed to form complexes for 15min at room temperature, 
then added to the HEK 293T/17 cells. The medium was changed to Opti-MEM 
(Gibco, #31985076) after 12hr of transfection. Conditioned medium containing 
viral particles was harvested after 48hr, concentrated 200-fold using Vivaspin 
20 columns (GE Healthcare #28-9323-63) according to manufacturer’s 
instructions, and frozen at -80°C.  
MDA-MB-231 breast cancer cells (negative for TFAP-2α and TFAP-2β 
expression) were seeded in 6-well cell culture plates at a density of 3 x 105 
cells/well and infected with pDRM13 or pDRM14 viral particles at a 
multiplicity of infection of 1. MFM-223 breast cancer cells (negative for 
TFAP-2β expression) were seeded in 6-well cell culture plates at a density of 4 
x 105 cells/well and infected with pDRM23 viral particles at a multiplicity of 
infection of 1. After 48hr, the Opti-MEM medium was replaced with normal 
growth media, and antibiotic (5µg/ml blasticidin) was added to select for 
transfected cells. Cells were expanded under antibiotic selection for two 
passages then used for proliferation or western blot analysis (Appendix 3C). 
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4.2.3 Proliferation and apoptosis assays 
MDA-MB-453 mKATE2-labelled cells were seeded at a density of 1.5 x 104 
cells/well in 96-well cell culture plates (CoStar) and reverse transfected with 
increasing concentrations (2.5, 5, and 10nM) of one of two distinct siRNAs 
(Integrated DNA technologies, # hs.Ri. TFAP2B.13.1 and hs.Ri. 
TFAP2B.13.7) specifically targeted to TFAP-2β (siAP-2β, Appendix 3B) using 
the Lipofectamine RNAiMax reagent (Thermo Scientific, #13778150) 
according to the manufacturer's instructions. Transfection of a non-specific 
siRNA (Qiagen AllStars Negative Control siRNA, Qiagen, #1027281) was 
used at a concentration of 10nM as a negative control. IncuCyte® Caspase-3/7 
Green Apoptosis Assay Reagent (Essen Bioscience, #4440) was added to the 
culture media at a final concentration of 5µM to detect cell death.  
MFM-223 tomato-labelled cells engineered to express TFAP-2β were seeded at 
a density of 7 x 103 cells/well in 96-well cell culture plates (CoStar) and then 
treated with vehicle (EtOH) or 10nM DHT and 100ng doxycycline. Treatments 
were refreshed every 3 days. Plates were imaged over a period of 5-7 days, 
collecting four images per well every 3 hours with a 10x objective on the 
IncuCyte S3 (Essen Bioscience). The resultant images were analysed using the 
associated IncuCyte S3 software, adjusting the mask and filter settings for 




4.2.4 Western blot 
To confirm specificity of the C-6 (Santa Cruz, sc-390119) and PA5 (Thermo 
Scientific, # PA5-17348) anti-TFAP-2β antibodies, MDA-MB-231 cells 
engineered to express TFAP-2α or TFAP-2β were seeded in 6-well cell culture 
plates (CoStar) at a seeding density of 2 x 105 cells/well and allowed to attach 
for 48hr. For silencing TFAP-2β, MDA-MB-453 cells were seeded at a density 
of 7.5 x 105 cells/well in 6-well cell culture plates and transfected with siNC 
(10nM) or increasing concentrations (2.5, 5, and 10nM) of siAP-2β(a) or siAP-
2β(b) using the Lipofectamine RNAiMax reagent for 72hr or 32hr, respectively 
(time points were selected based on the pre-determined potency of siAP-2β). 
Cells were harvested by scraping into ~150µl cold RIPA buffer, supplemented 
with 1x cOmplete Protease Inhibitor (Roche). Protein concentration was 
quantified by Pierce BCA protein assay (Thermo Scientific) before 
immunoblotting. Protein electrophoresis & immunoblotting were conducted as 
described in Chapter 2 section 2.2.5. Membranes were probed with the 
following primary antibodies: TFAP-2β (Thermo Scientific, # PA5-17348, 
1:1000), TFAP-2α (Santa Cruz, SC-12726, 1:500), C-MYC (Cell Signaling 
Technology, #9402, 1:1000), AR (Santa Cruz, #SC-816, 1:1000), HER2 
(DAKO, #A0485, 1:1000), and GAPDH (Millipore, #MAB374, 1:2000). 
Detection of primary antibodies was performed using HRP-conjugated anti-
mouse (DAKO, #P0161, 1:1000) or anti-rabbit (DAKO, #P0448, 1:1000) 
secondary antibodies. Signals were visualized with Clarity Western ECL 
Substrate (Bio-Rad) as described by the manufacturer and imaged using 
ChemiDoc MP (Bio-Rad) imaging system.  
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4.2.5 RNA isolation and quantitative RT-PCR  
MDA-MB-453 cells were seeded at a density of 7.5 x 105 cells/well in 6-well 
cell culture plates and transfected with siNC (10nM) or increasing 
concentrations (2.5, 5, and 10nM) of siAP-2β(a) using the Lipofectamine 
RNAiMax reagent for 48hr. RNA was purified using Trizol (Sigma, #T9424) 
and DNAse treatment was performed using the TurboDNase kit (Thermo 
Scientific) following manufacturer’s instructions. RNA was quantified using a 
Nanodrop 1000 spectrophotometer (Thermo Scientific). Total RNA (1μg) was 
reverse transcribed into cDNA using an iScript Select cDNA Synthesis Kit 
(Bio-Rad, #1706691) following manufacturer’s instructions in the presence of 
both oligo (dT) and random primers. Quantitative RT-PCR was conducted with 
iQ SYBR Green Supermix (Bio-Rad, #1708866) using a CFX384 Real-Time 
PCR Detection System (Bio-Rad). Primers and RT-PCR conditions are listed 
in Chapter 2 (Table 2.3). Relative gene expression was determined by the 
ΔΔCT method using GAPDH as an internal control for quantification analyses 
of gene targets. 
4.2.6 Cell cycle analysis 
MDA-MB-453 cells treated with siNC (10nM) or siAP-2β(a) (5 and 10nM) 
were washed once in PBS and centrifuged at 2700 rpm for 5min. Cell pellets 
were resuspended in 500μL PBS and slowly dropped into 4.5mL of pre-chilled 
70% ethanol and incubated overnight at 4°C. The fixed cells were washed with 
PBS, then pelleted and resuspended in 1mL of PI solution containing 50μg/mL 
PI, 100µg/mL RNase A (Sigma, #R4642), 0.1% Triton X-100, and incubated 
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for 30min at RT. Cells were then analysed using FACS Canto II (BD 
Biosciences). 
4.2.7 Immunohistochemistry (IHC) 
Paraffin-embedded tissue sections (5µm) were baked onto adhesive 
microscope slides (TRAJAN) for 45min at 50°C before xylene 
deparaffinization and dehydration with 100% ethanol. Slides were incubated 
with 0.9% hydrogen peroxide (Chem-Supply, Australia) to quench endogenous 
peroxidase activity before subjected to heat‐induced epitope retrieval using a 
Decloaking Chamber (BioCare-medical) and 10mM citrate buffer (pH 6.5). 
The slides were subsequently incubated for 1hr at RT with 5% goat serum 
followed by monoclonal mouse antibody to TFAP-2β (C-6, Santa Cruz, #sc-
390119, 1:400); AR (AR (Abcam, # ab108341, 1:1000); and ERα (DAKO, 
#M7047, 1:300)  in a humidified chamber at 4°C. Slides were washed two 
times with 1x PBS and incubated with Goat Anti-Mouse 
Immunoglobulins/Biotin (DAKO, #E0433, 1:400) or Goat Anti-Rabbit 
Immunoglobulins/Biotin (DAKO, #E0432, 1:400) secondary antibody for 1hr 
at RT, developed using 3‐3′‐diaminobenzidine chromogen (Sigma, #D9015), 
and counterstained with hematoxylin. Slides were scanned using a 
NanoZoomer 2.0HT Microscopy System (Hamamatsu).  
4.2.8 Co-immunoprecipitation 
MDA-MB-453 cells were seeded in 150mm tissue culture dishes (Corning) at a 
seeding density of 6 x 106 cells/dish in DMEM media supplemented with 10% 
FBS and allowed to grow for 72hr. Two independent replicate experiments 
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were performed, representing consecutive passages of cells. Cells were cross-
linked with 1%formaldehyde for 10min, quenched with glycine pH 7.5 (final 
concentration 0.2M), washed with ice-cold PBS, and harvested into ice-cold 
PBS containing protease inhibitors (1x PI Cocktail) using a cell scraper. For 
nuclear extraction, cell pellets were resuspended in lysis buffer-1 (LB1) 
followed by rotation mixing for 10 min at 4°C. Then, nuclei were pelleted and 
resuspended in LB2 buffer and rotated at 4°C for 5min. The samples were 
resuspended in LB3 buffer and sonicated for 10 cycles (30 seconds on, 30 
seconds off) using a Diagenode Bioruptor. Lysates were immunoprecipitated 
overnight with 5µg TFAP-2β antibody (Santa Cruz, #SC-390119) bound to 
Protein G Dynabeads (Thermo Scientific, #10004D). The following day, beads 
were washed twice with wash buffer and bound protein was eluted by boiling 
beads in SDS sample buffer then analysed by Western blot using AR (Santa 
Cruz, #SC-816, 1:1000), TFAP-2β (Thermo Scientific, #PA5-17348, 1:1000), 
HRP-conjugated anti-rabbit (DAKO, #P0448, 1:1000), and mouse anti-rabbit 
IgG conformation specific (Cell signalling, # 5127, 1:1000). 
4.2.9 Chromatin immunoprecipitation (ChIP) coupled with 
PCR (ChIP-PCR) or sequencing (ChIP-seq) 
For TFAP-2β or AR ChIP, MDA-MB-453 cells were seeded at a density of 8 x 
106 into 150mm tissue culture dishes (3x dishes per treatment) in DMEM 
media supplemented with 5%(v/v) charcoal-stripped FBS (DCC-FBS). Cells 
were left to grow for 48hr and then treated with vehicle or DHT (10nM) for 
4hr. For H3K27ac ChIP, MDA-MB-453 cells were cultured with 5nM siNC or 
siAP-2β(a) for 48hr under steroid-stripped conditions and then treated with 
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vehicle (EtOH) or DHT (10nM) for 4hr. Crosslinking, isolation of nuclear 
pellets and chromatin sonication were performed as per the co-
immunoprecipitation protocol. Sonicated lysates were immunoprecipitated 
overnight with 5µg of mouse monoclonal TFAP-2β antibody (Santa Cruz, # 
SC-390119) bound to Protein G Dynabeads (Thermo Scientific, #10004D), 
5µg of rabbit polyclonal AR antibody (Abcam, #ab108341) or 2µg rabbit 
polyclonal H3K27ac antibody (Abcam, # Ab4729) bound to Protein A 
Dynabeads (Thermo Scientific, #10002D). The following day, beads were 
washed six times with ice-cold RIPA buffer followed by one wash with cold 
TE buffer supplemented with 50mM NaCl to remove unbound DNA. Protein-
DNA complexes were eluted from the beads using 200μL elution buffer. 
150μL of the elution buffer was also added to the input sample and both the 
input and ChIP samples were incubated overnight at 65°C to reverse protein-
DNA crosslinks. The following day, the supernatant was collected and diluted 
with 200μL elution buffer, ready for DNA purification. For DNA extraction, 
8μL of 1mg/mL RNase A (Sigma, #R4642) was added to the samples and 
incubated at 37°C for 1hr. Proteins were digested by incubation with 20mg/mL 
Proteinase K for 2hr at 55°C. DNA was purified using 400μL phenol-
chloroform-isoamyl alcohol (25:24:1). DNA precipitation was performed 
overnight at 80°C with 2μL glycogen and 800μL 75% isopropanol. DNA was 
pelleted at 14,000g for 30min, washed with 70% ethanol and air-dried. The 
pellets were resuspended in 20μL 10mM Tris-HCl pH 8.0. DNA concentration 
was measured using Qubit® 2.0 fluorometer (Invitrogen). For ChIP-seq, DNA 
was sequenced using an Illumina NextSeq 500 (High Output v2) with 75 bp 
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single-end reads to a depth of 20 million reads per sample. PCR was conducted 
as described in Section 4.2.5.  
ChIP-seq data was analysed as described in Chapter 3 (section 3.2.2.2). In 
brief, FastQ files were quality checked using FastQC (Galaxy v0.72+galaxy1) 
and then trimmed using the default parameters of Filter by quality tool (Galaxy 
v1.0.2+galaxy0) to remove poor-quality reads and adapters. Trimmed reads 
were aligned to the hg19 genome assembly using Bowtie2 (Langmead et al. 
2009). Poorly mapped (MAPQ < 10) and duplicate reads were removed using 
filter SAM/BAM tools (Galaxy v1.8+galaxy1). Peaks were called using 
MACS2 (default settings) against a pooled input sample. An overview of the 
number of the reads that passed through the quality control assessment steps, 
mapping efficiency, and number of called ChIP peaks for each sample are 
listed in Appendix 3D-E. Consensus cistromes were created using Bedtool 
intersect intervals (Galaxy v2.29.0) and combine overlapping-nearby intervals 
(Galaxy v2.29.2). Consensus cistromes included peaks called in at least two of 
the three independent replicates for a given factor and experimental condition. 
Differential analysis was performed using the edgeR package as previously 
described (Hickey, TE et al. 2021). ChIP-seq data were visualized on the 
genome using the Integrative Genomics Viewer (Robinson, JT et al. 2011); 
where an average enrichment signal was generated from all replicates by 
combining mapping files (bam) to a given condition using Merge bam Files 
(Galaxy Version 1.2.0), followed by conversion to bigwig format using 
bamCoverage tool (Galaxy Version 3.3.2.0.0). Venn diagrams were prepared 
using Galaxy Cistrome (Venn Diagram (version 1.0.0)). A principal component 
analysis (PCA) plot and heatmaps were generated from multiBigwigSummary 
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using Generate PCA plots (Galaxy v3.3.2.0.0) and plotHeatmap (Galaxy 
Version 3.3.2.0.1) tools, respectively. Gene ontology analysis was conducted 
using the default parameters of GREAT (Genomic Regions Enrichment of 
Annotations Tool) (McLean et al. 2010).  
ChIP–PCR data were analysed by the percentage input method and further 
analysed as fold enrichment over negative control (NC) for DNA binding.  
4.2.10 In situ proximity ligation assay (PLA) 
For tumour tissues, the standard IHC protocol was followed until the protein 
blocking step. For 2D adherent cells, MDA-MB-453 cells were seeded on glass 
coverslips (20 x 20 mm) at a density of 3.5 x 105 cells/well in 6 well tissue 
culture plates in DMEM media supplemented with 5% DCC-FBS. Following a 
48hr incubation to allow cell adherence, cells were treated with vehicle (EtOH) 
or DHT (10nM) for 4hr and then fixed with 10% neutral buffered formalin for 
10min at RT and permeabilized with 0.1% Triton X-100 in PBS for 1hr. 
Tumour tissues and cell line samples were protein blocked by adding 10% 
donkey serum in PBS (matching the host species of the labelled secondary 
antibody) and incubated for 30min at RT in a humidity chamber. The blocking 
solution was then replaced with a 1:400 dilution of rabbit anti-AR (LifeSpan 
Biosciences, #B3326) and 1:400 dilution of mouse anti-TFAP-2β (Santa Cruz, 
# SC-390119) antibodies and incubated overnight in a humidified chamber at 
4°C. Secondary antibodies conjugated to unique DNA probes (PLA probe 
MINUS and PLA probe PLUS) were added for 1hr. PLA probes were ligated 
by incubating with ligase enzyme diluted 1:40 in ligation buffer for 30min at 
37°C in a humidity chamber. Samples were washed three times with 1x wash 
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buffer A before incubation with polymerase enzyme (diluted 1:80 in 
amplification buffer) for 40min at 37°C in a humidity chamber. Following 
incubation, samples were washed twice for 10min in 1x wash buffer B and then 
washed once in 1:100 diluted wash buffer B for 1min. After that, samples were 
incubated with nuclear stain DAPI (1/1000 in PBS) for 1min, washed twice for 
5min in PBS in the dark, and covered with DAKO mounting medium. Positive 
protein interaction signal was visualised as distinct fluorescent spot foci and 
was captured using Texas red and UV filters on the Olympus FV3000 confocal 
microscope (Adelaide Microscopy, The University of Adelaide). 
4.2.11 Animal models and surgical procedures 
Animal experiments involving the molecular apocrine patient-derived 
xenograft (PDX) breast cancer models were performed via collaboration (Prof. 
Elgene Lim, Connie Johnson Breast Cancer Research Laboratory, Garvan 
Institute for Medical Research, Sydney) using standard techniques as described 
(DeRose et al. 2011; Hickey, TE et al. 2021). In brief, pieces (~ 2mm3) of PDX 
tumours were placed into the fourth inguinal mammary fat pad of NSG mice 
(Australian BioResources). When tumours became palpable, they were 
measured twice weekly using electronic callipers to monitor growth, and 
volume was calculated using the formula (length x width2)/2. Tumour-bearing 
mice were randomly assigned into vehicle or DHT treatment groups when 
tumour volume reached ~200mm3 (n =4/arm). DHT pellets (60-day slow-
release; 10mg, Innovative Research of America) were surgically implanted 
subcutaneously. Upon reaching endpoint, mice were euthanised, and primary 
tumours collected. After weighing, the tumour was fixed overnight at 4°C in 
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10% neutral-buffered formalin. Formalin-fixed samples were processed for 
IHC by the Garvan Institute Histology Core Facility.  
4.2.12 Statistical analysis 
Statistics were performed using Graphpad Prism 9.0. Two-tailed Student t 
tests, or one-way or two-way ANOVA followed by Tukey post hoc multiple 
comparison tests were used as determined by the data. In the majority of cases, 
two independent experiments with three replicates per treatment condition 
were conducted. All data are expressed as the mean ± SEM. A value of 





4.3.1 Transcription factor AP-2β is highly expressed in 
molecular apocrine breast cancers.  
Expression levels of TFAP2B were examined using microarray-based gene 
expression data generated from breast tumours (n=176) that represented a sub-
group of the EORTC trial (Bonnefoi, Hervé et al. 2011). Luminal, molecular 
apocrine, and basal  breast tumours were identified using PAM50 classification 
as well as subtype-specific signature genes as described (Farmer et al. 2005; 
Iggo 2018). Molecular apocrine tumours comprised all ERα-negative tumours 
outside the basal group that were positive for expression of AR and displayed 
apocrine histological features (e.g., abundant eosinophilic cytoplasm and 
prominent nucleoli). Relative  expression of AR and ERBB2 (commonly 
overexpressed in molecular apocrine tumours (Banneau et al. 2010; Farmer et 
al. 2005; Sanga et al. 2009)) is included in the clustered mRNA data presented 
in Figure 4.1A. Analysis of TFAP2B mRNA expression among the three breast 
cancer sub-types demonstrated that it was most highly enriched in molecular 
apocrine tumours (Figure 4.1A). While some luminal tumours were positive for 
this factor, TFAP2B clearly demarcated the molecular apocrine phenotype 
(Figure 4.1A) among the ERα-negative tumour subset. High expression of 
TFAP-2β was verified at the protein level via immunoreactive staining in 
representative primary molecular apocrine breast cancer tissues (Figure 4.1B) 
and tumours derived from breast cancer cell line mammary intraductal (MIND) 
xenografts (Figure 4.1C). As expected, high TFAP-2β protein levels were 
evident in the prototypic molecular apocrine breast cancer cell line model, 
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MDA-MB-453, but absent in cell line models representing luminal and basal 
breast cancer, T47D and MDA-MB-468, respectively (Figure 4.1C). Moreover, 
TFAP2B was the only TFAP-2 family member that discriminated molecular 
apocrine breast tumours from the other two subtypes of breast cancer (Figure 
4.1D). Collectively, this data shows that expression of the TFAP-2β 
transcription factor is highly enriched in molecular apocrine breast cancers, 





















































Figure 4.1: TFAP-2β expression in breast cancer. (A) mRNA expression of 
TFAP2B and breast cancer subtype signature genes in clinical breast tumours 
(n =34 luminal A (LA), n= 25 luminal B (LB), n=32 molecular apocrine (MA), 
and n= 85 basal) from the EORTC trial. (B) Representative images of TFAP-
2β IHC staining in primary molecular apocrine breast cancer tissues. (C) 
TFAP-2β expression in cell line xenografts of molecular apocrine (MDA-MB-
453), luminal (T47D), and basal (MDA-MB-468) subtypes of breast cancer. 
Scale bar = 100µm. (D) mRNA expression of TFAP-2 family members in 
clinical breast tumours from the EORTC trial. ns p>0.05; *p<0.05; **p<0.01; 




4.3.2 TFAP-2β is required for growth and viability of molecular 
apocrine breast cancer cells. 
To test whether TFAP-2β is required for growth and viability of molecular 
apocrine breast cancer cells, the effect of silencing TFAP-2β on proliferation 
and apoptosis of the MDA-MB-453 cell line was investigated. Cells were 
transfected with increasing concentrations (2.5, 5, and 10 nM) of one of two 
distinct siRNAs targeted to TFAP-2β (siAP-2β) or a non-target control (siNC, 
10 nM). Knockdown of TFAP-2β expression significantly reduced 
proliferation (Figure 4.2A, Appendix 3C) and induced apoptosis, as shown by 
an increase in Caspase3/7 positivity and the appearance of a sub-G1 population 
in flow cytometry analysis (Figure 4.2B-D, Appendix 3C). siRNA-mediated 
knockdown of TFAP-2β did not affect TFAP-2α protein levels, indicating 
specificity of the siAP-2β and lack of compensation via increased expression of 
TFAP-2α (Figure 4.2E  ( . Importantly, the anti-cancer effect of silencing TFAP-
2β was accompanied by a significant reduction in expression of key oncogenes, 
including C-MYC and HER2 (Figure 4.2 E-F). Since AR is the predominant 
sex steroid receptor in MDA-MB-453 cells and has been implicated as a driver 
of molecular apocrine breast cancer (Cochrane et al. 2014; Doane et al. 2006; 
Farmer et al. 2005; Naderi & Hughes-Davies 2008; Ni et al. 2011; Park, S et al. 
2011; Robinson, JL et al. 2011), I examined whether loss of TFAP-2β 
expression affected AR protein levels in MDA-MB-453 cells. As shown in 
Figure 4.2E, silencing TFAP-2β did not affect AR protein levels. Collectively, 
these data provide novel evidence that TFAP-2β is critical for growth and 
viability of molecular apocrine breast cancer cells.  
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Figure 4.2: The effect of TFAP-2β knockdown on proliferation, viability, and 
the expression of specific factors in MDA-MB-453 cells. (A) Growth curve 
showing a dose-dependent inhibition of MDA-MB-453 cell proliferation with 
siRNA targeted to TFAP-2β (siAP-2β) but no effect with a non-target control 
(siNC). (B) Death curve to accompany results in (A), showing TFAP-2β 
knockdown increases Caspase 3/7-positive cells (as a dead-to live cells ratio) in 
a dose-dependent manner. All data represented as mean ± SEM of five 
replicate cell culture wells per condition and is a representative of two 
independent experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, 
versus siNC (One Way ANOVA). (C) Cell cycle analysis representing data 
from MDA-MB-453 cells with 5nM (left panel) or 10nM (right panel) siAP-2β 
for 72hr. FlowJo software v10.7 was used for the analysis of data. FACS 
diagrams were normalised to the mode to depict the data in terms of % of max. 
The % of max denotes the number of cells in each bin (the numerical ranges 
for the parameter on the x axis) divided by the number of cells in the bin that 
contains the largest number of cells. FlowJo uses 256 bins, and each graph was 
scaled to the percentage of its maximum bin. (D) Bar graph from siNC or 
siAP-2β-treated MDA-MB-453 cells showing percentages of cells in different 
phases of the cell cycle. All data represented as mean ± SEM; ****p<0.0001, 
versus siNC (One Way ANOVA). (E) Representative immunoblots from 
MDA-MB-453 cells treated with or without siAP-2β for 72hr. GAPDH used as 
a loading control. (F) mRNA expression of HER2 and C-MYC by RT-qPCR in 
MDA-MB-453 cells treated with siAP-2β for 48hr. All data represented as 
mean ± SEM of three replicate cell culture wells per condition and is a 
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representative of two independent experiments.; ****p<0.0001, versus siNC 




4.3.3 Activated AR interacts with TFAP-2β in MDA-MB-453 
breast cancer cells. 
Proteomic analysis of chromatin immunoprecipitated by AR revealed that 
TFAP-2β is part of the AR interactome in the MDA-MB-453 cell line but not 
in the MFM-223 cell line, a model of AR-positive/ TNBC breast cancer 
(Figure 4.3A-B). The presence of AR/TFAP-2β complexes was confirmed by 
co-immunoprecipitation (Figure 4.3C). To assess whether ligand activation of 
AR is required for AR/TFAP-2β interaction, we used a proximity ligation 
assay (PLA), which allows detection of endogenous protein-protein 
interactions with high sensitivity and specificity (Alam 2018). MDA-MB-453 
cells were plated in media containing 5% steroid-stripped FBS and treated with 
either vehicle (EtOH) or 10nM DHT for 4h prior to PLA assessment. DHT 
significantly increased the number of nuclear foci indicative of an AR/TFAP-
2β interaction (Figure 4.3D). Importantly, AR/TFAP-2β complexes were also 
detected in clinical molecular apocrine breast cancer tissues (Figure 4.3D).  
Independent validation confirmed that TFAP-2β protein levels were highly 
expressed in MDA-MB-453 cells but were not detectable in MFM-223 cells 
(Figure 4.4A). To examine whether introducing TFAP-2β could alter AR 
signalling activity in the MFM-223 cell line, the effect of ectopic expression of 
TFAP-2β on DHT-mediated growth inhibition was tested. As shown in Figure 
4.4 (B), expression of TFAP-2β did not alter basal proliferation of MFM-223 
cells, but it blocked the DHT-induced growth inhibitory effect. Since 
knockdown of TFAP-2β significantly reduced HER2 and C-MYC expression 
in MDA-MB-453 cells (Figure 4.2 E-F), we hypothesized that overexpression 
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of TFAP-2β in MFM-223 cells may have facilitated AR-mediated expression 
of these factors. Surprisingly, treatment with DHT increased basal expression 
of HER2 and C-MYC in MFM-223 cells independent of TFAP-2β expression 
(Figure 4.4C). Interestingly, treatment with DHT further increased TFAP-2β 
levels in MFM-223 cells stimulated to overexpress this factor but had no effect 
in cells lacking TFAP-2β expression, suggesting an effect on protein stability. 
Collectively, this data suggests that TFAP-2β may interfere with the ability of 
AR to inhibit growth of ERα-negative breast cancer cells, but whether it 
actively promotes AR oncogenic activity in this context requires further 












Figure 4.3: AR interacts with TFAP-2β in molecular apocrine breast cancers. 
(A) Peptide coverage of AR and TFAP-2β from AR RIME experiments in 
MDA-MB-453 cells. Orange and pink bars represent regions in which the 
peptides were identified; the combined sequence coverage of identified 
peptides is given as a percentage. (B) TFAP-2β unique peptides identified by 
RIME were tested by NCBI–Blast and five unique sequences with 100% query 
coverage & identities were verified (upper panel). TFAP2-β whole protein 
sequence was derived from NCBI and validated peptide sequences are shown 
(lower panel). (C) TFAP-2β co-immunoprecipitation (IP) validation of the AR: 
TFAP-2β interaction in MDA-MB-453 cells cultured in DMEM media 
supplemented with 10% FBS. (D) Proximity ligation assay experiments 
detecting co-localization of AR and TFAP-2β in MDA-MB-453 cells cultured 
under serum-deplete conditions then treated with either vehicle (Veh) or 10 nM 
DHT (left panels). PLA for AR and TFAP-2β in primary MABC tumours 
















Figure 4.4: Lentivirus-mediated ectopic expression of TFAP-2β or empty 
vector (Control) constructs into the TFAP-2β negative MFM-223 TNBC cell 
line. (A) Western blot comparing TFAP-2β and AR protein levels in MDA-
MB-453 and MFM-223 cell lines. (B) Growth curve data from MFM-223 cells 
engineered to ectopically express TFAP-2β then treated with either Vehicle 
(Veh) or 10 nM DHT. Data represents the mean ± SEM of three replicate 
wells, analysed using a two-way repeated measures ANOVA followed by 
Tukey’s multiple comparisons test. *p<0.05. (C) End-point immunoblot results 





4.3.4 Functional interplay between AR and TFAP-2β at the 
chromatin level in molecular apocrine breast cancer cells. 
Since TFAP-2β interacts with AR in MDA-MB-453 cells and AR activity has 
been implicated as a driver of growth in this cell line, the TFAP-2β cistrome 
was characterized in the presence and absence of DHT to determine whether 
AR signalling alters TFAP-2β cis-acting targets. MDA-MB-453 cells were 
cultured under steroid-depleted conditions then treated 4 hours with vehicle 
(EtOH) or DHT prior to crosslinking. Consensus TFAP-2β chromatin binding 
events were generated for each treatment condition using ChIP-seq datasets 
derived from 3 consecutive passages of cells.  As shown by the Venn diagram 
overlap and heat map analysis (Figure 4.5 A-B), DHT did not dramatically 
alter the TFAP-2β cistrome in MDA-MB-453 cells; 88% of TFAP-2β DNA 
binding events were shared under vehicle and DHT treatment conditions 
(Figure 4.5A). Moreover, our data showed that the consensus TFAP-2β was 
reduced by 5,315 peaks after treatment with DHT. Importantly, among the 
hormone-independent TFAP-2β binding sites, we identified loci at the 
enhancer of ERBB2 and the promoter of MYC (Figure 4.5C). It is possible that 
loss of these binding sites following siRNA-mediated knockdown of TFAP-2β 
was responsible for reduced expression levels of these genes (as shown above 
in Figure 4.2D). Moreover, we identified TFAP-2β peaks at the promoter of 
other genes involved in cell cycle progression, including WEE1 and E2F2, as 
well as the molecular apocrine signature genes CLCA2 and KMO (Figure 
4.5C). We hypothesized that knocking down TFAP-2β would alter 
transcriptional activity at TFAP-2β binding sites, so performed H3K27ac (a 
mark of transcriptional activation) ChIP-seq in MDA-MB-453 cells cultured 
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with siNC or 5nM siAP-2β for 48 hours. Globally, levels of H3K27ac were 
largely unchanged by knockdown of TFAP-2β (Appendix 3F). In total, 6,868 
sites had a significantly lower enrichment of H3K27ac following knockdown 
of TFAP-2β (Appendix 3F).  Gene ontology analysis of genes associated with 
these reduced H3K27ac ChIP-seq signals revealed enrichment for the Sterol 
regulatory element-binding proteins signalling pathway (SREBP, lipid 
metabolism pathway), chromatin remodelling, and cell cycle regulation 
(Appendix 3F). MYC, WEE1 and E2F2 were among the genes that showed a 
significant decrease in H3K27ac enrichment with siAP-2β (Figure 4.5C), 
consistent with their regulation by TFAP-2β.  
As expected from previous results showing an interaction, DHT-induced 
activation of AR resulted in an association between the AR and TFAP-2β 
cistromes, whereby AR was recruited to 36% of all TFAP-2β DNA binding 
sites, representing 45% of the AR cistrome (Figure 4.7A, B). While we 
expected that this interaction might be important for AR recruitment and 
transcriptional activity at co-occupied cis-regulatory elements, this was not the 
case, as knocking down TFAP-2β with siAP-2β for 48hr reduced but did not 
prevent AR enrichment at representative loci in MDA-MB-453 cells (Figure 
4.5C). Knockdown of TFAP-2β also had no significant effect on DHT-induced 
AR transactivation activity for associated genes (Figure 4.5C), indicating that 
TFAP-2β may facilitate AR binding but is not a critical determinant of AR 
DNA binding and transcriptional activity. Independent of AR signalling, siAP-
2β significantly decreased expression of CLCA2 (a molecular apocrine 
signature gene) and increased expression of FAR2 (lipid metabolism gene) 








Figure 4.5: Analysis of the TFAP-2β cistrome in MDA-MB-453 cells. (A) 
Venn diagram showing overlap of consensus TFAP-2β cistromes under vehicle 
control and DHT (10nM) treatment conditions. (B) Heatmaps and 
corresponding read density plots showing average consensus ChIP-seq signals 
(FPKM) and the number of shared, gained and lost TFAP-2β binding sites in 
MDA-MB-453 cells cultured in steroid-deplete conditions and treated for 4 
hours with either Vehicle (Veh) or 10 nM DHT. (C) Genome browser images 
of TFAP-2β and H3K27ac chromatin occupancy near genes involved in cell 





   




Figure 4.5: Interaction of AR and TFAP-2β at the chromatin level. (A) Venn 
diagram showing overlap of consensus AR and TFAP-2β cistromes in MDA-
MB-453 cells treated with 10 nM DHT for 4hr, showing that 45% of AR 
binding sites are co-occupied by TFAP-2β. (B) Representative genome 
browser images of TFAP-2β and AR shared DNA-binding sites associated with 
molecular apocrine breast cancer signature genes. (C) Representative examples 
of AR binding sites (assessed by ChIP-PCR) and associated genes (assessed by 
RT-PCR) showing that knockdown of TFAP-2β reduced but did not prevent 
AR enrichment at representative loci and did not significantly influence AR 
transcriptional activity. ChIP-seq, ChIP-PCR and RT-PCR experiments were 
conducted in MDA-MB-453 cells, cultured in serum-deplete conditions then 
treated for 4 hours with either Vehicle (Veh) or 10 nM DHT. ChIP-PCR data 
represented as mean ± SEM of three independent replicate experiments, 
representing consecutive passages of cells. RT-PCR data represented as mean 
± SEM of three well replicates of two independent experiments. ns p>0.05; 
*p<0.05; **p<0.01; ***p<0.001, using One Way ANOVA.  
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4.3.5 Effect of DHT in patient-derived xenograft (PDX) models 
of molecular apocrine breast cancer 
Activation of AR signalling with the AR agonist DHT has never been directly 
assessed in PDX models of molecular apocrine breast cancer. This study 
examined the effect of DHT on growth of three PDX models (CTPx3921, GAR 
14-06A, and HCI-008) that were chosen for being ERα-negative, AR-positive 
and HER2-positive to specifically classify them as molecular apocrine 
tumours. Treatment with DHT (60-day slow-release; 10mg) significantly 
decreased CTPx3921 xenograft growth, but increased growth of GAR 14-06A 
tumours (Figure 4.6C), providing compelling pre-clinical evidence for 
differential growth effects of AR in the molecular apocrine breast cancer 
context. A slight decrease in the growth of HCI-008 tumours was observed 
with DHT but it was not significant (Fig.4.6C). High TFAP-2β levels were 
detected in these three molecular apocrine PDX models (Figure 4.6B), 
confirming findings from Figure 1 and the molecular apocrine status of these 
models. However, the high expression of TFAP-2β in all models suggest that 
levels of TFAP-2β do not predict response to DHT, consistent with findings 
from section 4.3.3 that TFAP-2β influences but is not a critical determinant of 






















Figure 4.6: Differential growth effects of AR signalling in PDX models of 
molecular apocrine breast cancer. (A) PDX models derived from primary or 
metastatic deposits of clinical molecular apocrine breast cancers. (B) 
Representative IHC images of AR and TFAP-2β in molecular apocrine PDX 
models. Scale bars = 50 µm. (C) Tumour growth plots from three molecular 
apocrine PDX models treated in vivo with vehicle or DHT (60-day slow-
release DHT pellets (10 mg). N= 4 for each treatment arm for each experiment. 
All data represented as mean ± SEM; ns p>0.05; *p<0.05; **p<0.01; 
***p<0.001, using unpaired, one-tailed t-test.  
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Members of the TFAP-2 family of transcription factors have diverse biological 
roles and have been implicated in cancer. Herein, the biological role of TFAP-
2β in the molecular apocrine subtype of breast cancer was investigated. Using 
gene expression datasets and immunoreactive staining, we demonstrated high 
TFAP-2β expression in clinical molecular apocrine tumours and using a 
representative cell line (i.e., MDA-MB-453), showed that TFAP-2β was 
required to sustain proliferative capacity and cell viability. Although we reveal 
a novel interaction between TFAP-2β and AR, a putative driver of molecular 
apocrine breast cancer, we did not find evidence that this interaction was a 
critical determinant of oncogenic AR signalling. Hence, TFAP-2β is a 
transcription factor specifically enriched in molecular apocrine breast cancers 
that has a role in promoting cell viability and proliferative capacity, perhaps 
independent of AR signalling.  
Within the context of ERα-negative breast cancers, TFAP-2β was almost 
exclusively expressed in molecular apocrine tumours, with no or very little 
expression in basal tumours. This remarkable difference in TFAP-2β 
expression could be due to differential expression of the HER2 oncogene. 
Overexpression of HER2, particularly via ERBB2 amplification, commonly 
occurs in molecular apocrine breast cancers (Banneau et al. 2010; Farmer et al. 
2005; Sanga et al. 2009). In molecular apocrine tumours without ERBB2 
amplification, ERBB2 activating mutations are found in 9% of cases, 
suggesting that hyper-activation of the ERBB2 pathway may be a universal 
feature of this subtype (Jiang, Y-Z et al. 2019). Indeed, high ERBB2 expression 
was detected in the molecular apocrine tumours that were used in this study. 
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The higher expression of TFAP-2β in the context of HER2-enriched molecular 
apocrine disease compared to HER2-negative basal breast tumours suggests a 
direct association between TFAP-2β and HER2 expression. Using ChIP-seq 
analysis, this study showed that TFAP-2β binds to an enhancer region of HER2 
and that knockdown of TFAP-2β reduced the H3K27ac signal at this locus. 
These genomic findings were consistent with reduced expression of HER2 at 
the gene and protein level in MDA-MB-453 cells following TFAP-2β 
knockdown. Based on motif analyses, previous studies have suggested the 
ability of a member of the TFAP‐2 family to bind and activate the ERBB2 
promoter in breast cancer cells (Bosher et al. 1996; Bosher, Williams & Hurst 
1995; Hollywood & Hurst 1993). However, those studies pre-dated 
identification of specific members of the TFAP-2 family and the ability to 
interrogate the genomic occupancy of a specific member using ChIP-seq or 
ChIP-PCR technology.  Of notable significance, our study is the first to 
describe the TFAP-2β cistrome in any model system and to show that TFAP-
2β does not bind the promoter of the HER2 gene, but it binds to an enhancer 
element.  
Even though high expression of TFAP2B distinguished molecular apocrine 
tumours among other tumour sub-types, TFAP2B expression was also detected 
in some luminal tumours. Importantly, the TFAP-2β expression we saw in 
these luminal tumours is not due to the presence of lobular cancers because we 
excluded them from the analysis. Nearly all of the TFAP-2β positive luminal 
tumours fall into the luminal-A category. In contrast to luminal-B tumours, 
high differentiation status and low proliferation activity characterise the 
luminal A subtype (Sørlie et al. 2001; Yaşar et al. 2017; Yersal & Barutca 
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2014). Our data could indicate that TFAP‐2β plays a role in promoting a higher 
degree of differentiation in this particular phenotype. The exclusive expression 
of TFAP2B in luminal-A tumours is of interest and needs further investigation 
to understand the mechanisms underlying this finding. 
Our data also showed that MFM-223 cells lack the expression of TFAP-2β 
(Fig. 4.4A). While MFM-223 is known to have a high expression of AR that is 
comparable to MDA-MB-453 cells and accordingly Lehmann et al (2011) 
classified it as a luminal AR (another term for molecular apocrine) (Lehmann 
et al. 2011), our data indicate that AR expression alone is not sufficient for the 
identification of molecular apocrine cell lines and that TFAP‐2β can be used as 
a marker for this subgroup. Since MFM-223 cells have a basal phenotype and 
lack ERBB2 amplification, we speculated that they lack expression of TFAP-
2β. In contrast, MDA-MB-453 cells showed high expression of TFAP-2β 
(Figure 4.1C) .While some studies describe MDA-MB-453 cells as a triple-
negative breast cancer cell line because they lack ERBB2 amplification 
(Espinosa Fernandez et al. 2020; Lehmann et al. 2011), other studies consider 
MDA-MB-453 as a model for an ERα/HER2-positive cell line due to high 
levels of HER2 expression and used it to study resistance to HER2-targeted 
therapies (Goel et al. 2016; Narayan et al. 2009). Higher expression of HER2 
could be associated with high expression of TFAP-2β in this cell line model of 
molecular apocrine breast cancer. 
Is the TFAP-2β transcription factor important for maintaining proliferation and 
viability of molecular apocrine cells? To answer this question, we examined 
the effect of silencing TFAP-2β using the prototypic molecular apocrine cell 
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line MDA-MB-453. Silencing TFAP-2β exerted a potent growth inhibitory 
effect and induced caspase-dependent apoptosis in vitro, accompanied by a 
reduction in mRNA and protein levels of key oncogenes including C-MYC and 
HER2. While the ability of TFAP-2β to regulate the expression of C-MYC in 
breast cancers specifically and cancers in general was not reported prior to this 
study, a few studies have examined the interaction of TFAP-2 with C-MYC in 
other biological contexts (Gaubatz et al. 1995; Moser et al. 1997). Using motif 
analysis, a study by Gaubatz and colleagues (1995) showed that MYC-
response elements that transcriptionally regulate two MYC target genes, 
prothymosin-a and ornithine decarboxylase (ODC) from different organisms 
(e.g. human, rat, mouse and pig), contain a high-affinity binding site for a 
TFAP-2 factor (Gaubatz et al. 1995). The latter study also used electrophoretic 
mobility shift assay to show that recombinant TFAP-2 was able to recognise 
and bind the MYC-response elements from prothymosin-a and ODC, and the 
specificity of the interaction was verified using different competitors (Gaubatz 
et al. 1995). Mechanistically, the Gaubatz et al (1995) study found that TFAP-
2 did not affect the expression of C-MYC in HeLa cells transfected with MYC 
response elements and then co-transfected with a TFAP-2 or C-MYC 
expression plasmid, but it inhibited C-MYC-induced transactivation by 
competing for DNA binding by C-MYC and by directly interacting with the C-
MYC protein, which impaired DNA binding of the MYC/MAX complex 
(Gaubatz et al. 1995). A subsequent study provided further evidence, reporting 
that TFAP-2β knock-out in mice did not change C-MYC expression but it 
induced apoptotic cell death of renal epithelial cells via enhancement of C-
MYC transactivation (Moser et al. 1997). Herein, we demonstrated that TFAP-
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2β regulates C-MYC in molecular apocrine cells and this is likely due to a 
binding site at the promoter region as shown by the ChIP-seq data. Loss of 
TFAP-2β also impaired HER2 expression in MDA-MB-453 cells. HER2 
signalling pathways have shown growth-promoting effects in MDA-MB-453 
cells (Ni et al. 2011) and we know now that TFAP-2β regulates HER2 
expression in the context of this disease and that is likely through association 
with the enhancer region as shown in ChIP-seq analysis. Moreover, analysis of 
the TFAP-2β cistrome in MDA-MB-453 cells showed TFAP-2β binding sites 
at the promoter of genes involved in the cell cycle including WEE1 and E2F2. 
The WEE1 kinase is a key regulator of the G2 cell cycle checkpoint (Ghiasi et 
al. 2013). In response to DNA damage, WEE1 inhibits the activity of CDK1 
through phosphorylation, resulting in cell cycle arrest to allow for DNA repair 
(Ghiasi et al. 2013). E2F2 is a member of the E2F transcription family of 
transcription factors, which regulates transcription of several genes involve in 
cell cycle (Johnson & Schneider-Broussard 1998). Enforced E2F2 expression 
significantly increased MCM4 (DNA replication licensing factor) and CCNE2 
(regulates the transition from G1 to S phase) expression in SKOV3 and A2780 
ovarian cancer cell lines (Xie, Li & Yang 2017). In this study, we showed that 
knocking down TFAP-2β reduced H3K27ac enrichment at these genes but did 
not completely quench the signal. This may be because we did not fully 
knockdown TFAP-2β or may be the influence of TFAP-2β is not best reflected 
by H3K27ac and it could have had a very different effect on some other histone 
markers.  
Using several proteomic techniques to detect AR interacting proteins, we 
identified TFAP-2β as a candidate AR interacting factor. Activation of AR did 
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not majorly influence the TFAP-2β cistrome, but it induced an association 
between AR and TFAP-2β at 36% of TFAP-2β DNA-binding sites, supporting 
the fact that these two factors interact on chromatin. Another transcription 
factor,  FOXA1, has been shown to be present at approximately 100% of AR 
binding sites in MDA-MB-453 cells (Robinson, JL et al. 2011),  indicating that  
the interaction between AR and TFAP -2β is more selective. The data also 
suggests that TFAP-2β would have AR-independent effects. We were 
interested to see if AR/TFAP-2β complexes are critical for AR transcriptional 
activity and AR oncogenic effects in molecular apocrine breast cancer cells. 
Experiments in this study showed that knocking down TFAP-2β reduced but 
did not prevent the binding of AR to co-occupied loci. The reduced AR binding 
did not prevent transactivation of associated genes, suggesting that AR 
signalling is not reliant on TFAP-2β for transactivation capacity. However, we 
did not perform a complete knockdown of TFAP-2β for this experiment since 
complete silencing would have killed the cells, precluding a definitive 
conclusion. Alternatively, because the AR cistrome completely overlaps with 
the FOXA1 cistrome and it is clear that FOXA1 is a pioneer factor for AR 
binding in the MDA-MB-453 cell line, we deduced that AR is probably still 
bound to chromatin in the absence of TFAP-2β because FOXA1 is there.  
For the first time, three PDX models of molecular apocrine breast cancer were 
used in this study to examine the effect of AR agonist DHT in vivo. PDX 
models were selected on the basis of having high AR, no ERα and HER2 
amplification. Consistent with data from clinical molecular apocrine tumours, 
high expression of TFAP-2β was revealed in these PDX models. The response 
to DHT was different in all three molecular apocrine PDX models, a surprising 
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finding given the prevailing view that AR drives growth of this breast cancer 
sub-type. However, since all of these models are TFAP-2β positive, it is 
unlikely this factor is the key determinant of AR oncogenic activity, which 
aligns with our in vitro data.  
In summary, this work provides preliminary evidence for the clinical 
significance of TFAP-2β in the molecular apocrine subtype of breast cancer. 
High expression of TFAP-2β characterises molecular apocrine breast cancer, 
indicating a potential for being a candidate marker of this disease. We have 
also shown that TFAP-2β is critical for proliferation and viability of a cell line 
model of this disease. This preclinical data provides the rationale for creating a 
selective inhibitor of TFAP-2β. Indeed, a previous study described the 
development of a small molecule inhibitor against TFAP-2α/γ (Hu et al. 2018), 





A NOVEL AND HIGHLY SELECTIVE CDK9 INHIBITOR 
(D-11) EFFECTIVELY SUPPRESSES PROLIFERATION 




Triple negative breast cancers (TNBC) comprise a group of highly aggressive 
tumours that are negative for the three major diagnostic biomarkers of breast 
cancer: ERα, PR, and HER2 (Chen, J-Q & Russo 2009; Yersal & Barutca 
2014). Therefore, patients with TNBC are insensitive to ERα and HER2 
targeted therapies and are mainly clinically managed with cytotoxic 
chemotherapies, which are associated with a high rate of local and systemic 
relapse and death (Al-Mahmood et al. 2018; Dent et al. 2007). This highlights 
an important and unmet clinical need to develop targeted therapies for TNBC. 
One avenue of recent interest is to target cyclin dependent kinases (CDKs).  
CDKs are serine/threonine protein kinases that activate their substrates upon 
binding to a regulatory cyclin subunit bound to the substrate, with subsequent 
phosphate transfer (Echalier et al. 2010). To date, twenty different CDKs have 
been discovered in mammalian cells (Malumbres & Barbacid 2005) and based 
on their functional role, are broadly categorised into two main groups: 1) cell 
cycle CDKs (CDK1-6) that  control progression through various phases of the 
cell cycle by phosphorylating and activating cell cycle proteins (Hartwell & 
Kastan 1994; Lamb et al. 2013; Malumbres & Barbacid 2005), and 2) 
transcriptional CDKs (CDK7-9, 12 and 19) that control initiation and 
elongation of mRNA transcripts by phosphorylating and activating RNA 
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polymerase II (RNAPII) (Lim & Kaldis 2013; Malumbres & Barbacid 2005). 
Dysregulation in the expression or activity of CDKs has been associated with 
tumorigenesis and progression of multiple cancers, including breast cancer 
(Diaz-Padilla, Siu & Duran 2009; Ding et al. 2020; Romano 2013). 
Consequently, pharmacological inhibition of CDKs has been considered an 
attractive anti-cancer therapeutic strategy (Cicenas et al. 2014; Mayer 2015). 
Indeed, inhibition of CDK4/6 has shown therapeutic efficacy in both endocrine 
therapy naïve and resistant ERα-positive breast cancer and are now included as 
standard-of-care for metastatic disease (Finn et al. 2015; Finn et al. 2009; 
Herschkowitz et al. 2008; Turner et al. 2015). CDK4/6 inhibitors mainly act by 
blocking the phosphorylation of retinoblastoma protein (Rb), which arrests the 
cell cycle in G1 phase (Malumbres & Barbacid 2005). However, inhibition of 
CDK4/6 lacks therapeutic efficacy in TNBC since this type of cancer generally 
lacks Rb expression (Dean et al. 2012; Ribnikar, Volovat & Cardoso 2019; 
Witkiewicz et al. 2016). Hence, investigation of other CDK members as 
potential therapeutic targets for TNBC is warranted.  
Although CDK4/6 inhibitors cannot be targeted for TNBC, preclinical studies 
have reported that targeting CDK9 using small interference RNA or pan-CDK 
inhibitors (e.g., Flavopiridol and Dinaciclib) have anti-proliferative effects in 
models of TNBC (Horiuchi et al. 2012; McLaughlin et al. 2017; Rajput et al. 
2016). In complex with its cyclin partner cyclin T1, CDK9 forms the positive 
transcription elongation factor, P-TEFb (McLaughlin et al. 2017). Through 
phosphorylation of serine 2 (pSer2) in the heptapeptide repeat motif within the 
C-terminal domain (CTD) of RNAPII, P-TEFb releases RNAPII from a paused 
state to enable transcriptional elongation (Hsin, Manley & development 2012; 
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Malumbres & Barbacid 2005; Napolitano et al. 2000). Basal transcription 
(production of the basal level of transcripts) does not require phosphorylation 
of the RNAPII CTD (Serizawa, Conaway & Conaway 1993), but CDK9-
mediated RNAPII phosphorylation increases transcriptional activity (Bacon & 
D’Orso 2019; Nekhai, Petukhov & Breuer 2014). This increased RNAPII 
activity facilitates sustained expression of short-lived mRNA transcripts that 
encode oncogenic and anti-apoptotic proteins such as MYC and MCL1, which 
are important oncogenic drivers of TNBC (Horiuchi et al. 2012; Wang, S & 
Fischer 2008). While targeting CDK9 has shown promise, clinical translation 
of a CDK9 targeted therapy has been hampered by poor selectivity, and 
subsequent toxicity, of existing CDK9 inhibitors (CDK9i) (Boffo et al. 2018; 
Mariaule & Belmont 2014; Sonawane et al. 2016). Therefore, we tested the 
pre-clinical efficacy and established the mechanism of action of a newly 
synthesised, highly selective CDK9i (D-11) in TNBC, with view to providing a 





5.2.1 Test compounds 
The CDK9 inhibitors, D-11 and L-453, were provided by Professor Shudong 
Wang (Drug Discovery and Development Group, Cancer Research Institute, 
University of South Australia, Australia). For the in vitro assays, 10mM 
concentrated stock solutions of D-11 and L-453 was prepared in 100% DMSO 
and stored at -20°C and 4°C, respectively. Concentrated stocks were diluted in 
growth media as required on the day of treatment. For in vivo experiments, D-
11 was freshly formulated in 0.1M sodium acetate buffer, pH 4.5 and gavaged 
daily at a concentration of 150-200mg/kg/day.  
5.2.2 Kinase assay  
The in vitro kinase assay (Kinome scan) was performed by Reaction Biology 
Corporation (Malvern, USA) as described previously (Tadesse et al. 2018). D-
11 and L-453 were screened against 396 human kinases and enzyme activity 
was determined by percentage of remaining kinase activity in test samples 
compared to vehicle (DMSO) after subtraction of background (derived from 
control reactions containing inactive enzyme). The concentration required to 
produce half maximum inhibition (Ki) was calculated using the Cheng–Prusoff 
equation: Ki = IC50 / (1 + ([ATP]/Km (ATP))), where Km is the Michaelis 





5.2.3 Cell lines 
MDA-MB-453, MDA-MB-231 and MDA-MB-468 cell lines were obtained 
from the American Type Culture Collection (ATCC, USA) and maintained in 
DMEM-High glucose media, supplemented with 10% FBS, 2mM L-glutamine 
and 2mM sodium pyruvate. The MFM-223 cell line was purchased from the 
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell 
Cultures (Germany) and maintained in EMEM supplemented with 10% FBS, 
2 mM L-glutamine, and a 1x concentration of insulin–transferrin–sodium 
selenite (ITS) supplement. All cell lines were maintained at 37°C in a 
humidified incubator with 5% CO2. Cell lines were routinely tested for 
mycoplasma infection using Stratagene MycoSensor qPCR kit (#302106) and 
cell line identity by short tandem repeat profiling (Cell Bank Australia). 
5.2.4 Proliferation and apoptosis assays 
MDA-MB-453, MDA-MB-468, and MDA-MB-231 cell lines were plated at a 
density of 4 x 103 cells/well and MFM-223 at a density of 5 x 103 cells/well in 
96-well tissue culture plates (CoStar). Following a 24hr incubation period to 
allow cell adherence, the cell culture medium was removed and replaced with 
medium containing IncuCyte® Caspase-3/7 Green Apoptosis Assay Reagent 
(final concentration 5µM) and IncuCyte® NucLight Rapid Red Reagent for 
Live-Cell (diluted 1:2000). Concurrently, cells were treated with either vehicle 
(DMSO) or D-11 (150, 300, 600, and 1200nM doses). Plates were imaged over 
a period of 5 days, collecting four images per well every 3 hours with a 10x 
objective on the IncuCyte S3 (Essen Bioscience), with drug treatments 
refreshed every 72hr. The resultant images were analysed to determine the 
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number of live and dead cells using the associated IncuCyte S3 software, 
adjusting the mask and filter settings for image analysis using a small training 
set of images (6 images) from the vehicle and treated wells at early and late 
time points (Appendix 3A).  
For proliferation assays with L-453 compound, MDA-MB-453, MDA-MB-
468, and MDA-MB-231 cell lines were plated at a density of 3 x 104 cells/well 
and MFM-223 at a density of 5 x 104 cells/well in 12-well tissue culture plates 
(CoStar). Cells were left to grow for 24hr prior to treatment with either vehicle 
(DMSO) or L-453 (75, 150, 300, 600, and 1200nM doses). Treatments were 
refreshed every 3 days. Cells were quantified by haemocytometer counting 
using trypan blue dye.   
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5.2.5 Western blot 
Cells were seeded in 6-well cell culture plates (CoStar) at a seeding density of 
5x105 cells/well and allowed to attach for 48hr. Cells were treated with vehicle 
or with 2-fold increasing concentrations of D-11 for 6hr, then harvested by 
scraping into RIPA buffer, supplemented with 1x cOmplete Protease Inhibitor 
(Roche) and 1x Halt Phosphatase Inhibitor (Thermo Scientific). Protein 
concentration was quantified by Pierce BCA protein assay (Thermo Scientific) 
before immunoblotting. Protein electrophoresis & immunoblotting were 
conducted as described in Chapter 2 section 2.2.5. Membranes were probed 
with the following primary antibodies: CDK9 (Cell Signaling Technology, 
#2316, 1:1000 dilution), RNAPII (Abcam, #Ab817, 1:1000 dilution), RNAPII 
CTD repeat YSPTSPS (p-RNAPII Ser2, Abcam, # ab193468, 1:5000 dilution), 
C-MYC (Cell Signaling Technology, #9402, 1:1000 dilution), MCL1 (Cell 
Signaling Technology, #5453, 1:1000 dilution) and GAPDH (Millipore, 
#MAB374, 1:2000 dilution). Detection of primary antibodies was performed 
using HRP-conjugated anti-mouse (DAKO, #P0161, 1:1000 dilution) or anti-
rabbit (DAKO, #P0448, 1:1000 dilution) secondary antibodies. Signals were 
visualized with Clarity Western ECL Substrate (Bio-Rad) as described by the 
manufacturer and imaged using a ChemiDoc MP (Bio-Rad) imaging system.  
5.2.6 RNA isolation and quantitative RT-PCR 
Cells were treated with vehicle or D-11 (300 and 600nM) for 4hr prior to 
harvest with Trizol reagent (Sigma, #T9424). RNA was purified according to 
the Trizol protocol and DNase treatment was performed using the TurboDNase 
kit (Thermo Scientific) according to manufacturer's instructions. RNA was 
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quantified using a Nanodrop 1000 spectrophotometer (Thermo Scientific). 
Total RNA (1μg) was reverse transcribed into cDNA using an iScript Select 
cDNA Synthesis Kit (Bio-Rad, #1706691) in the presence of both oligo (dT) 
and random primers. Quantitative RT-PCR was conducted with iQ SYBR 
Green Supermix (Bio-Rad, #1708866) using a CFX384 Real-Time PCR 
Detection System (Bio-Rad). Relative gene expression was determined by the 
ΔΔCT method using GAPDH as an internal control for quantification analyses 
of gene targets. 
5.2.7 Cell cycle analysis 
Vehicle or D-11 (300 or 600nM) treated cells were washed once in 1x PBS and 
centrifuged at 2700 rpm for 5min. Cell pellets were resuspended in 500μL PBS 
and slowly dropped into 4.5mL of pre-chilled 70% ethanol and incubated 
overnight at 4°C. The fixed cells were washed with PBS, then pelleted and 
resuspended in 1mL of PI solution containing 50μg/mL PI, 100µg/mL RNase 
A (Sigma, #R4642), 0.1% Triton X-100, and incubated for 30min at room 
temperature. Stained cells were analysed using FACS Conto II (BD 
Biosciences). 
5.2.8 Ex vivo explant culture of normal human breast tissues. 
Normal breast tissues were collected from consenting women undergoing 
breast reduction surgery at the Flinders Medical Centre, Adelaide, South 
Australia (ethics approval number H-2015-175). Tissues were cultured ex vivo 
as previously described (Centenera et al. 2018; Dean et al. 2012). In brief, 
tissues were dissected into ~1 mm3 pieces and randomly placed onto gelatin 
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dental sponges (Ethicon) pre-soaked in phenol-red-free RPMI 1640 media 
supplemented with 10% FBS, 2mM L-glutamine, 10µg/mL human 
recombinant insulin (Sigma, #I0516), 10µg/mL hydrocortisone (Sigma, 
#H0888), and 1x antimycotic-antibiotic (Sigma, #A5955) and incubated at 
37°C with 5% CO2. After 24hr, the medium was replaced with new culture 
medium supplemented with vehicle or D-11 (900nM & 2.7µM), followed by 
culture for a further 48hr. Four tissue pieces from each case were randomly 
allocated to each treatment on a single sponge. Cultured tissue pieces were 
fixed in 10% neutral-buffered formalin at 4°C overnight, dehydrated and 
embedded in paraffin wax for H&E and IHC analyses.  
5.2.9 TNBC mammary intraductal (MIND) xenografts  
Animal experiments were approved by the University of Adelaide Animal 
Research Ethics Committee (approval number M-2018-088). The mammary 
intraductal (MIND) xenografting technique was employed following 
previously described protocols (Richard et al. 2016; Sflomos et al. 2016). A 
total of 2 x 105 MDA-MB-453 cells labelled with luciferase and dTomato 
fluorescent protein under puromycin resistance (LTP) were resuspended in 
10µL normal growth media and injected into one of the fourth inguinal 
mammary ducts of NSG mice. Tumours were allowed to establish for 5 days, 
and then mice allocated by simple randomisation to receive vehicle (n =10) or 
D-11 (10 mice received 8 doses of 200mg/kg/day and then 7 doses of 
150mg/kg/day due to toxicity concerns) for 15 consecutive days. The number 
of mice per treatment was determined based on previous in vivo studies 
(Hickey, TE et al. 2021), showing that a 20% reduction in tumour size 
240 
 
compared to vehicle can be achieved with 10 mice/treatment group (p<0.05; 
80% power). Tumour growth was monitored using an IVIS Lumina X5 
imaging system (PerkinElmer). IVIS imaging was conducted five days after 
injection and every two days after treatment. IVIS-Living images 64-bit 
software was used to quantify non-saturated bioluminescence in regions of 
interest (ROI) and bioluminescence was quantified as photons/second for each 
ROI.  
At the end of the experiment, the injected mammary glands were harvested for 
IHC (see section 5.2.10). Spleen, liver, and lung tissues were collected and 
stained with H&E to examine the effect of D-11 on normal tissue histology 
(see section 5.2.9).  
5.2.10 Histology and immunostaining 
General procedures for H&E and IHC were performed as described previously 
in Chapter 2 Section 2.2.9. Ki-67 IHC was performed using a monoclonal 
mouse antibody (DAKO #M7240, 1:400 dilution) and a Goat Anti-Mouse 
Immunoglobulins/Biotin (DAKO, #E0433, 1:400 dilution) secondary antibody 
Slides were scanned using a NanoZoomer 2.0HT Microscopy System 
(Hamamatsu). Ki67 staining was quantified by manual counting of all fields 
containing breast epithelia, over multiple representative areas using a FIJI cell 
counter. 
5.2.11 Statistical analysis 
Statistics were performed using Graphpad Prism 9.0. Two-tailed Student t 
tests, or one-way ANOVA followed by Tukey post hoc multiple comparison 
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tests were used as determined by the data. In the majority of cases, two 
independent experiments with three technical replicates per treatment condition 
were conducted. The half-maximal inhibitory concentration (IC50) was 
determined from the generated concentration-response curves using a non-
linear regression curve fit. All data are expressed as the mean ± SEM. A value 







5.3.1 Biochemical characteristics of newly developed CDK9 inhibitors 
D-11 and L-453 
The CDK9 inhibitors, D11-8 and L-453, was derived from the CDKI-73 parent 
compound (Lam et al. 2014) and synthesized by Professor Shudong Wang 
(Drug Discovery and Development Group, University of South Australia, 
Australia). D-11 and L-453 compounds were designed to have a suitable size 
that enable them to pass through the space that exists between CDK9 and 
cyclin T1 but does not enable it to reach the ATP binding site of other CDKs 
(see section 1.5.4.5). D-11 exhibited a Ki of 8nM against CDK9/cyclin T1 and 
displayed over 50-fold selectivity over CDK1, 2, 4, 6 and 7, (Figure 5.1A). 
While L-453 inhibited CDK9/cyclin T1 activity at low pM (100pM), it showed 
Ki of 177 and 238nM against CDK2/cyclin A and CDK7/cyclin H, 
respectively. Compared to other known CDK9 inhibitors, including Dinaciclib 
(Selleck chemicals) and CDKI-73 (obtained from S. Wang, Uni SA), both D-
11 and L-453 showed superior selectivity towards CDK9 (Figure 5.1A). These 
results were further substantiated via kinome analysis in which D-11 and L-453 
specificity were determined against a panel of 369 human kinases. At a 
screening concentration of 1µM, which is at least 125 times above the Ki 
measured in the CDK9 biochemical assay, TRKC, FLT3, KHS, MST, MINK, 
TNIK and NUAK were the only other kinases that displayed <10% residual 
activity by D-11, while CLK, DYRK, TRKC, FLT3 and TAO were affected to 












Figure 5.1: Kinase profiles of D-11 and L-453. (A) Comparison of Ki values 
for D-11, L-453 and non-selective CDK9 inhibitors Dinaciclib and CDKI-73. 
NA= not active (B) Phylogenetic tree representation of kinase targets of D-11 
(left panel) and L-453 (right panel) profiled against 369 kinases. Red circles 
represent <10% residual activity, respectively. 
 
A 
B D-11 L-453 
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5.3.2 Selective CDK9 inhibition effectively reduces in vitro proliferation 
of TNBC cell lines.  
To determine the therapeutic potential of CDK9 as a therapeutic target for 
TNBC, we began by examining protein expression of CDK9 and its known 
targets, the proto-oncogene C-MYC, and the anti-apoptotic marker MCL1 in a 
panel of TNBC cell lines. Two CDK9 isoforms are expressed in mammalian 
tissues: a major 42 kDa protein (CDK942) and a minor 55 kDa (CDK955) 
protein (Liu, H & Rice 2000; Shore et al. 2003). Western blotting analysis 
showed that both CDK9 isoforms are expressed in TNBC cell lines (MDA-
MB-453, MDA-MB-468, MFM-223, and MDA-MB-231) (Figure 5.2A). As 
expected, CDK942 was more highly expressed than CDK955 in all cell lines 
(Figure 5.2A). Therefore, in the rest of this study, we focused on the CDK942 
isoform and herein refer to it as CDK9. 
TNBC cell lines exhibited variable basal levels of CDK9 protein, whereby 
MDA-MB-453 cells had the highest and MDA-MB-468 cells the lowest level 
of expression (Figure 5.2A-B). Basal expression of C-MYC and MCL1 
proteins also varied in the four TNBC cell lines. C-MYC protein was higher in 
MFM-223 cells compared to the other TNBC cell lines evaluated (Figure 5.2A-
B). MDA-MB-231 cells also exhibited relatively high C-MYC expression 
compared to the MDA-MB-453 and MDA-MB-468 cell lines (Figure 5.2A-B). 
MCL1 was expressed in all TNBC cell lines assessed, with relatively higher 
expression in MFM-223 cells (Figure 2A-B). Hence, CDK9 and its key targets 
were present in all TNBC models assessed, suggesting that targeting this factor 
could have broad application in this disease context.  
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Next, we assessed the anti-proliferative efficacy of targeting CDK9 in TNBC 
cell lines in vitro. Cells were treated with 2-fold increasing concentrations of 
D-11 (150, 300, 600 and 1200nM) and cell nuclei counted over a period of five 
days. A time and dose-dependent inhibition of proliferation occurred in all 
TNBC cell lines in response to D-11 (Figure 2.5C-F). The results indicate that 
D-11 had cell line specific effects, whereby some cell lines were more sensitive 
to D-11 than others. The MDA-MB-453 cell line was most sensitive; 300nM 
D-11 incurred a 33% growth inhibition (evident after 72 hr of starting 
treatment) and the IC50 was 281nM at 120hr (Figure 2.5C). In contrast, MDA-
MB-231 and MFM-223 cells required 600nM of D-11 to inhibit proliferation at 
72hr and their IC50 values were 658 and 737nM at 120hr, respectively (Figure 
2.5 E-F). Although MDA-MB-453 cells may be more sensitive to CDK9 
inhibition due to higher expression of CDK9, MDA-MB-468 cells have 
relatively low CDK9 expression and a relatively high sensitivity to D-11 with 
IC50 of 342nM at 120 hr (Figure 2.5D), suggesting that the basal level of CDK9 
alone is not a good indicator of therapeutic efficacy. Results of the effect of 
another CDK9 inhibitor L-453 on the proliferation of TNBC cell lines are 
shown in the appendix 4. While this study started off with two compounds, D-
11 was chosen for further study because it evoked the greatest effect in 

































Figure 5.2: D-11 reduces in vitro proliferation of TNBC cell lines. (A) Protein 
expression of CDK9 and its known targets C-MYC and MCL1 in TNBC cell 
lines by western blot. GAPDH shown as a loading control. (B) Heat map 
showing expression of the GAPDH-normalised protein levels as assessed by 
densitometry of CDK9, C-MYC & MCL1 in TNBC cell lines. (C-F) 
Proliferation of TNBC cells measured by live cell count using the Incucyte S3 
at varying concentrations of D-11. Data represents mean ± SD of three 
replicate cell culture wells per condition and is a representative of two 
independent experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 

















5.3.3 D-11 has cytotoxic effects in TNBC cells by inducing apoptosis and 
G2/M cell cycle arrest. 
 
To examine whether the observed growth inhibitory effects of D-11 were 
accompanied by cell death, apoptotic cells were quantified using the Incucyte 
Caspase-3/7 green dye. Since there were significant growth inhibitory effects 
of D-11, a dead/live cell ratio was calculated to account for fewer cells present 
in wells with higher drug doses. D-11 significantly induced apoptosis in all of 
the TNBC cell lines tested (Figure 5.3A). At a dose of 600nM, a more dramatic 
induction of apoptosis (p<0.0001) was observed in MDA-MB-453 and MDA-
MB-468 cells compared to the MDA-MB-231 cell line (Figure 5.3A). A higher 
dose of 1200nM was required to induce apoptosis in MFM-223 cells (Figure 
5.3A). Moreover, a G2/M cell cycle arrest was observed upon treatment with 
300nM D-11 in MDA-MB-453 and 600nM D-11 in MDA-MB-468 and MFM-
223 for 72hr, while this occurred with only 600nM D-11 at 120hr in MDA-
MB-231 cells (Figure 5.3B-E). Collectively, these results provide evidence that 
D-11 has growth inhibitory effects through a dual mechanism: inducing 
























Figure 5.3: D-11 induces apoptosis & G2/M cell cycle arrest in TNBC cells. 
(A) Effect of D-11 on cell death measured using the Incucyte Caspase-3/7 
green Dye. Data represents mean ± SD of three replicate cell culture wells per 
condition and is a representative of two independent experiments. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001 (One-Way ANOVA). (B) Cell cycle 
analysis after exposure to D-11 for 72hr in MDA-MB-453, MDA-MB-468 & 
MFM-223 and 120hr in MDA-MB-231 cells. Results are representative of two 




5.3.4 D-11 reduces phosphorylation of RNAPII CTD and reduces 
expression of C-MYC and MCL1 
To confirm that the anti-proliferative and cell cycle effects of D-11 in TNBC 
cell lines were due to targeted inhibition of CDK9, expression levels of CDK9 
downstream targets were examined, including phosphorylated Ser2-RNAPII 
(pSer2-RNAPII), C-MYC, and MCL1 in TNBC cells following treatment with 
D-11 (300 and 600nM) for 4hr (mRNA expression) or 6hr (protein analysis). 
As expected, D-11 significantly reduced Ser2-RNAPII phosphorylation in 
TNBC cell lines without affecting total RNAPII (Figure 5.4). In MDA-MB-453 
cells, the most sensitive to D-11-induced growth inhibition, phosphorylation of 
RNAPII was reduced by approximately 70% after a 6hr treatment with 600nM 
D-11 (Figure 5.4A), and this effect was accompanied by a 70% reduction in 
mRNA and protein levels of C-MYC and MCL1 (Figure 5.4B). Treating 
MDA-MB-468 and MFM-223 cells with 600nM D-11 induced a 30-40% 
inhibition of pSer2-RNAPII (Figure 5.4A), which coincided with a significant 
inhibition of C-MYC and MCL1 protein and mRNA levels (Figure 5.4B). In 
MDA-MB-231 cells, MCL1 expression was almost abrogated by 600nM D-11 
(Figure 5.4B), but a higher dose of 1200nM was required to cause a decrease in 
C-MYC expression (Figure 5.4B). Together, these data clearly demonstrate the 
ability of D-11 to specifically target CDK9 activity and likely represent a key 







Figure 5.4: Targeting CDK9 activity using D-11 reduces phosphorylation of 
RNAPII and expression of C-MYC and MCL1 in TNBC cells in vitro. (A) 
Western blot analysis showing effects of D-11 on total RNAPII, p-RNAPII, C-
MYC & MCL1 in TNBC cell lines after 6hr of treatment. GAPDH was used as 
a loading control. Blots are representative of 2 independent experiments. (B) 
RT‐qPCR displaying the relative mRNA levels of C-MYC and MCL1 after 4hr 
treatment with D-11. GAPDH was used as a reference gene. Data represented 






5.3.5 In vivo anti-tumour efficacy of D-11 in TNBC models 
Since selective targeting of CDK9 effectively suppressed proliferation of 
TNBC cell lines in vitro, we established mammary intraductal (MIND) 
xenografts using the MDA-MB-453 breast cancer cell line to validate the effect 
of D-11 in vivo. MIND technique, in which cells are injected directly into the 
mouse milk ducts, has gains over the mammary fat pad technique, as it mimics 
the original breast tumour microenvironment (Richard et al. 2016; Sflomos et 
al. 2016). NSG mice were injected unilaterally with MDA-MB-453 cells, and 
after 5 days were allocated to treatment with vehicle or D-11 using simple 
randomisation. This was the first time of testing D-11 in vivo, so tolerated 
doses were estimated based on in vivo data of a parent compound (CDKi-73, 
(Rahaman, Yu, et al. 2019)). Mice received 200mg/kg/day of D-11 for eight 
days by daily oral gavage. After that, the D-11 dose was reduced to 
150mg/kg/day because one mouse became sick and there was concern that the 
cause might be D-11 toxicity. However, it was subsequently determined that 
the problem was technical (due to gavage damage), not due to inherent toxicity 
of the compound. As shown in Figure 5.5A-C, D-11 significantly reduced 
tumor growth of MDA-MB-453 MIND xenografts. No apparent behavioral or 
body weight changes were observed in treated mice, and there was no effect of 
D-11 on normal histology of liver and spleen tissues (Figure 5.5B), indicating 
that it was well tolerated and exerted no obvious harm to the animals. 
Collectively, these striking in vivo effects of D-11 strongly support the efficacy 


















Figure 5.5: In vivo antitumor efficacy of D-11 on TNBC MIND xenograft 
tumours. (A) Growth curve showing inhibition of MDA-MB-453 MIND 
xenograft tumor growth with D-11 as measured by in vivo bioluminescence 
(mean total flux [photons/s] ± SEM) (logarithmic scale). MDA-MB-453 MIND 
xenograft tumors treated 15 days with vehicle (n= 9) or D-11 (n=7). Four 
animals were excluded from the study due to technical reasons ( e.g. problems 
with oral gavage and cell injection). **p<0.01 (Two-tailed Student t tests). (B) 
Representative H&E images of liver and spleen tissues from endpoint vehicle 
and D-11 treated MDA-MB-453 MIND xenograft tumors. Scale bar depicts 50 
μm. (C) Representative images of the in vivo bioluminescence signals (flux 




5.3.6 D-11 does not affect proliferation and histology of patient-derived 
explants of normal human breast tissues treated ex vivo. 
CDK9 activity is not considered necessary to sustain homeostasis of normal 
cells, while cancer cells can rely on it to sustain expression of key oncogenic 
drivers (Falco, Giordano & therapy 2002; Serizawa, Conaway & Conaway 
1993). To `test lack of toxicity in normal human breast tissues, the effect of D-
11 was assessed using explants of reduction mammoplasty tissue samples (n=4 
independent cases) treated ex vivo as previously described (Dean et al. 2012). 
This technique has been shown to sustain the tissue architecture, viability, 
cellular complexity and hormone responsiveness of normal human breast 
tissues (Centenera et al. 2018; Hickey, TE et al. 2021) and is thereby more 
clinically relevant than the testing of non-transformed breast epithelial cell 
lines in 2-dimensional culture (e.g. MCF10A). Briefly, surgically resected 
breast tissue specimens were dissected into 1 mm3 pieces and placed on top of 
a gelatine sponge partly submerged in growth culture media, to which 
treatments were added (Figure 5.6A). Explants were treated with vehicle or 3-
fold increasing doses (900 & 2700 nM) of D-11 for 48 hr and harvested for 
assessment of Ki-67 positivity and histological features. Compared to vehicle-
treated explants, D-11 had no significant effect on Ki-67 positivity and 
histology of normal breast tissue explants (Figure 5.6 B-C). The absence of a 
toxic effect of D-11 in normal mammary cells is consistent with previous 
studies showing that the kinase function of CDK9 is not required for basal 














Figure 5.6: D-11 has no effect on proliferation and histology of normal human 
breast tissues. (A) Schematic showing ex vivo culture of normal breast tissue 
explants. (B) Quantification of Ki-67 positivity in normal breast tissues (n = 4 
independent cases) treated with Vehicle or D-11 for 48hr. Data represented as 
mean ± SEM; ns p>0.05 (Two-tailed Student t tests). (C) Representative 
images of Ki-67 IHC and H&E staining in normal breast tissues treated with 
Vehicle or 2.7µM D-11 for 48hr. Brown arrows demonstrate examples of Ki-







A potential therapeutic strategy to treat TNBC is to impair the sustained 
expression of oncogenes and pro-survival factors that drive growth of this 
aggressive subtype of breast cancer. This could be achieved by inhibiting 
CDK9 activity, which impedes RNAPII-mediated transcription of short-lived 
oncogenic gene transcripts. In the current pre-clinical study, we demonstrate 
the anti-tumour efficacy of a novel, potent, and highly selective CDK9 
inhibitor (D-11) in the context of TNBC using a panel of cell lines to provide 
in vitro evidence and a cell line mammary intraductal (MIND) xenograft model 
to provide in vivo evidence. The non-toxic nature of D-11 was demonstrated 
via lack of effect on several mouse tissues in vivo and human breast tissues ex 
vivo. Collectively, this data supports advancement of D-11 to clinical trials 
involving TNBC. 
Using cell-free assays for biochemical analysis, we showed that D-11 inhibits 
CDK9 kinase activity at a low Ki value (8nM) and displayed remarkable 
selectivity for CDK9 over other CDKs as well as other protein kinases in the 
kinome (Figure 5.1). D-11 suppressed proliferation and triggered apoptosis in 
TNBC cells in vitro and these effects are ascribed to the reduction of p-
RNAPII, C-MYC & MCL1 levels, indicative of targeted CDK9 inhibition. In 
surviving cells, D-11 induced a cell cycle block at the G2/M phase, consistent 
with previous data which reported that silencing CDK9, but not CDK1 or 
CDK2, reduced cyclin B1 protein levels in MDA-MB-231 and BT549 breast 
cancer cell lines, leading to G2/M cell cycle arrest (Rajput et al. 2016). 
Moreover, the data presented in our study highlight that some TNBC cell lines 
are more responsive to CDK9 inhibition than others. Initially, it was postulated 
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that variation in response may be due to the difference in endogenous CDK9 
levels, but our findings showed that the basal protein level of CDK9 alone is 
not sufficient to predict response to CDK9 inhibition in the context of the 
TNBC models used (Figure 5.2 A-B). A study conducted by Brisard and 
colleagues (2018) reported that TNBC cell lines with high mRNA levels of 
CDK9 (e.g., MDA-MB-231, MDA-MB-436, and MDA-MB-453) exhibited 
significantly higher sensitivity to atuveciclib (another newly developed CDK9 
inhibitor with IC50=13nM) as compared to a panel of low-CDK9 expressing 
cell lines (e.g., HCC1937, MDA-MB-157, and HCC3153) (Brisard et al. 2018). 
Interestingly, atuveciclib IC50 at 96h in MDA-MB-231 cells (identified as the 
cell line with the highest CDK9 mRNA expression based on the latter study) 
was 1.32 μM and was 0.63 μM in MDA-MB-436 cells, which express lower 
levels of CDK9 compared to MDA-MB-231. Similar observations were 
noticed in low CDK9 expressing cell lines, where 4μM of atuveciclib was used 
to inhibit HCC1937 cell line proliferation compared to 2.2 μM for the MDA-
MB-157 cell line (which has the lowest CDK9 expression), supporting our 
conclusion that the CDK9 level alone did not predict response to CDK9 
inhibition. Therefore, we examined the protein levels of CDK9 targets in an 
attempt to see if expression of these targets associated with response to D-11 
and the data showed that the less responsive cell lines had higher levels of C-
MYC. These observations suggest that the presence of amplification and/or 
overexpression of the downstream CDK9 target C-MYC could make TNBC 
cells less sensitive to selective CDK9 inhibition. However, further experiments 
such as analysis of CDK9i-induced changes to the p-RNAPII genome-wide 
chromatin binding profile and associated transcriptome in TNBC cells treated 
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with/without D-11 are needed to develop a biomarker signature of treatment 
response.  
The anti-tumour effect of D-11 was also investigated in vivo with MDA-MB-
453 mammary intraductal (MIND) xenografts. Our study is the first to use the 
MIND technique, in which cells are injected directly into the mouse milk ducts, 
to examine the efficacy of targeting CDK9 in breast cancer in vivo. 
Conventional mammary fat pad xenografting was used in previous studies to 
test transcriptional CDK inhibitors in breast cancer (Rajput et al. 2016; Sun, B 
et al. 2020; Wang, Yubao et al. 2015). The  MIND technique has advantages 
over the mammary fat pad technique, as it better mimics the breast tumour 
microenvironment where cancers normally develop (Richard et al. 2016; 
Sflomos et al. 2016). The outcomes of our study showed that oral 
administration of D-11 significantly inhibited MDA-MB-453 MIND tumour 
growth, was well tolerated and did not affect histology of normal tissues. Key 
future experiments that will further clarify therapeutic efficacy of D-11 could 
include testing D-11 in vivo using TNBC patient-derived xenograft (PDX) 
models and using the MIND model to assess the effect of D-11 on metastasis, 
as this model offers opportunities to study breast cancer progression (transition 
from in situ to invasive disease and metastasis to relevant sites).  
Taken altogether, this chapter demonstrates that selective CDK9 inhibition is 
an attractive therapeutic strategy for treatment of patients with TNBC, and that 
the novel and highly selective CDK9 inhibitor D-11 is a promising candidate 








6.1 General discussion  
Treatment options for ERα-negative breast cancers are largely limited to 
chemotherapy due to the lack of effective, clinically proven targeted 
therapies.  The studies presented in this thesis examined three potential 
therapeutic targets for ERα-negative breast cancer: the androgen receptor (AR), 
transcription factor AP-2β (TFAP-2β) and cyclin-dependent kinase 9 (CDK9). 
The major findings of the thesis are discussed below.  
6.1.1. Genomic parameters of AR signalling associated with 
proliferative versus anti-proliferative effects in ERα-negative breast 
cancers. 
The AR is expressed in approximately 20-50% of ERα and PR negative breast 
cancers (Liu, YX, Zhang & Tang 2018; McNamara, K et al. 2013; Niemeier et 
al. 2010; Xu, M et al. 2020). Although there is strong interest in targeting AR 
for treatment of breast cancer, the role AR signalling plays in different breast 
cancer contexts is controversial, which restricts clinical implementation of 
currently available AR-targeted therapies. Recently, this controversy was 
resolved in the context of ERα-positive breast cancer, in which AR was shown 
to be a tumour suppressor and use of an AR agonist, rather than an AR 
antagonist, the rational therapeutic strategy (Hickey, TE et al. 2021). However, 
the controversy remains in the context of ERα-negative breast cancers and is 
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complicated by the fact this disease context is comprised of many different 
molecular sub-types. To inform this controversy, the first part of this thesis 
(Chapter 3) aimed to define genomic parameters of AR signalling activity 
associated with proliferative versus anti-proliferative cellular responses in the 
ERα-negative breast cancer context, with the view to understanding the 
mechanistic basis of oncogenic versus anti-oncogenic potential. Two 
representative ERα-negative/AR-positive cell lines (MDA-MB-453 and MFM-
223) were investigated chosen for having comparable levels of AR expression 
but differing proliferative responses to AR activation with the endogenous 
ligand, DHT. Expression profiles of DHT-regulated genes were analysed in 
MDA-MB-453 (growth stimulated by DHT) and MFM-223 (growth inhibited 
by DHT) cell lines using next-generation sequencing (NGS) techniques, to 
determine whether differential expression of AR target genes could underpin 
differential proliferative responses. The potent androgen DHT stimulated the 
transcription of genes that mediate growth, development, and metabolism in 
MDA-MB-453 cells (Chapter 3, Figure 3.3). Many of these genes have been 
reported to have a growth-stimulating effect in several types of cancer. 
Examples are ISX (Hsu et al. 2013; Wang, S-N et al. 2016), EPHA2 (Brantley-
Sieders et al. 2008; Song, W et al. 2017), TOX3 (Dittmer et al. 2011; 
Seksenyan et al. 2015), SGK1 (Lang et al. 2010; Shanmugam et al. 2007), 
CAMKK1 (Brzozowski & Skelding 2019; Karacosta et al. 2012; Massie et al. 
2011), and WNT4 (Ni et al. 2011; Yang, D et al. 2020). Moreover, Gene 
Ontology analysis revealed up-regulation of several lipid metabolism genes 
upon treatment with DHT in MDA-MB-453 cells. Dysregulation of lipid 
metabolism pathways as a means of promoting cancer growth has been linked 
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to the progression of several types of cancer including colorectal, prostate, 
breast, and ovarian cancer (Butler, LM, Centenera & Swinnen 2016; Marino et 
al. 2020; Tania, Khan & Song 2010; Yeh, C-S et al. 2006). Increased lipid 
metabolism is thought to contribute to cancer cell proliferation in part by 
providing building materials for cell membrane synthesis needed for cell 
duplication, supplying energy, and increasing the synthesis of second 
messenger lipid molecules that mediate tumorigenesis pathways (Butler, L et 
al. 2020; Huang, C & Freter 2015). Hence, in addition to up-regulation of 
classic growth-stimulatory pathways, dysregulation of lipid metabolism 
pathways might be a critical mediator of DHT-induced proliferation in MDA-
MB-453 cells. In MFM-223 cells, DHT induced expression of known tumour 
suppressor genes, including ZBTB16, Nkx 3.1, and LRIG1 (Cao, JingPing et al. 
2013; Hedman & Henriksson 2007; Kikugawa et al. 2006; Krig et al. 2011; Li, 
Q et al. 2019; Lindquist et al. 2014; Ljuslinder et al. 2007), consistent with the 
anti-proliferative effect of DHT in this cell line. In addition, DHT reduced 
expression of genes involved in cell survival or with purported oncogenic 
activity (e.g., LGR5, TM4SF18, and BCL2) in MFM-223 cells (Chapter 3, 
section 3.3.1.3), another potential means of growth inhibition. Using a diverse, 
clinically relevant panel of cell-line and patient-derived models of ERα-
positive breast cancer, a study recently published by my host laboratory 
(Hickey, TE et al. 2021) showed that AR activation has antitumor activity in 
multiple contexts of ERα-positive breast cancer. Mechanistically, they found 
that agonist activation of AR altered the genomic distribution of ERα and 
essential co-activators, resulting in repression of cell cycle and pro-survival 
genes, including BCL2, and upregulation of known tumour suppressors, 
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including ZBTB16 (Hickey, TE et al. 2021). Importantly, these gene regulatory 
events (down-regulation of BCL2, up-regulation of ZBTB16) were 
recapitulated by AR signalling in MFM-223, a cell line that lacks ERα 
expression, suggesting that AR regulation of these genes can be independent of 
ERα signalling. The inability of DHT to stimulate a similar transcriptional 
program in MDA-MB-453 cells may explain the lack of anti-proliferative 
effects. Interestingly, genome-wide mapping of AR cis-regulatory binding sites 
in MDA-MB-453 cells showed that lack of AR enrichment at genomic loci 
associated with tumour suppressor genes exclusively upregulated by DHT in 
MFM-223 cells (Chapter3, Figure 3.7) did not explain the inability of AR to 
enhance transcription of these genes in MDA-MB-453 cells. This finding 
suggested that disparities in recruitment of AR co-regulatory proteins (nuclear 
factors that work with AR to regulate its transcriptional capacity) to these loci 
may be involved. To identify potential candidates, an unbiased proteomic 
technique called RIME was performed to identify and compare the AR 
interactomes in the two cell line models. Indeed, analysis of cooperating 
factors that are potentially involved in the regulation of AR signalling in MDA-
MB-453 and MFM-223 cells based on the RIME data showed that only 10% of 
the precipitated proteins were shared between the two cell lines, indicating a 
large discrepancy in the AR interactomes. Among the shared AR interacting 
proteins are SWI/SNF (chromatin remodelling complex) related proteins 
(SMCE1, SMRC2, SMRD2, and ARID1A), known to interact with AR in the 
context of prostate cancer (Chmelar et al. 2007) and are required for AR to 
reorganize chromatin upon activation (Marshall et al. 2003). It makes sense 
that these factors are common AR interacting proteins in the two breast cancer 
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cell lines as well as in prostate cancer cells because recruitment of chromatin 
remodellers is a standard feature of steroid receptor mediated transcriptional 
activity (Achinger-Kawecka et al. 2020; Orlando et al. 2019; Senapati, Kumari 
& Heemers 2020). The AR interacting proteins that were specific for MDA-
MB-453 cells included factors involved in cell cycle regulation (e.g., HCFC1, 
LAP2A, and NUDC), DNA repair (PAXX, PNKP, PRMT1, and UBA1), and 
transcription factors (e.g., TFAP-2β and TLF3). The MFM-223 specific AR 
partners were categorised into chromatin remodeling (e.g., HMGB1 H2AZ, 
and RCC1), RNA processing (e.g., EIF3A, CCAR2, and FUBP3), cell 
growth/death (ANXA7, and YWHAZ), response to stress (PRDX1 and 
PRDX2), as well as transcription repression (CBX5). The observed differences 
in the AR interactomes could feasibly be attributed to the mutational status of 
AR in MDA-MB-453 cells; the AR gene in MDA-MB-453 cells contains a G-T 
transversion in exon 7 (Moore et al. 2012b). In contrast, the AR gene is not 
mutated in MFM-223 cells (Magklara, Brown & Diamandis 2002). The MDA-
MB-453 AR mutation results in an AR protein variant consisting of a glutamine 
to histidine substitution at amino acid 865 (Q865H) of the ligand binding 
domain (Moore et al. 2012b). Molecular modelling of the mutated AR protein 
showed conformational changes likely to affect the structure of the ligand 
binding pocket (Moore et al. 2012b), which may lead to the recruitment of a 
distinct set of AR co-regulators. Another possibility is that the gene/protein 
expression of some of these co-regulators could be different between MDA-
MB-453 and MFM-223 cell lines, leading to differential recruitment to AR. 
The latter suggestion could be supported by the results of Transcription factor 
AP-2β (TFAP-2β). The TFAP-2β transcription factor is known to regulate 
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many important biological processes and was detected as an AR co-regulatory 
protein in MDA-MB-453 cells but not the MFM-223 cells. Independent 
validation showed that TFAP-2β protein levels were highly expressed in 
MDA-MB-453 cells but were not detectable in MFM-223 cells. These data 
inspired the hypothesis that TFAP-2β may be a critical determinant of AR 
oncogenic action in ERα-negative breast cancers, which was explored in 
Chapter 4.  
6.1.2 TFAP-2β is critical for growth of molecular apocrine breast cancer 
cells. 
Identification of TFAP-2β as an AR interacting protein in MDA-MB-453 cells 
and not MFM-223 cells stirred further investigation of this factor in the context 
of all breast cancers and then in the specific context of ERα-negative disease, 
the theme of my thesis. Examining TFAP2B expression levels in a cohort of 
176 clinical breast cancers showed strong enrichment in tumours classified as 
molecular apocrine breast cancers. Our demonstration that TFAP-2β 
expression is also high in MDA-MB-453 cells but not in other AR-positive cell 
line models of ERα-negative breast cancer, is consistent with the fact that the 
MDA-MB-453 cell line is commonly considered and utilized as the prototypic 
model of the molecular apocrine disease sub-type (Doane et al. 2006; Farmer et 
al. 2005; Ni et al. 2011). As a sequence-specific DNA-binding transcription 
factor, TFAP-2β regulates the expression of genes with roles in important 
biological processes such as development and cell survival (Moser et al. 1997; 
Satoda et al. 2000; Wenke & Bosserhoff 2010). Therefore, we aimed to 
investigate the biological role of TFAP-2β in the context of molecular apocrine 
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disease before specifically investigating its potential role as a regulator of 
oncogenic AR signalling. Experimental knockdown of TFAP-2β strongly 
suppressed proliferation and induced apoptosis in MDA-MB-453 cells. An 
oncogenic effect of TFAP-2β has been demonstrated in several cancer types 
(Fu, L et al. 2014; Fu, X et al. 2019; Hara et al. 2019). For example, silencing 
TFAP-2β inhibited cell growth and induced apoptosis in lung adenocarcinoma 
models in vitro and in vivo, whereas TFAP-2β overexpression promoted cell 
growth (Fu, L et al. 2014). The observed regulation of cell growth by TFAP-2β 
in the latter study was accompanied by modulation of cancer-associated 
pathways including stimulation of ERK/p38 and VEGF/PEDF-dependent 
signalling  (Fu, L et al. 2014). In our study, we showed that ectopic expression 
of TFAP-2β in MFM-233 cells did not stimulate growth of this cell line, 
suggesting that this effect is context specific. 
Other pre-clinical data reported that TFAP-2β mediates thyroid cancer cell 
proliferation and migration via the COX-2 signaling pathway (Fu, X et al. 
2019). Herein, we showed that TFAP-2β promotes growth and viability of 
MDA-MB-453 cells by maintaining expression of C-MYC and HER2 
oncogenes. Moreover, genome-wide mapping of the TFAP-2β cistrome 
showed TFAP-2β binding sites at the enhancer region of HER2 and in the 
promoter region of C-MYC and other genes involved in cell cycle progression. 
Consistent with this finding, siRNA-mediated knockdown of TFAP-2β reduced 
enrichment of H3K27ac (a mark of transcriptional activation) at loci associated 
with these genes, including WEE1, a G2/M checkpoint regulator protein 
(Ghiasi et al. 2013), E2F2, a transcriptional regulator of G1/S target genes 
(Johnson & Schneider-Broussard 1998), and DKC1, another transcriptional 
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regulator of G1 target genes (Miao et al. 2019). However, examining global 
changes in H3K27ac at the ChIP-seq level did not capture the full effect of 
TFAP-2β knockdown on genomic changes, and thus experiments investigating 
TFAP-2β gene regulation by RNA-seq to capture global gene expression 
changes with siRNA-mediated inhibition of TFAP-2β are in progress.  
As mentioned above, we hypothesized that TFAP-2β might be a mediator of 
oncogenic AR signalling in the context of ERα-negative breast cancer. Using 
several proteomic techniques, we identified and validated the interaction of AR 
with TFAP-2β in MDA-MB-453 cells but not in MFM-223 cells (Chapter 4, 
Figure 4.3). These results were explained by showing that TFAP-2β is highly 
expressed in MDA-MB-453 cells and is not detectable in MFM-223 cells. As 
we were interested in identifying AR genomic activity that differentiates 
proliferative from the anti-proliferative androgenic effects, we further 
examined TFAP-2β/AR interplay. Cistrome analysis showed a substantial co-
localization of these two factors (at about 45% of loci) when AR was 
stimulated by DHT, supporting the results of our proteomic data and showing 
that these two transcription factors may have interactive as well as independent 
signalling events and physiological effects. Subsequent investigation showed 
that TFAP-2β knockdown reduced but did not prevent AR enrichment at 
representative co-occupied loci in MDA-MB-453 cells and had no significant 
effect on DHT-induced AR transactivation activity for associated genes. While 
this data indicates that TFAP-2β is not a critical determinant of AR binding or 
transactional capacity, the results are not definitive because the full effect of 
silencing TFAP-2β may have been masked because we did not perform a 
complete knockdown due to the toxic effect on cells. However, a previous 
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study has reported that the pioneer factor FOXA1 co-occupies ~ 100% of the 
AR cistrome in MDA-MB-453 cells (Robinson, JL et al. 2011), indicating a 
more global influence compared to TFAP-2β. Our data indicate that a subset of 
FOXA1-AR binding sites is co-occupied by TFAP-2β, so that TFAP-2β 
silencing may not have a strong impact on AR binding at these co-occupied 
loci because the chromatin was opened due to the presence of FOXA1.  
PDX models are now considered the gold standard for modelling breast cancer 
and to date, no one has examined the effect of AR signalling on models that 
represent molecular apocrine breast cancer. Three PDX models selected on the 
basis of being ERα-negative and having high AR expression and HER2 
amplification were treated in vivo with DHT to shed critical light on the fact 
that even within the context of molecular apocrine PDXs, AR does not have a 
universal oncogenic effect. Interestingly, immunoreactive staining of TFAP-2β 
showed high expression of TFAP-2β in all of the tested molecular apocrine 
PDX models, supporting our conclusion that TFAP-2β plays a major role in 
determining this disease subtype and also showing that expression of TFAP-2β 
alone does not determine response to androgen in this disease context.  
While the current study provides preliminary evidence for the clinical 
significance of TFAP-2β in molecular apocrine breast cancer, all in vitro data 
presented here were generated using one representative cell line (i.e., MDA-
MB-453). Whether this result could be extrapolated to clinical molecular 
apocrine breast cancer remains unknown. We tried to address this limitation by 
investigating another representative molecular apocrine cell line model (HCC-
202) but experiments with this cell line were hampered by failure to 
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successfully revive old frozen stocks provided by a collaborator and delays to 
receiving new stocks from ATCC due to COVID-19. Future studies will test 
whether HCC-202 cells are also dependent on TFAP-2β for growth and 
survival. This limitation could be further addressed by future studies with the 
PDX models of molecular apocrine breast cancer we characterised, which all 
have high expression of TFAP-2β. These studies could involve genetic 
knockdown of TFAP-2β or treatment with an inhibitor. While a specific 
inhibitor targeting TFAP-2β is still not available, there is a small molecule 
inhibitor previously used to target TFAP-2α / TFAP-2γ (Hu et al. 2018) and 
from our experience in developing a selective inhibitor of CDK9 (Chapter 5), it 
may be possible to modify this inhibitor to be specific for TFAP-2β. Our study 
provides a rational for creating a selective inhibitor of TFAP-2β. Moreover, as 
the finding of this work showed that TFAP-2β is not the main determinant of 
AR action in this disease, further studies are required to identify biomarkers 
that can be used in patient selection to predict what type of AR target therapy 
(i.e., agonist or antagonist) would be appropriate. In the context of molecular 
apocrine breast cancers, a key future experiment is to interrogate AR signalling 
at the molecular level using our panel of PDX models of this disease sub-type 
that we have shown to have differential growth responses to DHT. Comparison 
of genomic factors that mediate AR signalling in more clinically relevant 
models such as molecular apocrine PDXs, with those of cell line models may 
facilitate the identification of biomarkers of androgen response in this disease 
context and avoid cell line biases, for example, the MDA-MB-453 cell line 





6.1.3 A new highly selective CDK9 inhibitor, D-11, effectively suppresses 
growth of triple negative breast cancer (TNBC) 
CDK9 inhibition is an attractive therapeutic strategy for TNBC tumours, as 
they are addicted to continuous transcription of short half-life oncogene and 
pro-survival factors (Brisard et al. 2018; Rajput et al. 2016). Although several 
inhibitors (e.g., Dinaciclib and Flavopiridol) have shown high potency against 
CDK9 activity, the lack of strong selectivity for CDK9 has limited their 
clinical utility due to off-target side effects (Aklilu et al. 2003; Boffo et al. 
2018; Criscitiello et al. 2014; Parry et al. 2010). Therefore, developing highly 
selective CDK9 inhibitors is important to advance the field and clinical 
implementation of this targeting strategy for TNBC or other relevant cancers. 
Here, we report development and pre-clinical efficacy of a novel and highly 
selective CDK9 inhibitor, D-11, which exhibited high potency against CDK9 
and displayed excellent selectivity over 369 human kinases. D-11 effectively 
suppressed the proliferation of TNBC cell line models in vitro. Through 
inhibition of RNAPII phosphorylation at Ser-2, D-11 decreased levels of the 
anti-apoptotic protein MCL1 and induced Caspase-dependent apoptosis in 
TNBC cells. These data are consistent with previous studies that have 
associated CDK9 inhibition with MCL1 depletion and subsequent induction of 
tumour cell death (Cidado et al. 2020; O’Reilly et al. 2018; Rahaman, Yu, et al. 
2019; Tong et al. 2019). In addition, our study demonstrated that D-11 impairs 
proliferation of TNBC cells by diminishing protein levels of C-MYC and 
arresting cells in the G2/M phase. C-MYC regulates expression of a variety of 
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genes involved in cell cycle progression, including genes encoding CDK1 and 
cyclin B1, which mediate cell cycle progression from the G2/M phase, (Albihn, 
Johnsen & Henriksson 2010; Dang, CVJM & biology 1999). Consistent with 
our findings, a previous study by Yang and colleagues reported that silencing 
C-MYC suppressed cyclin B1 expression in leukemia cells (Yang, Y et al. 
2018). These data indicate that G2/M cell cycle arrest induced by D-11 could 
be a result of down-regulation of the C-MYC target gene cyclin B1. 
The anti-tumour efficacy of D-11 was also observed in vivo using mammary 
intraductal (MIND) xenografting of a TNBC cell line. Our study is the first to 
test in vivo efficacy of D-11 but also to use this more clinically relevant 
xenografting technique to examine the effect of CDK9 inhibition in vivo. The 
MIND technique is preferred over mammary fat-pad xenografting because it 
establishes a tumour where breast cancers naturally develop (within the 
mammary ducts) and retains the capacity to recapitulate stages of disease 
progression (in situ, invasive, metastatic) (Richard et al. 2016; Sflomos et al. 
2016). Oral administration of D-11 resulted in a significant inhibition in 
tumour growth (p < 0.01) without causing body weight loss and without 
affecting histology of normal tissues such as the liver and spleen. In contrast to 
its cytotoxic effect against cancer cells, D-11 also showed no toxicity on 
histology of normal human breast tissues that were cultured and treated ex vivo 
as explants, an important pre-clinical model that sustains tissue architecture, 
viability, and cellular complexity (Centenera et al. 2018; Flores, Taylor & 
Clinics 2015; Hickey, TE et al. 2021). These observations demonstrate the 
potential safety of D-11 and support its selectively for CDK9. To further 
clarify the relevance of selective CDK9 inhibition in TNBC and to provide 
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more compelling evidence that D-11 is a promising drug for clinical 
development, examining D-11’s effect in vivo using TNBC PDX would be a 
key future experiment for clinical translation.  
6.2 Conclusion 
 
The findings of this project expand current knowledge about the action of AR 
signalling in ERα-negative breast cancer and provide a descriptive 
investigation of the molecular factors associated with its oncogenic versus anti-
oncogenic potential that can serve as an important resource for generating and 
testing new hypotheses. Moreover, this project provides preclinical evidence 
for novel therapeutic targets in ERα-negative breast cancer. TFAP-2β is highly 
expressed in molecular apocrine breast cancer tumours and is critical for the 
growth and viability of a cell line model of this disease sub-type. Our study 
presented TFAP-2β as a growth-promoting factor and a potential treatment 
strategy in molecular apocrine disease and highlighted the importance of 
identifying inhibitors of this factor. Targeting CDK9 with a novel, potent, and 
highly selective inhibitor is an effective treatment strategy for ERα-negative 
breast tumours. The new CDK9 inhibitor D-11 has marked anti-cancer efficacy 
in vitro and in vivo. With its high oral bioactivity along with an appreciable 
safety profile, D-11 offers a very exciting prospect as a clinical development 
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Appendix 1A: Map of mKate2 plasmid. mKate2 plasmid was prepared by 





























Appendix 1B: Map of LTP plasmid. LTP plasmid was derived from pRRL-
MND-GFP (Addgene, #36247) by replacing the GFP insert with a firefly 










Appendix 1C: Map of TFAP-2α and TFAP-2β plasmids. Plasmids were 
















Appendix 1D: Map of tet-TFAP-2β plasmids. Doxycycline-inducible TFAP-
2β vector (pDRM23) was generated from pCW57.1 (Addgene #41393) by 
Gateway cloning (Invitrogene) from an entry vector containing the TFAP-2β 










AR RNA-seq and ChIP-seq in  
ERα-/AR+ cell lines 
 
Table 2A: Common DHT up-regulated genes in MDA-MB-453 and MFM-223 
cell lines. 
Ensembl gene ID Gene symbol 
MDA-MB-453 MFM-223 
FC p-value FC p-value 
ENSG00000132142 ACACA 1.54930830 0.003643008 1.962977602 6.66E-16 
ENSG00000155893 ACPL2 1.57319551 0.005032503 2.031462973 5.77E-15 
ENSG00000143199 ADCY10 2.64671725 0.035150762 2.569958563 0.012046592 
ENSG00000150594 ADRA2A 7.97068569 0 2.630504506 0.000175059 
ENSG00000121057 AKAP1 1.76228945 0.000253703 1.529244503 2.46E-07 
ENSG00000179841 AKAP5 2.26434562 4.19E-06 1.75080106 3.69E-08 
ENSG00000116337 AMPD2 1.67674713 0.00092076 1.543486089 5.70E-07 
ENSG00000165272 AQP3 16.5941171 0 2.715839098 5.38E-05 
ENSG00000047648 ARHGAP6 2.32230975 1.54E-06 2.492723778 0 
ENSG00000114790 ARHGEF26 1.50161506 0.009455329 1.861935896 8.08E-14 
ENSG00000183111 ARHGEF37 1.62619576 0.001801174 1.571240408 3.57E-07 
ENSG00000160862 AZGP1 1.92989916 1.95E-05 1.890118221 6.55E-07 
ENSG00000214313 AZGP1P1 3.94583335 0 3.001392647 6.20E-11 
ENSG00000113916 BCL6 1.88621609 6.49E-05 1.60840286 2.07E-05 
ENSG00000107815 C10orf2 1.83348908 0.00013962 1.505589429 2.71E-06 
ENSG00000182795 C1orf116 9.44545292 6.43841E-12 3.89568152 2.8017E-16 
ENSG00000187889 C1orf168 2.61711788 0.001596461 1.878678201 1.51E-13 
ENSG00000181744 C3orf58 1.56384625 0.005161988 1.564446415 7.60E-07 
ENSG00000105879 CBLL1 1.60907415 0.003807358 2.43735679 2.01E-10 
ENSG00000110104 CCDC86 2.46332104 1.21E-08 1.528903236 7.29E-06 
ENSG00000111666 CHPT1 3.11101356 6.98E-13 1.581644734 9.15E-08 
ENSG00000174469 CNTNAP2 2.31352734 6.53E-08 1.8002665 2.15E-12 
ENSG00000005469 CROT 3.10415186 5.13E-09 1.747539059 1.02E-11 
ENSG00000101441 CST4 4.92083303 0.035326788 1.867938175 0.013473705 
ENSG00000171954 CYP4F22 9.61657439 5.59E-05 3.210659845 0.01227653 
ENSG00000186526 CYP4F8 59.6631906 0 13.24234328 0 
ENSG00000102780 DGKH 1.56185747 0.006451761 1.564756041 0.00697099 
ENSG00000116133 DHCR24 1.67336482 0.001008527 1.613123669 3.78E-09 
456 
 
ENSG00000137976 DNASE2B 4.94106208 1.54E-06 2.941899426 4.78E-05 
ENSG00000128512 DOCK4 1.70134589 0.000846856 4.231370492 6.41E-11 
ENSG00000158050 DUSP2 2.18554893 1.70E-06 1.701970583 3.07E-08 
ENSG00000145088 EAF2 1.80397111 0.003693614 1.777603583 8.85E-09 
ENSG00000135373 EHF 1.95239492 1.20E-05 1.508092057 0.002530622 
ENSG00000149218 ENDOD1 1.88859850 0.000149669 2.754202834 0 
ENSG00000145569 FAM105A 3.17524376 1.30E-10 6.240225868 0 
ENSG00000096060 FKBP5 4.14547218 6.64182E-11 3.296009 9.65666E-15 
ENSG00000111816 FRK 3.77557783 0.011001938 1.575328143 0.01808232 
ENSG00000172159 FRMD3 8.1128943 1.07E-07 2.689795615 1.31E-08 
ENSG00000116717 GADD45A 1.69640104 0.000946689 1.668119554 7.71E-09 
ENSG00000099860 GADD45B 1.71887687 0.000795294 1.656246064 3.03E-05 
ENSG00000135821 GLUL 1.70563310 0.001130029 1.816466439 3.54E-13 
ENSG00000146535 GNA12 1.84440606 5.51E-05 1.678553412 2.65E-10 
ENSG00000138641 HERC3 1.95543014 1.20E-05 1.700848463 0.000362568 
ENSG00000100644 HIF1A 1.53321459 0.005388702 1.637905886 3.31E-05 
ENSG00000125430 HS3ST3B1 2.24435692 0.000211439 1.949457 1.90E-05 
ENSG00000145703 IQGAP2 2.88158052 2.83E-11 4.849193546 0 
ENSG00000177508 IRX3 2.21012894 2.92E-07 2.238061361 2.16E-08 
ENSG00000177606 JUN 1.82528263 0.00012674 1.513985227 2.42E-06 
ENSG00000178695 KCTD12 2.16723262 0.001138853 3.362106071 3.16E-08 
ENSG00000127663 KDM4B 2.08412368 2.66E-06 2.037094301 0 
ENSG00000102554 KLF5 1.85370315 0.000411496 2.163470023 3.33E-16 
ENSG00000124743 KLHL31 3.13770321 0.013000129 1.929752132 0.010681415 
ENSG00000138795 LEF1 2.04916218 0.007492439 1.690393963 0.042001843 
ENSG00000113594 LIFR 2.864589 0.000129388 1.552406336 0.008977533 
ENSG00000171517 LPAR3 3.3277719 0.005748094 10.08532713 1.81E-08 
ENSG00000079691 LRRC16A 2.74045622 1.69E-10 1.787534752 9.81E-07 
ENSG00000204103 MAFB 1.99333217 0.000671161 1.50935327 9.81E-06 
ENSG00000172175 MALT1 1.56126794 0.004447891 2.399247353 0 
ENSG00000131844 MCCC2 1.60208995 0.002013681 1.853007737 5.88E-14 
ENSG00000166391 MOGAT2 5.53765204 1.34E-05 5.48788837 3.36E-10 
ENSG00000143158 MPC2 1.99337491 7.83E-06 1.570848897 5.38E-08 
ENSG00000196091 MYBPC1 63.0307981 0 4.723398333 7.66E-08 
ENSG00000136997 MYC 3.67025796 1.11E-16 1.756900166 3.03E-05 
ENSG00000005810 MYCBP2 1.61924376 0.002654789 1.743754646 0.002275898 
ENSG00000229644 NAMPTL 1.78133380 0.02556212 1.553184516 0.040893481 
ENSG00000100906 NFKBIA 3.53990344 2.20E-06 1.512224923 2.74E-06 
ENSG00000198435 NRARP 1.97626208 1.11E-05 1.761083429 3.73E-05 
ENSG00000169116 PARM1 2.24056498 3.54E-07 2.179843596 2.21E-11 
ENSG00000179094 PER1 1.80896392 0.00023487 2.942630637 7.77E-16 
ENSG00000123836 PFKFB2 1.65206954 0.001506376 1.914014192 2.77E-13 
ENSG00000241878 PISD 2.10804734 1.68E-06 1.619990324 7.60E-08 
ENSG00000170927 PKHD1 2.51750881 0.001990599 7.02470649 1.89E-11 
ENSG00000125630 POLR1B 1.60282537 0.002272145 1.563571638 1.36E-07 







ENSG00000085377 PREP 2.47378173 3.81E-07 1.615088365 1.29E-08 
ENSG00000131791 PRKAB2 1.79862228 0.00022834 1.666133938 1.78E-05 
ENSG00000150687 PRSS23 1.60452403 0.002211462 2.086964791 2.90E-08 
ENSG00000156675 RAB11FIP1 2.03159453 4.92E-06 1.894745784 9.39E-11 
ENSG00000164188 RANBP3L 18.5221481 1.25300E-11 16.36094124 5.56776E-18 
ENSG00000100302 RASD2 3.72759255 0.049620006 1.56017092 0.017346732 
ENSG00000111961 SASH1 1.52314963 0.005802305 1.967749583 5.09E-06 
ENSG00000100003 SEC14L2 52.7691783 1.18446E-13 5.290915021 2.11620E-16 
ENSG00000174705 SH3PXD2B 1.77494095 0.001083022 2.149331528 1.24E-06 
ENSG00000142178 SIK1 2.43883252 3.11E-06 1.511856519 3.13E-06 
ENSG00000163406 SLC15A2 2.19647344 0.008799525 1.585633617 3.49E-05 
ENSG00000108932 SLC16A6 2.18537148 4.08E-07 2.088967028 9.11E-10 
ENSG00000197208 SLC22A4 1.53661894 0.014743124 2.047084088 0.017529513 
ENSG00000197375 SLC22A5 1.54540730 0.005245623 1.779704126 3.39E-11 
ENSG00000155850 SLC26A2 2.03272792 0.003878015 2.30156232 1.95E-09 
ENSG00000091138 SLC26A3 11.2563002 6.36E-09 8.721099322 0 
ENSG00000212588 SNORA26 2.10513955 0.032047452 3.092683638 0.029528089 
ENSG00000198142 SOWAHC 1.51042259 0.008565055 1.885831802 4.41E-14 
ENSG00000139351 SYCP3 2.00351017 0.007373518 1.575516141 0.010317472 
ENSG00000141384 TAF4B 3.33981727 2.75E-10 1.620475894 1.21E-07 
ENSG00000198650 TAT 2.26766307 5.24E-06 2.293465992 0.001061457 
ENSG00000167291 TBC1D16 1.84042165 5.01E-05 1.611580792 1.83E-05 
ENSG00000090447 TFAP4 1.64791209 0.001944944 1.578344206 7.56E-07 
ENSG00000042832 TG 2.21893251 0.021289033 3.911816447 6.74E-06 
ENSG00000249242 TMEM150C 2.58170825 0.000352122 1.627825473 0.004433852 
ENSG00000157600 TMEM164 1.67129966 0.000761814 1.549158523 2.72E-07 
ENSG00000179104 TMTC2 2.00353108 9.08E-06 2.390760724 9.90E-13 
ENSG00000109814 UGDH 1.77651936 0.000213616 2.405049811 0 
ENSG00000213759 UGT2B11 139.984007 0 27.34309596 0 
ENSG00000135226 UGT2B28 32.099369 1.12183E-08 14.21662551 2.34450E-07 
ENSG00000169884 WNT10B 1.84242252 0.001162088 1.593431267 0.012519392 
ENSG00000188064 WNT7B 4.64794852 0 1.836853797 1.32E-10 
ENSG00000113645 WWC1 2.03895404 3.72E-06 1.933281086 7.89E-14 
ENSG00000047644 WWC3 2.85301189 1.64E-11 2.299163257 4.38E-10 
ENSG00000198740 ZNF652 1.81913455 0.000105432 1.589266322 0.003213479 
ENSG00000183779 ZNF703 1.51121351 0.008802198 1.513742752 6.84E-07 
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Table 2B: Common DHT down-regulated genes in MDA-MB-453 and MFM-
223 cell lines. 




FC p-value FC p-value 
ENSG00000139211 AMIGO2 0.471174647 1.26E-06 0.33035501 0 
ENSG00000169083 AR 0.538193762 6.08E-05 0.59594927 1.02E-05 
ENSG00000102048 ASB9 0.484062903 0.032143436 0.41791152 0.000605009 
ENSG00000180347 CCDC129 0 0.017578627 0.20553627 0.04119962 
ENSG00000197599 CCDC154 0.37540699 0.021690816 0.56385417 0.000388605 
ENSG00000163823 CCR1 0.197445904 0.038244651 0.31298030 0.038593696 
ENSG00000175264 CHST1 0.433237474 9.50E-08 0.17322701 1.26E-07 
ENSG00000077063 CTTNBP2 0.38528894 0.000952371 0.40091238 0 
ENSG00000121966 CXCR4 0.362292072 9.42E-06 0.17714627 0 
ENSG00000153071 DAB2 0.345190367 0.000321009 0.40530817 8.28E-06 
ENSG00000171617 ENC1 0.554977665 0.00022448 0.33520464 0 
ENSG00000091831 ESR1 0.304409448 0.018632583 0.56346681 2.49E-05 
ENSG00000159784 FAM131B 0 0.017250037 0.58787891 0.038464954 
ENSG00000185112 FAM43A 0.567327323 0.000492306 0.56182214 1.82E-06 
ENSG00000162645 GBP2 0.438738495 1.84E-05 0.48416342 0 
ENSG00000117009 KMO 0.347940775 2.76E-11 0.30154472 0.002119881 
ENSG00000108244 KRT23 0.276203258 3.88E-09 0.54480202 5.53E-07 
ENSG00000212766 LINC0027 0.151333246 0.00532552 0.57284453 3.38E-05 
ENSG00000153714 LURAP1L 0.591364913 0.002954293 0.50553609 7.52E-12 
ENSG00000178573 MAF 0.456576366 3.49E-05 0.39778311 0.013983257 
ENSG00000144063 MALL 0.260259638 0.037183871 0.56774638 6.22E-05 
ENSG00000122584 NXPH1 0.331040753 0.021589538 0.46888825 0.003740489 
ENSG00000179715 PCED1B 0.592220844 0.004058584 0.54589347 2.47E-06 
ENSG00000184588 PDE4B 0.475303352 2.47E-06 0.34234393 8.60E-10 
ENSG00000086717 PPEF1 0.36058859 0.002044024 0.54749317 0.001742634 
ENSG00000128045 RASL11B 0.539492162 0.00037267 0.48494931 0.00722323 
ENSG00000112246 SIM1 0 0.035281118 0.44492123 0.007234161 
ENSG00000116991 SIPA1L2 0.583455529 0.000486588 0.49290527 1.41E-10 
ENSG00000243244 STON1 0.331097304 0.011945442 0.46744381 6.66E-16 
ENSG00000067715 SYT1 0.120542341 0.029658818 0.52825936 0.006064981 
ENSG00000137501 SYTL2 0.584500813 0.014080706 0.54707167 1.68E-11 
ENSG00000073282 TP63 0.171369783 0 0.55858652 9.88E-05 
ENSG00000188001 TPRG1 0.257075082 2.66E-10 0.53238956 1.81E-05 
ENSG00000038427 VCAN 0.377796831 0.000309025 0.45946620 1.51E-07 
ENSG00000134258 VTCN1 0.589920878 0.014100951 0.51019568 0.000289626 
ENSG00000115596 WNT6 0 0.047759347 0.30297769 1.73E-07 
ENSG00000158125 XDH 0.346436245 6.43E-08 0.50138935 2.42E-05 
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Table 2C: GO analysis of genes up-regulated in MDA-MB-453 in response 
to DHT  
Ensembl gene ID Gene symbol FC p-value 
Lipid and steroid metabolism  
ENSG00000186204 CYP4F12 11.29847623 0.00148 
ENSG00000196620 UGT2B15 6.852113975 0.025572 
ENSG00000137841 PLCB2 4.789161047 2.31E-05 
ENSG00000215009 ACSM4 4.096730518 0.032372 
ENSG00000171903 CYP4F11 3.453236418 0.030478 
ENSG00000184254 ALDH1A3 3.336076817 0.002098 
ENSG00000180616 SSTR2 3.314596609 0.043959 
ENSG00000064763 FAR2 2.372752424 3.20E-06 
ENSG00000176387 HSD11B2 2.307855786 3.16E-07 
ENSG00000155380 SLC16A1 2.237470805 3.90E-06 
ENSG00000068366 ACSL4 2.230804542 1.57E-05 
ENSG00000149527 PLCH2 2.200475337 0.015289 
ENSG00000142798 HSPG2 1.992454438 0.001598 
ENSG00000165914 TTC7B 1.976457087 0.020896 
ENSG00000005249 PRKAR2B 1.854497244 0.000912 
ENSG00000136826 KLF4 1.793416267 0.00023 
ENSG00000163659 TIPARP 1.774055202 0.000243 
ENSG00000137124 ALDH1B1 1.752036847 0.000418 
ENSG00000095637 SORBS1 1.746265876 0.022469 
ENSG00000179477 ALOX12B 1.736814273 0.012048 
ENSG00000162409 PRKAA2 1.719414107 0.000613 
ENSG00000152270 PDE3B 1.719106133 0.009149 
ENSG00000162139 NEU3 1.707558114 0.000625 
ENSG00000069667 RORA 1.668606742 0.00202 
ENSG00000060971 ACAA1 1.654766404 0.001194 
ENSG00000166261 ZNF202 1.576397017 0.004351 
ENSG00000001630 CYP51A1 1.575518615 0.011111 
ENSG00000168118 RAB4A 1.556500713 0.00437 
ENSG00000156804 FBXO32 1.544733587 0.005102 
ENSG00000158470 B4GALT5 1.531618539 0.005212 
ENSG00000120833 SOCS2 1.530637678 0.005858 
ENSG00000151726 ACSL1 1.526910654 0.005322 
ENSG00000148459 PDSS1 1.52047039 0.009912 
ENSG00000084676 NCOA1 1.513640736 0.007494 
ENSG00000184886 PIGW 1.502449243 0.009868 
Carbohydrate, RNA, or small molecules metabolism 
ENSG00000162882 HAAO 3.833677042 0.012874 
ENSG00000132437 DDC 2.922265229 4.07E-08 
ENSG00000211448 DIO2 2.916671575 0.009179 
ENSG00000133424 LARGE 2.165574202 5.83E-07 
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ENSG00000065989 PDE4A 1.814179654 0.016966 
ENSG00000124357 NAGK 1.755051672 0.000267 
ENSG00000247626 MARS2 1.708388402 0.00071 
ENSG00000123009 NME2P1 1.673724911 0.017106 
ENSG00000162174 ASRGL1 1.66404022 0.009369 
ENSG00000112541 PDE10A 1.643067235 0.047395 
ENSG00000171004 HS6ST2 1.605527612 0.002243 
ENSG00000185818 NAT8L 1.604394102 0.018098 
ENSG00000103222 ABCC1 1.60346301 0.00267 
ENSG00000147224 PRPS1 1.555132923 0.004636 
ENSG00000168282 MGAT2 1.504005709 0.031181 
Development  
ENSG00000175329 ISX 16.98644844 2.25E-12 
ENSG00000138311 ZNF365 7.615307453 2.72E-12 
ENSG00000117148 ACTL8 3.81358398 0.000668 
ENSG00000179111 HES7 3.541165881 8.70E-05 
ENSG00000163884 KLF15 3.435058132 1.39E-10 
ENSG00000198812 LRRC10 3.172554735 0.042075 
ENSG00000005073 HOXA11 3.045195236 0.006563 
ENSG00000128606 LRRC17 2.844360398 0.047881 
ENSG00000181418 DDN 2.1832350143 1.00E-07 
ENSG00000154734 ADAMTS1 2.788841121 9.78E-11 
ENSG00000144218 AFF3 2.742996312 1.61E-08 
ENSG00000027869 SH2D2A 2.507451966 0.000129 
ENSG00000166833 NAV2 2.408425851 4.08E-06 
ENSG00000117013 KCNQ4 2.2903795 3.49E-05 
ENSG00000043039 BARX2 2.220582083 0.011631 
ENSG00000204335 SP5 2.211365742 0.031964 
ENSG00000166068 SPRED1 1.94836328 1.52E-05 
ENSG00000142627 EPHA2 1.910921643 0.000197 
ENSG00000187210 GCNT1 1.888984057 0.001337 
ENSG00000104998 IL27RA 1.790499839 0.003786 
ENSG00000164442 CITED2 1.78822987 0.037307 
ENSG00000179041 RRS1 1.785078772 0.000192 
ENSG00000166197 NOLC1 1.78506511 0.000155 
ENSG00000120254 MTHFD1L 1.771780655 0.000316 
ENSG00000253293 HOXA10 1.731867885 0.033346 
ENSG00000015133 CCDC88C 1.725847281 0.000618 
ENSG00000101384 JAG1 1.714762713 0.000552 
ENSG00000145220 LYAR 1.69390364 0.000776 
ENSG00000176171 BNIP3 1.684580549 0.002039 
ENSG00000066468 FGFR2 1.618614325 0.018231 
ENSG00000133816 MICAL2 1.655069307 0.015757 
ENSG00000172458 IL17D 1.65357437 0.011307 
ENSG00000123572 NRK 1.633050311 0.001524 
ENSG00000107731 UNC5B 1.619729065 0.001739 
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ENSG00000177283 FZD8 1.61648453 0.005014 
ENSG00000159216 RUNX1 1.612041124 0.002038 
ENSG00000091127 PUS7 1.609290622 0.003 
ENSG00000115318 LOXL3 1.599386611 0.010691 
ENSG00000115758 ODC1 1.589324114 0.002652 
ENSG00000033867 SLC4A7 1.585988788 0.003748 
ENSG00000112578 BYSL 1.563360078 0.01025 
ENSG00000160712 IL6R 1.561482828 0.007081 
ENSG00000128059 PPAT 1.561419154 0.004327 
ENSG00000105835 NAMPT 1.556106619 0.00583 
ENSG00000136068 FLNB 1.550254856 0.003498 
ENSG00000163251 FZD5 1.531333743 0.022149 
ENSG00000083307 GRHL2 1.513602229 0.006714 
ENSG00000136205 TNS3 1.51328749 0.008395 
ENSG00000057294 PKP2 1.509345763 0.042056 
ENSG00000168234 TTC39C 1.501861728 0.017602 
Growth or cell signalling 
ENSG00000124140 SLC12A5 7.079760201 0.039799 
ENSG00000118160 SLC8A2 4.634768249 0.039592 
ENSG00000120162 MOB3B 3.533618072 0.005469 
ENSG00000143507 DUSP10 3.355452682 4.16E-14 
ENSG00000124743 KLHL31 3.137703217 0.013 
ENSG00000111666 CHPT1 3.111013563 6.98E-13 
ENSG00000131711 MAP1B 2.485615134 0.000114 
ENSG00000118515 SGK1 2.425439788 0.002339 
ENSG00000127863 TNFRSF19 2.39644025 3.46E-05 
ENSG00000158050 DUSP2 2.185548938 1.70E-06 
ENSG00000113739 STC2 2.138432242 2.14E-06 
ENSG00000125931 CITED1 2.13084488 0.000595 
ENSG00000101695 RNF125 2.107823575 0.000712 
ENSG00000138795 LEF1 2.049162182 0.007492 
ENSG00000113645 WWC1 2.038954048 3.72E-06 
ENSG00000120899 PTK2B 2.030820446 1.17E-05 
ENSG00000178607 ERN1 2.024484801 2.03E-05 
ENSG00000162552 WNT4 2.016264669 0.017307 
ENSG00000135333 EPHA7 2.013460906 0.000319 
ENSG00000198915 RASGEF1A 1.908842172 0.019618 
ENSG00000118965 WDR35 1.894844207 8.39E-05 
ENSG00000146376 ARHGAP18 1.872828878 8.54E-05 
ENSG00000165732 DDX21 1.81428836 0.000103 
ENSG00000017797 RALBP1 1.789178839 0.000163 
ENSG00000104369 JPH1 1.72779145 0.000559 
ENSG00000170345 FOS 1.684710549 0.036036 
ENSG00000149089 APIP 1.635251949 0.002569 
ENSG00000106785 TRIM14 1.625044711 0.001563 
ENSG00000111845 PAK1IP1 1.539082341 0.005211 
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Table 2D: Biological processes associated with DHT down-regulated genes 
in MDA-MB-453 cells 
 
Ensembl gene ID Gene symbol FC p-value 
Cell motility, adhesion, or extracellular structure  
ENSG00000065618 COL17A1 0 0.029081 
ENSG00000189056 RELN 0 0.018671 
ENSG00000102837 OLFM4 0 0.015949 
ENSG00000134757 DSG3 0 0.011299 
ENSG00000132205 EMILIN2 0 0.040211 
ENSG00000160791 CCR5 0 0.001599 
ENSG00000081041 CXCL2 0 0.03163 
ENSG00000211890 IGHA2 0 0.019882 
ENSG00000211895 IGHA1 0.056928 0.014989 
ENSG00000175899 A2M 0.098361 0.044878 
ENSG00000137673 MMP7 0.105178 0.033412 
ENSG00000255604 VTN 0.119487 0.041232 
ENSG00000166670 MMP10 0.127361 0.012948 
ENSG00000173432 SAA1 0.152622 0.017424 
ENSG00000101335 MYL9 0.166702 0.003006 
ENSG00000152268 SPON1 0.20093 0.049172 
ENSG00000120217 CD274 0.231999 0.041468 
ENSG00000080573 COL5A3 0.233182 0.033674 
ENSG00000130300 PLVAP 0.240275 0.040161 
ENSG00000152583 SPARCL1 0.252878 0.015347 
ENSG00000147065 MSN 0.265894 0.010835 
ENSG00000121807 CCR2 0.276147 0.023726 
ENSG00000146555 SDK1 0.279631 0.031706 
ENSG00000148702 HABP2 0.285999 1.23E-09 
ENSG00000143520 FLG2 0.305903 0.026992 
ENSG00000091986 CCDC80 0.309876 0.038893 
ENSG00000113140 SPARC 0.311592 0.021068 
ENSG00000120896 SORBS3 0.326719 0.044562 
ENSG00000142156 COL6A1 0.329797 0.01876 
ENSG00000140945 CDH13 0.329891 0.005766 
ENSG00000138829 FBN2 0.338722 1.73E-07 
ENSG00000139329 LUM 0.338983 0.008498 
ENSG00000171119 NRTN 0.361854 0.030735 
ENSG00000011465 DCN 0.369724 0.005076 
ENSG00000148926 ADM 0.378075 0.025102 
ENSG00000163359 COL6A3 0.383347 0.039275 
ENSG00000185499 MUC1 0.386519 0.014089 
ENSG00000148948 LRRC4C 0.392653 0.003831 
ENSG00000163638 ADAMTS9 0.404246 0.019345 
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ENSG00000146197 SCUBE3 0.420484 0.000807 
ENSG00000116141 MARK1 0.424395 5.09E-05 
ENSG00000144824 PHLDB2 0.435167 3.17E-06 
ENSG00000116106 EPHA4 0.437109 5.84E-07 
ENSG00000164692 COL1A2 0.445433 0.048807 
ENSG00000106541 AGR2 0.447506 0.021201 
ENSG00000118785 SPP1 0.455873 0.04846 
ENSG00000161638 ITGA5 0.458459 0.000395 
ENSG00000140092 FBLN5 0.462107 0.024721 
ENSG00000150672 DLG2 0.483081 0.0019 
ENSG00000163536 SERPINI1 0.487389 0.04999 
ENSG00000125966 MMP24 0.493843 0.034174 
ENSG00000166106 ADAMTS15 0.500032 0.026533 
ENSG00000076706 MCAM 0.504521 0.035845 
ENSG00000143546 S100A8 0.510126 0.021648 
ENSG00000172638 EFEMP2 0.522717 0.015174 
ENSG00000140859 KIFC3 0.525971 0.04516 
ENSG00000106571 GLI3 0.537247 8.86E-05 
ENSG00000157227 MMP14 0.547407 0.011157 
ENSG00000129038 LOXL1 0.549336 0.006255 
ENSG00000076716 GPC4 0.549964 0.00024 
ENSG00000078401 EDN1 0.562732 0.001351 
ENSG00000137699 TRIM29 0.573743 0.029525 
ENSG00000138772 ANXA3 0.573972 0.005354 
ENSG00000041982 TNC 0.57471 0.000328 
ENSG00000119535 CSF3R 0.582702 0.04323 
ENSG00000170577 SIX2 0.584349 0.002824 
ENSG00000171444 MCC 0.59113 0.000698 
ENSG00000151914 DST 0.593161 0.000586 
Sex differentiation 
ENSG00000157404 KIT 0 0.001431 
ENSG00000138207 RBP4 0 0.03071 
ENSG00000081051 AFP 0.155244 1.64E-08 
ENSG00000134853 PDGFRA 0.311845 0.018887 
ENSG00000104332 SFRP1 0.361703 0.001642 
ENSG00000244588 RAD21L1 0.555058 0.010347 
ENSG00000125398 SOX9 0.56725 0.000673 
ENSG00000132130 LHX1 0.599839 0.00593 
Regulation of cell growth or death 
ENSG00000164741 DLC1 0 0.020456 
ENSG00000136160 EDNRB 0 0.043352 
ENSG00000118971 CCND2 0.091317 0.014621 
ENSG00000010671 BTK 0.153937 0.042683 
ENSG00000070808 CAMK2A 0.206164 0.028214 
ENSG00000177398 UMODL1 0.357873 7.12E-09 
ENSG00000104081 BMF 0.412629 0.010613 
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ENSG00000157613 CREB3L1 0.435743 5.11E-07 
ENSG00000009709 PAX7 0.478992 0.028605 
ENSG00000121858 TNFSF10 0.541056 0.000164 
ENSG00000109670 FBXW7 0.54639 9.84E-05 
ENSG00000124762 CDKN1A 0.549035 0.000263 
ENSG00000035664 DAPK2 0.580864 0.001622 
 
Table 2E: GO biological pathways associated with MFM-223 DHT up-
regulated genes  
Ensembl gene ID Gene symbol FC p-value 
Regulation of transmembrane or ion transport  
ENSG00000139209 SLC38A4 11.30529 0.009143 
ENSG00000163380 LMOD3 6.209539 8.88E-16 
ENSG00000080618 CPB2 6.096618 0.016526 
ENSG00000018625 ATP1A2 5.344711 5.59E-10 
ENSG00000147257 GPC3 4.855859 0.00779 
ENSG00000125257 ABCC4 4.79848 9.71E-14 
ENSG00000184408 KCND2 4.382823 0.010199 
ENSG00000166828 SCNN1G 4.154343 0.001087 
ENSG00000143473 KCNH1 3.97686 0.014758 
ENSG00000149295 DRD2 3.265144 0 
ENSG00000082482 KCNK2 3.167954 0.020869 
ENSG00000138741 TRPC3 3.103477 0.003382 
ENSG00000143318 CASQ1 2.987924 1.41E-14 
ENSG00000123643 SLC36A1 2.504679 2.12E-10 
ENSG00000132681 ATP1A4 2.456964 5.60E-10 
ENSG00000144285 SCN1A 2.410777 1.61E-05 
ENSG00000173210 ABLIM3 2.262304 0.046962 
ENSG00000106688 SLC1A1 1.907325 5.45E-09 
ENSG00000112041 TULP1 1.886675 0.045893 
ENSG00000026559 KCNG1 1.886335 4.70E-10 
ENSG00000084628 NKAIN1 1.834272 0.013169 
ENSG00000116396 KCNC4 1.828824 0.003081 
ENSG00000168214 RBPJ 1.721868 7.54E-08 
ENSG00000126016 AMOT 1.686845 0.002559 
ENSG00000154309 DISP1 1.663872 0.001331 
ENSG00000149177 PTPRJ 1.612114 1.39E-08 
ENSG00000187486 KCNJ11 1.609128 1.94E-07 
ENSG00000136040 PLXNC1 1.601103 0.00942 
ENSG00000182324 KCNJ14 1.589181 0.03406 
ENSG00000165548 TMEM63C 1.582025 0.000622 
ENSG00000123607 TTC21B 1.556649 2.61E-07 
ENSG00000117586 TNFSF4 1.537133 0.007957 
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ENSG00000144136 SLC20A1 1.530727 3.80E-07 
Cell death 
ENSG00000109906 ZBTB16 29.2781610 6.4662908E-21 
ENSG00000144749 LRIG1 6.9595 0 
ENSG00000116741 RGS2 6.524396 0 
ENSG00000164120 HPGD 5.950249 0 
ENSG00000167034 NKX3-1 2.798494 7.22E-15 
ENSG00000118503 TNFAIP3 2.447703 1.85E-06 
ENSG00000162734 PEA15 2.323361 0 
ENSG00000176720 BOK 2.258723 0.014772 
ENSG00000146674 IGFBP3 2.211972 3.91E-08 
ENSG00000064393 HIPK2 1.797362 0.001531 
ENSG00000140538 NTRK3 1.771558 0.012716 
ENSG00000135116 HRK 1.641136 0.023305 
ENSG00000130222 GADD45G 1.585375 0.033787 
ENSG00000168209 DDIT4 1.522963 2.03E-07 
ENSG00000124664 SPDEF 1.507525 4.67E-07 
Response to hormones 
ENSG00000131482 G6PC Inf 0.001605 
ENSG00000070886 EPHA8 4.352906 0.006751 
ENSG00000166147 FBN1 2.827927 2.33E-14 
ENSG00000124225 PMEPA1 2.734252 0 
ENSG00000153162 BMP6 2.409597 0.001848 
ENSG00000112293 GPLD1 2.1688 9.69E-05 
ENSG00000127955 GNAI1 2.164146 2.54E-05 
ENSG00000084207 GSTP1 2.078986 0.049464 
ENSG00000125820 NKX2-2 1.872614 0.011729 
ENSG00000140538 NTRK3 1.771558 0.012716 
ENSG00000149212 SESN3 1.732872 2.71E-05 
ENSG00000126368 NR1D1 1.613607 0.007678 
ENSG00000160999 SH2B2 1.608908 0.020263 
ENSG00000119138 KLF9 1.553361 1.69E-05 
ENSG00000171345 KRT19 1.511443 4.78E-06 
Adhesion 
ENSG00000120332 TNN Inf 0.033456 
ENSG00000117090 SLAMF1 Inf 0.002694 
ENSG00000182636 NDN Inf 0.019755 
ENSG00000179399 GPC5 Inf 0.032426 
ENSG00000248383 PCDHAC1 Inf 0.029648 
ENSG00000103647 CORO2B 7.538193 0.000599 
ENSG00000128218 VPREB3 2.898465 0.027351 
ENSG00000173391 OLR1 2.893267 1.81E-09 
ENSG00000075618 FSCN1 2.732786 1.31E-06 
ENSG00000117155 SSX2IP 2.519799 0 
ENSG00000163638 ADAMTS9 2.231762 0.026749 
ENSG00000137809 ITGA11 2.153337 0.008607 
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ENSG00000149294 NCAM1 2.140775 5.35E-06 
ENSG00000124721 DNAH8 2.114258 0.000948 
ENSG00000170873 MTSS1 1.91149 4.00E-15 
ENSG00000023902 PLEKHO1 1.897235 4.15E-08 
ENSG00000162729 IGSF8 1.769201 3.44E-09 
ENSG00000133121 STARD13 1.638316 4.05E-05 
ENSG00000106852 LHX6 1.535011 0.000322 
ENSG00000162849 KIF26B 1.515107 0.00038 
ENSG00000053747 LAMA3 1.501032 0.046309 
  
Table 2F: GO biological processes of DHT down-regulated genes in MFM-
223 cells 
Ensembl gene ID Gene symbol FC p-value 
Homeostatic process 
ENSG00000160883 HK3 0.158131 0.042946 
ENSG00000163464 CXCR1 0.254358 1.79E-07 
ENSG00000118729 CASQ2 0.273788 0.003166 
ENSG00000105929 ATP6V0A4 0.323451 0.020668 
ENSG00000104321 TRPA1 0.359585 5.06E-08 
ENSG00000185745 IFIT1 0.372191 0.003263 
ENSG00000149596 JPH2 0.416853 0.007092 
ENSG00000158055 GRHL3 0.455516 3.08E-10 
ENSG00000165029 ABCA1 0.497136 0.007483 
ENSG00000143153 ATP1B1 0.5163 6.56E-13 
ENSG00000118432 CNR1 0.521622 1.71E-05 
ENSG00000050628 PTGER3 0.528846 2.23E-10 
ENSG00000023171 GRAMD1B 0.552507 0.014104 
ENSG00000171992 SYNPO 0.554048 0.026481 
ENSG00000116701 NCF2 0.55722 0.000106 
ENSG00000134489 HRH4 0.559335 0.038385 
ENSG00000160183 TMPRSS3 0.572814 0.004362 
Development 
ENSG00000170819 BFSP2 0 0.019912 
ENSG00000171431 KRT20 0.065582 0.011373 
ENSG00000159307 SCUBE1 0.115028 0.002501 
ENSG00000139445 FOXN4 0.177594 0.000374 
ENSG00000164093 PITX2 0.203694 0.018669 
ENSG00000171587 DSCAM 0.271705 0.013973 
ENSG00000179520 SLC17A8 0.29233 0.011191 
ENSG00000110876 SELPLG 0.294518 0.046485 
ENSG00000101265 RASSF2 0.335381 5.63E-13 
ENSG00000162891 IL20 0.361448 0.010907 
ENSG00000085276 MECOM 0.380544 9.42E-11 
467 
 
ENSG00000163207 IVL 0.387175 0.01111 
ENSG00000006611 USH1C 0.393003 0.000862 
ENSG00000075223 SEMA3C 0.420552 1.88E-10 
ENSG00000113262 GRM6 0.424882 0.041047 
ENSG00000167601 AXL 0.4513 0.034799 
ENSG00000181291 TMEM132E 0.453828 0.039378 
ENSG00000095585 BLNK 0.477283 2.00E-15 
ENSG00000171243 SOSTDC1 0.489361 0.003318 
ENSG00000089692 LAG3 0.496164 0.037682 
ENSG00000134256 CD101 0.499421 0.002275 
ENSG00000083857 FAT1 0.502946 0.013436 
ENSG00000144821 MYH15 0.512367 0.026756 
ENSG00000166527 CLEC4D 0.55608 0.026184 
ENSG00000125730 C3 0.569549 0.001001 
ENSG00000176788 BASP1 0.58235 2.58E-08 
ENSG00000150893 FREM2 0.59069 0.015254 
Proliferation 
ENSG00000137440 FGFBP1 0 0.008424 
ENSG00000206557 TRIM71 0 0.024306 
ENSG00000139292 LGR5 0.0316 0.000252 
ENSG00000064300 NGFR 0.066346 0.034876 
ENSG00000122641 INHBA 0.368664 0.02877 
ENSG00000182533 CAV3 0.372131 0.026081 
ENSG00000064989 CALCRL 0.375284 0.000798 
ENSG00000163762 TM4SF18 0.387838 8.24E-07 
ENSG00000106278 PTPRZ1 0.423705 0.008775 
ENSG00000110492 MDK 0.477215 0.027137 
ENSG00000166333 ILK 0.480452 0.009005 
ENSG00000118523 CTGF 0.558853 8.66E-08 





































1 24,670,557 18,525,351 6,145,206 75 67 
2 22,508,937 16,886,198 5,622,739 75 33 
3 23,066,473 17,251,151 5,815,322 74 20 
DHT 
(10nM) 
1 23,173,996 17,879,708 5,294,288 77 15,612 
2 22,949,494 18,145,749 4,803,745 79 17,942 
3 23,629,638 18,255,961 5,373,677 77 26,162 










1 22,245,909 16,681,820 5,564,089 75 159 
2 21,741,731 16,341,733 5,399,998 75 113 
3 22,510,571 16,924,370 5,586,201 75 418 
DHT 
(10nM) 
1 19,893,313 15,258,535 4,634,778 76 8,951 
2 21,718,681 16,621,578 5,097,103 76 15,512 
3 23,066,473 17,251,151 5,815,323 74 20,224 






Incucyte analysis parameters and supplementary data  
of TFAP-2β study  
 

























400 Red 0.2 0 50 - 
Caspase 
3/7 












400 Red 0.2 -30 50 3000 
Caspase 
3/7 











400 Red 0.2 -10 20 - 
Caspase 
3/7 












400 Red 0.3 -20 10 1500 
Caspase 
3/7 
300 Green 0.6 -45 20 800 




mKate2 400 Red 0.5 -20 100 1000 
Caspase 
3/7 
300 Green 5 -60 50 1000 




mKate2 400 Red 2 5 150 1000 
Caspase 
3/7 






































Appendix 3C: Confirm the anti-cancer effects of silencing TFAP-β using a 
second siAP-2β. (I) Immunoblotting of MDA-MB-231 cells transfected with 
TFAP2A, or TFAP2B to test specificity of TFAP-2β antibodies. NC represents 
non-transfected MDA-MB-231 cells. (II) Western blot showing TFAP-2β 
protein expression in MDA-MB-453 and MFM-223 cells.  (III) Growth curve 
showing a dose-dependent inhibition of MDA-MB-453 cell proliferation with 
siAP-2β (b). (IV) Death curve to accompany results in (A), showing TFAP-





ratio) in a dose-dependent manner. All data represented as mean ± SEM; 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.000, versus siNC (One Way 
ANOVA). (V) Immunoblotting showing decrease in C-MYC and HER2 






















1 27,633,239 21,001,033 6,632,206 76.0 26,084 
2 28,414,833 21,628,889 6,785,944 76.1 32,931 
3 29,435,241 22,356,807 7,078,434 76.0 26,612 
DHT 
(10nM) 
1 27,195,060 20,571,210 6,623,850 75.6 19,302 
2 25,861,959 19,683,755 6,178,204 76.1 26,399 
3 27,674,199 20,955,863 6,718,336 75.7 24,671 
Pooled input 28,865,500 21,783,262 7,082,238 75.5  
 
Table 3E High throughput sequencing of H3K27ac ChIP. 


































































































5,256,265 80.04 40,906 




























Appendix 3F: The effect of TFAP-2β knockdown on H3K27ac cistrome in 
MDA-MB-453 cells. (I) Heatmaps and corresponding read density plots 
showing consensus ChIP-seq signals and the number of unchanged, siNC 
enriched and siAP-2β enriched peaks in MDA-MB-453 cells treated with 5nM 
siAP-2β for 48 hr and then treated with DHT for 4hr. (II) PCA plot displaying 






samples and treatment conditions in MDA-MB-453 cells. (III) Differentially 
enriched H3K27ac binding sites were analysed using GREAT to determine 





Effect of L-453 compound on proliferation of TNBC cell lines  
 
 
Appendix 4: Proliferation of TNBC cells measured by live cell count at 
varying concentrations of L-453. Data represents mean ± SEM of three 
replicate cell culture wells per condition and is a representative of two 
independent experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
(One Way ANOVA).  
 
 
 
477 
 
 
